
<!DOCTYPE html>
<html lang="en" >
    <head >

        <meta charset="UTF-8" />
        <meta http-equiv="X-UA-Compatible" content="IE=edge" />
        <meta name="HandheldFriendly" content="True" />
        <meta name="MobileOptimized" content="320" />
        <meta name="viewport" content="width=device-width, initial-scale=1.0" />

        
        

        
        
  <link rel="stylesheet" href="/static/assets/style-8258669d.css" />
<script type="module" crossorigin="" src="/static/assets/base_style-f4a99799.js"></script>

  <link rel="stylesheet" href="/static/assets/style-ef962842.css" />
<link rel="stylesheet" href="/static/assets/style-3ade8b5c.css" />
<script type="module" crossorigin="" src="/static/assets/article_style-d757a0dd.js"></script>

  
  
    <style>
  
  
  @media screen and (min-width: 64em) {
    div.pmc-wm {
      background: repeat-y;
      background-image: url("data:image/svg+xml,%3Csvg xmlns='http://www.w3.org/2000/svg' width='20' height='350' xmlns:xlink='http://www.w3.org/1999/xlink'%3E%3Cdefs%3E%3Cfilter x='-.02' y='0' width='1.05' height='1' id='c'%3E%3CfeFlood flood-color='%23FFF'/%3E%3CfeComposite in='SourceGraphic'/%3E%3C/filter%3E%3Ctext id='b' font-family='Helvetica' font-size='11pt' style='opacity:1;fill:%23005ea2;stroke:none;text-anchor:middle' x='175' y='14'%3E%3C/text%3E%3Cpath id='a' style='fill:%23005ea2' d='M0 8h350v3H0z'/%3E%3C/defs%3E%3Cuse xlink:href='%23a' transform='rotate(90 10 10)'/%3E%3Cuse xlink:href='%23b' transform='rotate(90 10 10)' filter='url(%23c)'/%3E%3C/svg%3E");
      padding-left: 3rem;
    }
  }
</style>

  



        
            <link rel="apple-touch-icon"
                  sizes="180x180"
                  href="/static/img/favicons/apple-touch-icon.png" />
            <link rel="icon"
                  type="image/png"
                  sizes="48x48"
                  href="/static/img/favicons/favicon-48x48.png" />
            <link rel="icon"
                  type="image/png"
                  sizes="32x32"
                  href="/static/img/favicons/favicon-32x32.png" />
            <link rel="icon"
                  type="image/png"
                  sizes="16x16"
                  href="/static/img/favicons/favicon-16x16.png" />
            <link rel="manifest" href="/static/img/favicons/site.webmanifest" />
            <link rel="mask-icon"
                  href="/static/img/favicons/safari-pinned-tab.svg"
                  color="#0071bc" />
            <meta name="msapplication-config"
                  content="/static/img/favicons/browserconfig.xml" />
            <meta name="theme-color" content="#ffffff" />
        

        <title>
            Design, synthesis, and cytotoxic evaluation of quinazoline-based derivatives as VEGER-2 inhibitors: comparative study against EGFR kinase activity, induction of apoptosis, and molecular docking study - PMC
        </title>

        
        
  
  <!-- Logging params: Pinger defaults -->
<meta name="ncbi_app" content="cloudpmc-viewer" />
<meta name="ncbi_db" content="pmc" />
<meta name="ncbi_phid" content="D2E4A4DC8AF229F305A4DC003D688113.m_1" />
<meta name="ncbi_pinger_stat_url" content="https://pmc.ncbi.nlm.nih.gov/stat" />
<!-- Logging params: Pinger custom -->
<meta name="ncbi_pdid" content="article" />
  
    <link rel="preconnect" href="https://www.google-analytics.com" />

    
        <link rel="preconnect" href="https://cdn.ncbi.nlm.nih.gov" />
    

    <!-- Include USWDS Init Script -->
    <script src="/static/assets/uswds-init.js"></script>


    <meta name="ncbi_domain" content="rscadv">
<meta name="ncbi_type" content="fulltext">
<meta name="ncbi_pcid" content="journal">
<meta name="ncbi_feature" content="associated_data">
<link rel="canonical" href="https://pmc.ncbi.nlm.nih.gov/articles/PMC12377202/">
<meta name="robots" content="INDEX,NOFOLLOW,NOARCHIVE">
<meta name="citation_journal_title" content="RSC Advances">
<meta name="citation_title" content="Design, synthesis, and cytotoxic evaluation of quinazoline-based derivatives as VEGER-2 inhibitors: comparative study against EGFR kinase activity, induction of apoptosis, and molecular docking study">
<meta name="citation_author" content="Reda R Mabrouk">
<meta name="citation_author_institution" content="Pharmaceutical Medicinal Chemistry&amp; Drug Design Department, Faculty of Pharmacy (Boys), Al-Azhar University, Cairo 11884, Egypt, Email: alaaelwan34@azhar.edu.eg, Email: malzahaby@azhar.edu.eg">
<meta name="citation_author_institution" content="Directorate of Health Affairs in Buhaira-Clinical Research Department, Ministry of Health and Population, Damanhour 22511, Egypt">
<meta name="citation_author" content="Arafa Musa">
<meta name="citation_author_institution" content="Department of Pharmacognosy, College of Pharmacy, Jouf University, Sakaka, Aljouf 72341, Saudi Arabia, Email: akmusa@ju.edu.sa">
<meta name="citation_author" content="Maged Mohammed Saleh Al Ward">
<meta name="citation_author_institution" content="Pharmaceutical Medicinal Chemistry&amp; Drug Design Department, Faculty of Pharmacy (Boys), Al-Azhar University, Cairo 11884, Egypt, Email: alaaelwan34@azhar.edu.eg, Email: malzahaby@azhar.edu.eg">
<meta name="citation_author_institution" content="Medicinal Chemistry Department, Faculty of Pharmacy, Al Razi University, Sana&#x27;a, Yemen">
<meta name="citation_author" content="Shaimaa Hussein">
<meta name="citation_author_institution" content="Department of Pharmacology, College of Pharmacy, Jouf University, Sakaka, Aljouf 72341, Saudi Arabia">
<meta name="citation_author" content="Ahmed K B Aljohani">
<meta name="citation_author_institution" content="Pharmacognosy and Pharmaceutical Chemistry Department, College of Pharmacy, Taibah University, Medina, Saudi Arabia">
<meta name="citation_author" content="Mohamed Ayman El-Zahabi">
<meta name="citation_author_institution" content="Pharmaceutical Medicinal Chemistry&amp; Drug Design Department, Faculty of Pharmacy (Boys), Al-Azhar University, Cairo 11884, Egypt, Email: alaaelwan34@azhar.edu.eg, Email: malzahaby@azhar.edu.eg">
<meta name="citation_author" content="Alaa Elwan">
<meta name="citation_author_institution" content="Pharmaceutical Medicinal Chemistry&amp; Drug Design Department, Faculty of Pharmacy (Boys), Al-Azhar University, Cairo 11884, Egypt, Email: alaaelwan34@azhar.edu.eg, Email: malzahaby@azhar.edu.eg">
<meta name="citation_publication_date" content="2025 Aug 21">
<meta name="citation_volume" content="15">
<meta name="citation_issue" content="36">
<meta name="citation_firstpage" content="29593">
<meta name="citation_doi" content="10.1039/d5ra03829d">
<meta name="citation_abstract_html_url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC12377202/">
<meta name="citation_fulltext_html_url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC12377202/">
<meta name="citation_pdf_url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC12377202/pdf/RA-015-D5RA03829D.pdf">
<meta name="description" content="A novel series of quinazoline-based compounds were designed and synthesized as modified analogues to certain known VEGFR-2 inhibitors, as an extension of our work on the design and synthesis of new VEGFR-2 inhibitors. The anti-proliferative ...">
<meta name="og:title" content="Design, synthesis, and cytotoxic evaluation of quinazoline-based derivatives as VEGER-2 inhibitors: comparative study against EGFR kinase activity, induction of apoptosis, and molecular docking study">
<meta name="og:type" content="article">
<meta name="og:site_name" content="PubMed Central (PMC)">
<meta name="og:description" content="A novel series of quinazoline-based compounds were designed and synthesized as modified analogues to certain known VEGFR-2 inhibitors, as an extension of our work on the design and synthesis of new VEGFR-2 inhibitors. The anti-proliferative ...">
<meta name="og:url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC12377202/">
<meta name="og:image" content="https://cdn.ncbi.nlm.nih.gov/pmc/cms/images/pmc-card-share.jpg?_=0">
<meta name="twitter:card" content="summary_large_image">
<meta name="twitter:site" content="@ncbi">
    
    

    </head>
    <body >
        
    <a class="usa-skipnav " href="#main-content">
      Skip to main content
    </a>


        
            

<section class="usa-banner " aria-label="Official website of the United States government" >
    <div class="usa-accordion">
        <header class="usa-banner__header">
            <div class="usa-banner__inner">
                <div class="grid-col-auto">
                    <img aria-hidden="true"
                         class="usa-banner__header-flag"
                         src="/static/img/us_flag.svg"
                         alt="" />
                </div>

                <div class="grid-col-fill tablet:grid-col-auto" aria-hidden="true">
                    <p class="usa-banner__header-text">
                        An official website of the United States government
                    </p>
                    <span class="usa-banner__header-action">Here's how you know</span>
                </div>

                



















    
        <button
            type="button"
        
    
    class="usa-accordion__button usa-banner__button
           

           
               
               
               
               
            

           
           
           
           "
    aria-expanded="false"
    aria-controls="gov-banner-default"
    
    data-testid="storybook-django-banner"
    
    >
    
        

        
                    <span class="usa-banner__button-text">Here's how you know</span>
                

        
    
        
            </button>
        


            </div>
        </header>

        <div class="usa-banner__content usa-accordion__content"
             id="gov-banner-default"
             hidden>
            <div class="grid-row grid-gap-lg">
                <div class="usa-banner__guidance tablet:grid-col-6">
                    <img class="usa-banner__icon usa-media-block__img"
                         src="/static/img/icon-dot-gov.svg"
                         alt=""
                         aria-hidden="true" />
                    <div class="usa-media-block__body">
                        <p>
                            <strong>Official websites use .gov</strong>
                            <br />
                            A
                            <strong>.gov</strong> website belongs to an official
                            government organization in the United States.
                        </p>
                    </div>
                </div>

                <div class="usa-banner__guidance tablet:grid-col-6">
                    <img class="usa-banner__icon usa-media-block__img"
                         src="/static/img/icon-https.svg"
                         alt=""
                         aria-hidden="true" />

                    <div class="usa-media-block__body">
                        <p>
                            <strong>Secure .gov websites use HTTPS</strong>
                            <br />
                            A <strong>lock</strong> (
                            <span class="icon-lock">
                                <svg xmlns="http://www.w3.org/2000/svg"
                                     width="52"
                                     height="64"
                                     viewBox="0 0 52 64"
                                     class="usa-banner__lock-image"
                                     role="graphics-symbol"
                                     aria-labelledby="banner-lock-description"
                                     focusable="false">
                                    <title id="banner-lock-title">Lock</title>
                                    <desc id="banner-lock-description">
                                    Locked padlock icon
                                    </desc>
                                    <path fill="#000000"
                                          fill-rule="evenodd"
                                          d="M26 0c10.493 0 19 8.507 19 19v9h3a4 4 0 0 1 4 4v28a4 4 0 0 1-4 4H4a4 4 0 0 1-4-4V32a4 4 0 0 1 4-4h3v-9C7 8.507 15.507 0 26 0zm0 8c-5.979 0-10.843 4.77-10.996 10.712L15 19v9h22v-9c0-6.075-4.925-11-11-11z" />
                                </svg>
</span>) or <strong>https://</strong> means you've safely
                                connected to the .gov website. Share sensitive
                                information only on official, secure websites.
                            </p>
                        </div>
                    </div>
                </div>
            </div>
        </div>
    </section>

        

        
    
    
    

<div class="usa-overlay">
</div>



<header class="usa-header usa-header--extended usa-header--wide" data-header data-testid="header"    >
    <div class="ncbi-header">
        <div class="ncbi-header__container">
            <a class="ncbi-header__logo-container"
               href="https://www.ncbi.nlm.nih.gov/">
                <img alt="NCBI home page"
                     class="ncbi-header__logo-image"
                     src="/static/img/ncbi-logos/nih-nlm-ncbi--white.svg"
                     width="410"
                     height="100" />
            </a>

            <!-- Mobile menu hamburger button -->
            



















    
        <button
            type="button"
        
    
    class="usa-menu-btn ncbi-header__hamburger-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    aria-label="Show menu"
    data-testid="navMenuButton"
    
    >
    
        

        
                <svg aria-hidden="true"
                     class="ncbi-hamburger-icon"
                     fill="none"
                     focusable="false"
                     height="21"
                     viewBox="0 0 31 21"
                     width="31"
                     xmlns="http://www.w3.org/2000/svg">
                    <path clip-rule="evenodd"
                          d="M0.125 20.75H30.875V17.3333H0.125V20.75ZM0.125 12.2083H30.875V8.79167H0.125V12.2083ZM0.125 0.25V3.66667H30.875V0.25H0.125Z"
                          fill="#F1F1F1"
                          fill-rule="evenodd" />
                </svg>
            

        
    
        
            </button>
        



            
                <!-- Desktop buttons-->
                <div class="ncbi-header__desktop-buttons">
                    
                        <!-- Desktop search button -->
                        



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           usa-button--unstyled ncbi-header__desktop-button
           "
    aria-expanded="false"
    aria-controls="search-field-desktop-navigation"
    aria-label="Show search overlay"
    data-testid="toggleSearchPanelButton"
    data-toggle-search-panel-button
    >
    
        

        
                            



    <svg class="usa-icon " role="graphics-symbol" aria-hidden="true" >
        
        <use xlink:href="/static/img/sprite.svg#search" />
    </svg>


                            Search
                        

        
    
        
            </button>
        


                    

                    <!-- Desktop login dropdown -->
                    
                        <div class="ncbi-header__login-dropdown">
                            



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           usa-button--unstyled ncbi-header__desktop-button ncbi-header__login-dropdown-button
           "
    aria-expanded="false"
    aria-controls="login-dropdown-menu"
    aria-label="Show login menu"
    data-testid="toggleLoginMenuDropdown"
    data-desktop-login-button
    >
    
        

        
                                



    <svg class="usa-icon " role="graphics-symbol" aria-hidden="true" >
        
        <use xlink:href="/static/img/sprite.svg#person" />
    </svg>



                                <span data-login-dropdown-text>Log in</span>

                                <!-- Dropdown icon pointing up -->
                                



    <svg class="usa-icon ncbi-header__login-dropdown-icon ncbi-header__login-dropdown-icon--expand-less ncbi-header__login-dropdown-icon--hidden" role="graphics-symbol" aria-hidden="true" data-login-dropdown-up-arrow>
        
        <use xlink:href="/static/img/sprite.svg#expand_less" />
    </svg>



                                <!-- Dropdown icon pointing down -->
                                



    <svg class="usa-icon ncbi-header__login-dropdown-icon ncbi-header__login-dropdown-icon--expand-more ncbi-header__login-dropdown-icon--hidden" role="graphics-symbol" aria-hidden="true" data-login-dropdown-down-arrow>
        
        <use xlink:href="/static/img/sprite.svg#expand_more" />
    </svg>


                            

        
    
        
            </button>
        



                            <!-- Login dropdown menu -->
                            <ul class="usa-nav__submenu ncbi-header__login-dropdown-menu"
                                id="login-dropdown-menu"
                                data-desktop-login-menu-dropdown
                                hidden>
                                
                                    <li class="usa-nav__submenu-item">
                                        <!-- Uses custom style overrides to render external and document links. -->
                                        









    <a href="https://www.ncbi.nlm.nih.gov/myncbi/" class="usa-link  "  >
        

        
            Dashboard
        

        
    </a>


                                    </li>
                                
                                    <li class="usa-nav__submenu-item">
                                        <!-- Uses custom style overrides to render external and document links. -->
                                        









    <a href="https://www.ncbi.nlm.nih.gov/myncbi/collections/bibliography/" class="usa-link  "  >
        

        
            Publications
        

        
    </a>


                                    </li>
                                
                                    <li class="usa-nav__submenu-item">
                                        <!-- Uses custom style overrides to render external and document links. -->
                                        









    <a href="https://www.ncbi.nlm.nih.gov/account/settings/" class="usa-link  "  >
        

        
            Account settings
        

        
    </a>


                                    </li>
                                
                                <li class="usa-nav__submenu-item">
                                    



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           usa-button--outline ncbi-header__login-dropdown-logout-button
           "
    
    
    
    data-testid="desktopLogoutButton"
    data-desktop-logout-button
    >
    
        

        Log out

        
    
        
            </button>
        


                                </li>
                            </ul>
                        </div>
                    
                </div>
            
        </div>
    </div>

    <!-- Search panel -->
    
        <div class="ncbi-search-panel ncbi--show-only-at-desktop"
             data-header-search-panel
             hidden>
            <div class="ncbi-search-panel__container">
                <form action="https://www.ncbi.nlm.nih.gov/search/all/"
                      
                      autocomplete="off"
                      class="usa-search usa-search--big ncbi-search-panel__form"
                      data-testid="desktop-navigation-search-form"
                      method="GET"
                      role="search">
                    <label class="usa-sr-only" for="search-field-desktop-navigation">
                        Search…
                    </label>
                    <input class="usa-input"
                           id="search-field-desktop-navigation"
                           name="term"
                           
                               placeholder="Search NCBI"
                           
                           type="search"
                           value="" />
                    



















    
        <button
            type="submit"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    
    
    
    >
    
        

        
                        <span class="usa-search__submit-text">
                            Search NCBI
                        </span>
                    

        
    
        
            </button>
        


                </form>

                
            </div>
        </div>
    

    <nav aria-label="Primary navigation" class="usa-nav">
        <p class="usa-sr-only" id="primary-navigation-sr-only-title">
            Primary site navigation
        </p>

        <!-- Mobile menu close button -->
        



















    
        <button
            type="button"
        
    
    class="usa-nav__close ncbi-nav__close-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    aria-label="Close navigation menu"
    data-testid="navCloseButton"
    
    >
    
        

        
            <img src="/static/img/usa-icons/close.svg" alt="Close" />
        

        
    
        
            </button>
        



        
            <!-- Mobile search component -->
            <form class="usa-search usa-search--small ncbi--hide-at-desktop margin-top-6"
                  action="https://www.ncbi.nlm.nih.gov/search/all/"
                  
                  autocomplete="off"
                  data-testid="mobile-navigation-search-form"
                  method="GET"
                  role="search">
                <label class="usa-sr-only" for="search-field-mobile-navigation">
                    Search
                </label>

                <input class="usa-input"
                       id="search-field-mobile-navigation"
                       type="search"
                       
                           placeholder="Search NCBI"
                       
                       name="term" />

                



















    
        <button
            type="submit"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    
    
    
    >
    
        

        
                    <!-- This SVG should be kept inline and not replaced with a link to the icon as otherwise it will render in the wrong color -->
                    <img src="data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIGhlaWdodD0iMjQiIHZpZXdCb3g9IjAgMCAyNCAyNCIgd2lkdGg9IjI0Ij48cGF0aCBkPSJNMCAwaDI0djI0SDB6IiBmaWxsPSJub25lIi8+PHBhdGggZmlsbD0iI2ZmZiIgZD0iTTE1LjUgMTRoLS43OWwtLjI4LS4yN0E2LjQ3MSA2LjQ3MSAwIDAgMCAxNiA5LjUgNi41IDYuNSAwIDEgMCA5LjUgMTZjMS42MSAwIDMuMDktLjU5IDQuMjMtMS41N2wuMjcuMjh2Ljc5bDUgNC45OUwyMC40OSAxOWwtNC45OS01em0tNiAwQzcuMDEgMTQgNSAxMS45OSA1IDkuNVM3LjAxIDUgOS41IDUgMTQgNy4wMSAxNCA5LjUgMTEuOTkgMTQgOS41IDE0eiIvPjwvc3ZnPg=="
                         class="usa-search__submit-icon"
                         alt="Search" />
                

        
    
        
            </button>
        


            </form>

            
        

        <!-- Primary navigation menu items -->
        <!-- This usa-nav__inner wrapper is required to correctly style the navigation items on Desktop -->
        

        
            <div class="ncbi-nav__mobile-login-menu ncbi--hide-at-desktop"
                 data-mobile-login-menu
                 hidden>
                <p class="ncbi-nav__mobile-login-menu-status">
                    Logged in as:
                    <strong class="ncbi-nav__mobile-login-menu-email"
                            data-mobile-login-email-text></strong>
                </p>
                <ul class="usa-nav__primary usa-accordion">
                    
                        <li class="usa-nav__primary-item">
                            









    <a href="https://www.ncbi.nlm.nih.gov/myncbi/" class="usa-link  "  >
        

        
            Dashboard
        

        
    </a>


                        </li>
                    
                        <li class="usa-nav__primary-item">
                            









    <a href="https://www.ncbi.nlm.nih.gov/myncbi/collections/bibliography/" class="usa-link  "  >
        

        
            Publications
        

        
    </a>


                        </li>
                    
                        <li class="usa-nav__primary-item">
                            









    <a href="https://www.ncbi.nlm.nih.gov/account/settings/" class="usa-link  "  >
        

        
            Account settings
        

        
    </a>


                        </li>
                    
                </ul>
            </div>
        

        



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           ncbi-nav__mobile-login-button ncbi--hide-at-desktop
           "
    
    
    
    data-testid="mobileLoginButton"
    data-mobile-login-button
    >
    
        

        Log in

        
    
        
            </button>
        


    </nav>
</header>

    
    
        

<section class="pmc-header pmc-header--basic" aria-label="PMC Header with search box">
    <div class="pmc-nav-container">
        <div class="pmc-header__bar">
           <div class="pmc-header__logo">
               <a href="/" title="Home" aria-label="PMC Home"></a>
           </div>
            <button
                    type="button"
                    class="usa-button usa-button--unstyled pmc-header__search__button"
                    aria-label="Open search"
                    data-ga-category="search"
                    data-ga-action="PMC"
                    data-ga-label="pmc_search_panel_mobile"
            >
                <svg class="usa-icon width-4 height-4 pmc-icon__open" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#search"></use>
                </svg>
                <svg class="usa-icon width-4 height-4 pmc-icon__close" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#close"></use>
                </svg>
            </button>
        </div>
        <div class="pmc-header__search">
            


<form class="usa-search usa-search--extra usa-search--article-right-column  pmc-header__search__form" id="pmc-search-form" autocomplete="off" role="search">
<label class="usa-sr-only" for="pmc-search">Search PMC Full-Text Archive</label>
<span class="autoComplete_wrapper flex-1">
<input class="usa-input width-full maxw-none" required="required" placeholder="Search PMC Full-Text Archive" id="pmc-search"  type="search" name="term" data-autocomplete-url="https://pmc.ncbi.nlm.nih.gov/autocomp/search/autocomp/"/>
</span>
<button
class="usa-button"
type="submit"
formaction="https://www.ncbi.nlm.nih.gov/pmc/"
data-ga-category="search"
data-ga-action="PMC"
data-ga-label="PMC_search_button"
>
<span class="usa-search__submit-text">Search in PMC</span>
<img
src="/static/img/usa-icons-bg/search--white.svg"
class="usa-search__submit-icon"
alt="Search"
/>
</button>
</form>
            <div class="display-flex flex-column tablet:flex-row tablet:flex-justify flex-justify-center flex-align-center width-full desktop:maxw-44">
                <ul class="pmc-header__search__menu">
                    <li>
                        
                            <a class="usa-link" href="/journals/" data-ga-action="featured_link" data-ga-label="journal list">
                                Journal List
                            </a>
                        
                    </li>
                    <li>
                        
                            <a class="usa-link" href="/about/userguide/" data-ga-action="featured_link"
                            data-ga-label="user guide">
                                User Guide
                            </a>
                        
                    </li>
                </ul>
                
                    <button form="pmc-search-form" formaction="https://pmc.ncbi.nlm.nih.gov/search/" type="submit" class="usa-button usa-button--unstyled hover:text-no-underline text-no-underline width-auto margin-top-1 tablet:margin-top-0">
     <span class="bg-green-label padding-05 text-white">New</span><span class="text-underline text-primary">Try this search in PMC Beta Search</span>
</button>
                
            </div>
        </div>
    </div>
</section>

    


        
        

       
  <div class="usa-section padding-top-0 desktop:padding-top-6 pmc-article-section" data-article-db="pmc" data-article-id="12377202">

    

   



<div class="grid-container pmc-actions-bar" aria-label="Actions bar" role="complementary">
    <div class="grid-row">
        <div class="grid-col-fill display-flex">
             <div class="display-flex">
                <ul class="usa-list usa-list--unstyled usa-list--horizontal">
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex mob">
                        <button
                                type="button"
                                class="usa-button pmc-sidenav__container__open usa-button--unstyled width-auto display-flex"
                                aria-label="Open resources"
                                data-extra-class="is-visible-resources"
                                data-ga-category="resources_accordion"
                                data-ga-action="click"
                                data-ga-label="mobile_icon"
                        >
                            <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                <use xlink:href="/static/img/sprite.svg#more_vert"></use>
                            </svg>
                        </button>
                    </li>
                    
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex mob">
                        <a
                                href="https://doi.org/10.1039/d5ra03829d"
                                class="usa-link display-flex usa-tooltip"
                                role="button"
                                target="_blank"
                                rel="noreferrer noopener"
                                title="View on publisher site"
                                data-position="bottom"
                                aria-label="View on publisher site"
                                data-ga-category="actions"
                                data-ga-action="click"
                                data-ga-label="publisher_link_mobile"
                        >
                                <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                    <use xlink:href="/static/img/sprite.svg#launch"></use>
                                </svg>
                        </a>
                    </li>
                    
                    
                        <li class="margin-right-2 mobile-lg:margin-right-4 display-flex">
                             <a
                                     href="pdf/RA-015-D5RA03829D.pdf"
                                     class="usa-link display-flex usa-tooltip"
                                     role="button"
                                     title="Download PDF"
                                     data-position="bottom"
                                     aria-label="Download PDF"
                                     data-ga-category="actions"
                                     data-ga-action="click"
                                     data-ga-label="pdf_download_mobile"
                             >
                                <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                    <use xlink:href="/static/img/sprite.svg#file_download"></use>
                                </svg>
                            </a>
                        </li>
                    
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex">
                        <button
                            class="usa-button usa-button--unstyled  usa-tooltip collections-dialog-trigger collections-button display-flex collections-button-empty"
                            title="Add to Collections"
                            data-position="bottom"
                            aria-label="Save article in MyNCBI collections."
                            data-ga-category="actions"
                            data-ga-action="click"
                            data-ga-label="collections_button_mobile"
                            data-collections-open-dialog-enabled="false"
                            data-collections-open-dialog-url="https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpmc.ncbi.nlm.nih.gov%2Farticles%2FPMC12377202%2F%3Freport%3Dclassic%23open-collections-dialog"
                            data-in-collections="false"
                        >
                            <svg class="usa-icon width-4 height-4 usa-icon--bookmark-full" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-full.svg#icon"></use>
                            </svg>
                            <svg class="usa-icon width-4 height-4 usa-icon--bookmark-empty" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-empty.svg#icon"></use>
                            </svg>
                        </button>
                    </li>
                    
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex">
                        <button role="button" class="usa-button usa-button--unstyled usa-tooltip citation-dialog-trigger display-flex"
                            aria-label="Open dialog with citation text in different styles"
                            title="Cite"
                            data-position="bottom"
                            data-ga-category="actions"
                            data-ga-action="open"
                            data-ga-label="cite_mobile"
                            data-all-citations-url="/resources/citations/12377202/"
                            data-citation-style="nlm"
                            data-download-format-link="/resources/citations/12377202/export/"
                        >
                            <svg class="usa-icon width-4 height-4 usa-icon--bookmark-empty" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/sprite.svg#format_quote"></use>
                            </svg>
                        </button>
                    </li>
                    
                    <li class="pmc-permalink display-flex" >
                         <button
                                 type="button"
                                 title="Permalink"
                                 data-position="bottom"
                                 class="usa-button usa-button--unstyled display-flex usa-tooltip"
                                 aria-label="Show article permalink"
                                 aria-expanded="false"
                                 aria-haspopup="true"
                                 data-ga-category="actions"
                                 data-ga-action="open"
                                 data-ga-label="permalink_mobile"
                         >
                            <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                <use xlink:href="/static/img/sprite.svg#share"></use>
                            </svg>
                        </button>
                        

<div class="pmc-permalink__dropdown" hidden>
    <div class="pmc-permalink__dropdown__container">
          <h2 class="usa-modal__heading margin-top-0 margin-bottom-2 text-uppercase font-sans-xs">PERMALINK</h2>
          <div class="pmc-permalink__dropdown__content">
              <input type="text" class="usa-input" value="https://pmc.ncbi.nlm.nih.gov/articles/PMC12377202/" aria-label="Article permalink">
              <button class="usa-button display-inline-flex pmc-permalink__dropdown__copy__btn margin-right-0" title="Copy article permalink" data-ga-category="save_share" data-ga-action="link" data-ga-label="copy_link">
                  <svg class="usa-icon" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#content_copy"></use>
                  </svg>
                  <span class="margin-left-1">Copy</span>
              </button>
          </div>
    </div>
</div>
                    </li>
                </ul>
            </div>
            <button
                    type="button"
                    class="usa-button pmc-sidenav__container__open usa-button--unstyled width-auto display-flex"
                    aria-label="Open article navigation"
                    data-extra-class="is-visible-in-page"
                    data-ga-category="actions"
                    data-ga-action="open"
                    data-ga-label="article_nav_mobile"
            >
                <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#list"></use>
                </svg>
            </button>
        </div>
    </div>
</div>
    <div class="grid-container desktop:padding-left-6">
      <div id="article-container" class="grid-row grid-gap">
        <div class="grid-col-12 desktop:grid-col-8 order-2 pmc-layout__content">
            <div class="grid-container padding-left-0 padding-right-0">
                <div class="grid-row desktop:margin-left-neg-6">
                    <div class="grid-col-12">
                        <div class="pmc-layout__disclaimer" role="complementary" aria-label="Disclaimer note">
    As a library, NLM provides access to scientific literature. Inclusion in an NLM database does not imply endorsement of, or agreement with,
    the contents by NLM or the National Institutes of Health.<br/>
    Learn more:
    <a class="usa-link" data-ga-category="Link click" data-ga-action="Disclaimer" data-ga-label="New disclaimer box" href="/about/disclaimer/">PMC Disclaimer</a>
    |
    <a class="usa-link" data-ga-category="Link click" data-ga-action="PMC Copyright Notice" data-ga-label="New disclaimer box" href="/about/copyright/">
        PMC Copyright Notice
    </a>
</div>
                    </div>
                </div>
                <div class="grid-row pmc-wm desktop:margin-left-neg-6">
                    <!-- Main content -->
                    <main
                      id="main-content"
                      class="usa-layout-docs__main usa-layout-docs grid-col-12 pmc-layout pmc-prose padding-0"
                    >

                      
                        <section class="pmc-journal-banner text-center line-height-none" aria-label="Journal banner"><img src="https://cdn.ncbi.nlm.nih.gov/pmc/banners/logo-rscadv.png" alt="RSC Advances logo" usemap="#pmc-banner-imagemap" width="500" height="75"><map name="pmc-banner-imagemap"><area alt="Link to RSC Advances" title="Link to RSC Advances" shape="default" href="https://www.rsc.org/journals-books-databases/about-journals/rsc-advances/" target="_blank" rel="noopener noreferrer"></map></section><article lang="en"><section aria-label="Article citation and metadata"><section class="pmc-layout__citation font-secondary font-xs"><div>
<div class="display-inline-block"><button type="button" class="cursor-pointer text-no-underline bg-transparent border-0 padding-0 text-left margin-0 text-normal text-primary" aria-controls="journal_context_menu">RSC Adv</button></div>. 2025 Aug 21;15(36):29593–29612. doi: <a href="https://doi.org/10.1039/d5ra03829d" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">10.1039/d5ra03829d</a>
</div>
<nav id="journal_context_menu" hidden="hidden"><ul class="menu-list font-family-ui" role="menu">
<li role="presentation"><a href="https://www.ncbi.nlm.nih.gov/pmc/?term=%22RSC%20Adv%22%5Bjour%5D" class="usa-link" role="menuitem">Search in PMC</a></li>
<li role="presentation"><a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22RSC%20Adv%22%5Bjour%5D" lang="en" class="usa-link" role="menuitem">Search in PubMed</a></li>
<li role="presentation"><a href="https://www.ncbi.nlm.nih.gov/nlmcatalog?term=%22RSC%20Adv%22%5BTitle%20Abbreviation%5D" class="usa-link" role="menuitem">View in NLM Catalog</a></li>
<li role="presentation"><a href="?term=%22RSC%20Adv%22%5Bjour%5D" class="usa-link" role="menuitem" data-add-to-search="true">Add to search</a></li>
</ul></nav></section><section class="front-matter"><div class="ameta p font-secondary font-xs">
<hgroup><h1>Design, synthesis, and cytotoxic evaluation of quinazoline-based derivatives as VEGER-2 inhibitors: comparative study against EGFR kinase activity, induction of apoptosis, and molecular docking study</h1></hgroup><div class="cg p">
<a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Mabrouk%20RR%22%5BAuthor%5D" class="usa-link" aria-describedby="id1"><span class="name western">Reda R Mabrouk</span></a><div hidden="hidden" id="id1">
<h3><span class="name western">Reda R Mabrouk</span></h3>
<div class="p">
<sup>a</sup>Pharmaceutical Medicinal Chemistry&amp; Drug Design Department, Faculty of Pharmacy (Boys), Al-Azhar University, Cairo 11884, Egypt, Email: alaaelwan34@azhar.edu.eg, Email: malzahaby@azhar.edu.eg</div>
<div class="p">
<sup>b</sup>Directorate of Health Affairs in Buhaira-Clinical Research Department, Ministry of Health and Population, Damanhour 22511, Egypt</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Mabrouk%20RR%22%5BAuthor%5D" class="usa-link"><span class="name western">Reda R Mabrouk</span></a>
</div>
</div>
<sup>a,</sup><sup>b</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Musa%20A%22%5BAuthor%5D" class="usa-link" aria-describedby="id2"><span class="name western">Arafa Musa</span></a><div hidden="hidden" id="id2">
<h3><span class="name western">Arafa Musa</span></h3>
<div class="p">
<sup>c</sup>Department of Pharmacognosy, College of Pharmacy, Jouf University, Sakaka, Aljouf 72341, Saudi Arabia, Email: akmusa@ju.edu.sa</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Musa%20A%22%5BAuthor%5D" class="usa-link"><span class="name western">Arafa Musa</span></a>
</div>
</div>
<sup>c,</sup><sup>✉</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Saleh%20Al%20Ward%20MM%22%5BAuthor%5D" class="usa-link" aria-describedby="id3"><span class="name western">Maged Mohammed Saleh Al Ward</span></a><div hidden="hidden" id="id3">
<h3><span class="name western">Maged Mohammed Saleh Al Ward</span></h3>
<div class="p">
<sup>a</sup>Pharmaceutical Medicinal Chemistry&amp; Drug Design Department, Faculty of Pharmacy (Boys), Al-Azhar University, Cairo 11884, Egypt, Email: alaaelwan34@azhar.edu.eg, Email: malzahaby@azhar.edu.eg</div>
<div class="p">
<sup>d</sup>Medicinal Chemistry Department, Faculty of Pharmacy, Al Razi University, Sana'a, Yemen</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Saleh%20Al%20Ward%20MM%22%5BAuthor%5D" class="usa-link"><span class="name western">Maged Mohammed Saleh Al Ward</span></a>
</div>
</div>
<sup>a,</sup><sup>d</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Hussein%20S%22%5BAuthor%5D" class="usa-link" aria-describedby="id4"><span class="name western">Shaimaa Hussein</span></a><div hidden="hidden" id="id4">
<h3><span class="name western">Shaimaa Hussein</span></h3>
<div class="p">
<sup>e</sup>Department of Pharmacology, College of Pharmacy, Jouf University, Sakaka, Aljouf 72341, Saudi Arabia</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Hussein%20S%22%5BAuthor%5D" class="usa-link"><span class="name western">Shaimaa Hussein</span></a>
</div>
</div>
<sup>e</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Aljohani%20AKB%22%5BAuthor%5D" class="usa-link" aria-describedby="id5"><span class="name western">Ahmed K B Aljohani</span></a><div hidden="hidden" id="id5">
<h3><span class="name western">Ahmed K B Aljohani</span></h3>
<div class="p">
<sup>f</sup>Pharmacognosy and Pharmaceutical Chemistry Department, College of Pharmacy, Taibah University, Medina, Saudi Arabia</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Aljohani%20AKB%22%5BAuthor%5D" class="usa-link"><span class="name western">Ahmed K B Aljohani</span></a>
</div>
</div>
<sup>f</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22El-Zahabi%20MA%22%5BAuthor%5D" class="usa-link" aria-describedby="id6"><span class="name western">Mohamed Ayman El-Zahabi</span></a><div hidden="hidden" id="id6">
<h3><span class="name western">Mohamed Ayman El-Zahabi</span></h3>
<div class="p">
<sup>a</sup>Pharmaceutical Medicinal Chemistry&amp; Drug Design Department, Faculty of Pharmacy (Boys), Al-Azhar University, Cairo 11884, Egypt, Email: alaaelwan34@azhar.edu.eg, Email: malzahaby@azhar.edu.eg</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22El-Zahabi%20MA%22%5BAuthor%5D" class="usa-link"><span class="name western">Mohamed Ayman El-Zahabi</span></a>
</div>
</div>
<sup>a,</sup><sup>✉</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Elwan%20A%22%5BAuthor%5D" class="usa-link" aria-describedby="id7"><span class="name western">Alaa Elwan</span></a><div hidden="hidden" id="id7">
<h3><span class="name western">Alaa Elwan</span></h3>
<div class="p">
<sup>a</sup>Pharmaceutical Medicinal Chemistry&amp; Drug Design Department, Faculty of Pharmacy (Boys), Al-Azhar University, Cairo 11884, Egypt, Email: alaaelwan34@azhar.edu.eg, Email: malzahaby@azhar.edu.eg</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Elwan%20A%22%5BAuthor%5D" class="usa-link"><span class="name western">Alaa Elwan</span></a>
</div>
</div>
<sup>a,</sup><sup>✉</sup>
</div>
<ul class="d-buttons inline-list">
<li><button class="d-button" aria-controls="aip_a" aria-expanded="false">Author information</button></li>
<li><button class="d-button" aria-controls="anp_a" aria-expanded="false">Article notes</button></li>
<li><button class="d-button" aria-controls="clp_a" aria-expanded="false">Copyright and License information</button></li>
</ul>
<div class="d-panels font-secondary-light">
<div id="aip_a" class="d-panel p" style="display: none">
<div class="p" id="affa">
<sup>a</sup>Pharmaceutical Medicinal Chemistry&amp; Drug Design Department, Faculty of Pharmacy (Boys), Al-Azhar University, Cairo 11884, Egypt, Email: alaaelwan34@azhar.edu.eg, Email: malzahaby@azhar.edu.eg</div>
<div id="affb">
<sup>b</sup>Directorate of Health Affairs in Buhaira-Clinical Research Department, Ministry of Health and Population, Damanhour 22511, Egypt</div>
<div id="affc">
<sup>c</sup>Department of Pharmacognosy, College of Pharmacy, Jouf University, Sakaka, Aljouf 72341, Saudi Arabia, Email: akmusa@ju.edu.sa</div>
<div id="affd">
<sup>d</sup>Medicinal Chemistry Department, Faculty of Pharmacy, Al Razi University, Sana'a, Yemen</div>
<div id="affe">
<sup>e</sup>Department of Pharmacology, College of Pharmacy, Jouf University, Sakaka, Aljouf 72341, Saudi Arabia</div>
<div id="afff">
<sup>f</sup>Pharmacognosy and Pharmaceutical Chemistry Department, College of Pharmacy, Taibah University, Medina, Saudi Arabia</div>
<div class="author-notes p"><div class="fn" id="_fncrsp93pmc__">
<sup>✉</sup><p class="display-inline">Corresponding author.</p>
</div></div>
</div>
<div id="anp_a" class="d-panel p" style="display: none"><div class="notes p"><section id="historyarticle-meta1" class="history"><p>Received 2025 May 30; Accepted 2025 Aug 6; Collection date 2025 Aug 18.</p></section></div></div>
<div id="clp_a" class="d-panel p" style="display: none">
<div>This journal is © The Royal Society of Chemistry</div>
<p>This article is licensed under a <a href="https://creativecommons.org/licenses/by/3.0/" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Creative Commons Attribution 3.0 Unported Licence</a>. You can use material from this article in other publications without requesting further permissions from the RSC, provided that the correct acknowledgement is given.</p>
<div class="p"><a href="/about/copyright/" class="usa-link">PMC Copyright notice</a></div>
</div>
</div>
<div>PMCID: PMC12377202</div>
</div></section></section><section aria-label="Article content"><section class="body main-article-body"><section class="abstract" id="abstract1"><h2>Abstract</h2>
<p>A novel series of quinazoline-based compounds were designed and synthesized as modified analogues to certain known VEGFR-2 inhibitors, as an extension of our work on the design and synthesis of new VEGFR-2 inhibitors. The anti-proliferative properties of the synthesized compounds were assessed <em>in vitro</em> against three tumor cell lines (MCF-7, HepG-2, and K-562). Compounds 8a (IC<sub>50</sub> = 0.6955, 0.1871, 0.1884 μM), 8b (IC<sub>50</sub> = 0.1908, 0.2242, 0.4642 μM), 8c (IC<sub>50</sub> = 0.1875, 0.7344, 0.5444 μM), 8e (IC<sub>50</sub> = 0.5523, 1.4357, 0.2664 μM), 9a (IC<sub>50</sub> = 0.2824, 0.1871, 0.3858 μM), 9b (IC<sub>50</sub> = 0.2090, 0.1944, 0.1902 μM), and 9d (IC<sub>50</sub> = 0.2042, 0.3227, 2.2742 μM) showed the highest levels of the cytotoxic activity against the cell lines under investigation respectively, with IC<sub>50</sub> values that were comparable to those of sorafenib (IC<sub>50</sub> = 0.1283, 0.0844, 0.0606 μM). Next, the inhibitory action against VEGFR-2 kinase activity was also estimated for the synthesized compounds to confirm their mechanism of action to induce antiproliferative actions. The cytotoxicity and VEGFR-2 inhibition results were highly consistent, identifying compounds 8a (IC<sub>50</sub> = 67.623, 74.864, 62.505 nM), 8b (IC<sub>50</sub> = 80.740, 88.327, 78.668 nM), 9a (IC<sub>50</sub> = 80.036, 85.240, 64.017 nM), 9b (IC<sub>50</sub> = 19.320, 66.436, 43.052 nM), and 9d (IC<sub>50</sub> = 47.042, 58.752, 80.182 nM) as top VEGFR-2 inhibitors comparing to sorafenib (IC<sub>50</sub> = 87.993, 92.775, 95.735 nM). In addition, the implemented comparative study against EGFR kinase activity specifies the inhibition of VEGFR-2 kinase activity as the major mechanism correlated to the cytotoxic activity of the synthesized compounds. Furthermore, extra mechanistic studies were conducted for the synthesized compounds, including cell cycle analysis that revealed the ability of compounds 8a and 9b to arrest the HepG-2 cells at the sub-G1 phase while increasing the population of the cells to 96.3% for 8a and 94.68% for 9b in comparison to the control 68.12%. Additionally, the titled compounds caused a significant decrease in Bcl-2 expression levels, a significant increase in caspase-3, caspase-9, and BAX gene expression levels, and a suppression of TNF-α and IL-6R protein levels, indicating their significant apoptotic impact. Ultimately, the synthesized compounds' high affinity and proper binding manner inside the VEGFR-2 active site were demonstrated by molecular docking modeling.</p></section><section class="abstract" id="abstract2"><hr class="headless">
<p>A novel series of quinazoline-based compounds were designed and synthesized as modified analogues to certain known VEGFR-2 inhibitors, as an extension of our work on the design and synthesis of new VEGFR-2 inhibitors.<img class="graphic" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/83ca/12377202/011a84839a66/d5ra03829d-ga.jpg" loading="lazy" id="ga" height="629" width="622" alt="graphic file with name d5ra03829d-ga.jpg"></p></section><section id="sec1"><h2 class="pmc_sec_title">1. Introduction</h2>
<p>Cancer is a disease defined by uncontrolled and excessively accelerated cell division and differentiation processes and cancerous cells have the propensity to invade or spread to other body areas through a process known as metastasis, which ultimately results in death.<sup><a href="#cit1" class="usa-link" aria-describedby="cit1">1</a></sup> Cancer cells are characterized by intercellular irregularities different than normal cells.<sup><a href="#cit2" class="usa-link" aria-describedby="cit2">2</a></sup> Cancerous cells must be close to blood vessels to gain access to the blood circulation system, since they require oxygen and nutrients to survive and grow uncontrollably.<sup><a href="#cit3" class="usa-link" aria-describedby="cit3">3</a></sup> Angiogenesis has long been recognized as a key component of tumor growth, progression, and metastasis.<sup><a href="#cit4" class="usa-link" aria-describedby="cit4">4</a></sup> Angiogenesis, the formation of new blood vessels from existing ones, is an essential process that occurs in all tumors for their progression into a clinically significant disease.<sup><a href="#cit5" class="usa-link" aria-describedby="cit5">5</a></sup> Inhibiting angiogenesis is a compelling strategy for creating potent anticancer drugs to treat a wide variety of cancers.<sup><a href="#cit6" class="usa-link" aria-describedby="cit6">6</a></sup> Angiogenesis is controlled by a variety of protein kinases, including growth factors.<sup><a href="#cit7" class="usa-link" aria-describedby="cit7">7</a></sup> Vascular endothelial growth factor (VEGF) is a tyrosine kinase that is important for controlling angiogenesis.<sup><a href="#cit8" class="usa-link" aria-describedby="cit8">8</a></sup> Its biological role includes regulating the formation of embryonic vessels and increasing vascular permeability, which in turn regulates all angiogenic processes implicated in various cancer types.<sup><a href="#cit9" class="usa-link" aria-describedby="cit9">9</a></sup> VEGFs interact with three different receptors (VEGFR-1, -2, and -3) to produce their angiogenic effects.<sup><a href="#cit10" class="usa-link" aria-describedby="cit10">10</a></sup> Nearly all solid tumors release VEGFR-2, the subtype that drives angiogenesis, in response to hypoxia.<sup><a href="#cit4" class="usa-link" aria-describedby="cit4">4</a></sup> Increased vascular density with an additional supply of oxygen and nutrients is linked to excessive VEGFR-2 expression levels, which are then followed by the growth, metastasis, and recurrence of cancer. The VEGF/VEGFR-2 pathway is consequently a highly effective target that selectively targets malignant cells instead of healthy cells.<sup><a href="#cit11" class="usa-link" aria-describedby="cit11">11</a></sup> In addition, the capacity of cancer cells to evade apoptosis is one of the main guarantees of cancer. Apoptosis, known as a process of planned cell death, is a series of metabolic responses that lead to particular cell alterations and eventual cell death.<sup><a href="#cit12" class="usa-link" aria-describedby="cit12">12</a></sup> There is strong evidence that blocking VEGFR-2 can directly stop the growth of tumors by triggering apoptosis without the need for angiogenesis.<sup><a href="#cit13" class="usa-link" aria-describedby="cit13">13</a></sup> From these verdicts, it is evident that one important strategy for finding new, powerful, and specific anticancer drugs is to disrupt the VEGF/VEGFR-2 signaling pathway.<sup><a href="#cit14" class="usa-link" aria-describedby="cit14">14</a></sup></p>
<p>Over the past few years, a wide range of VEGFR-2 inhibitors have been designed; these small molecules can inhibit the VEGFR-2 pathway, resulting in diminished VEGF signal transduction in cancer cells. These include sorafenib I,<sup><a href="#cit15" class="usa-link" aria-describedby="cit15">15</a></sup> sunitinib II,<sup><a href="#cit16" class="usa-link" aria-describedby="cit16">16</a></sup> tivozanib III,<sup><a href="#cit17" class="usa-link" aria-describedby="cit17">17</a></sup> lucitanib IV,<sup><a href="#cit18" class="usa-link" aria-describedby="cit18">18</a></sup> lenvatinib V,<sup><a href="#cit19" class="usa-link" aria-describedby="cit19">19</a></sup> and AZD-2923 VI.<sup><a href="#cit20" class="usa-link" aria-describedby="cit20">20</a></sup></p>
<p>These therapeutically prescribed VEGFR-2 inhibitors were linked to detrimental side effects, including back pain, neutropenia, thrombocytopenia, left ventricular dysfunction, hand-foot syndrome, diarrhea, exhaustion, itchy skin rash, hypothyroidism, hypertension, increased alkaline phosphatase, high bilirubin, elevated AST and ALT, and osteonecrosis.<sup><a href="#cit21" class="usa-link" aria-describedby="cit21">21–25</a></sup> These serious drawbacks come from the inability of traditionally used VEGFR-2 inhibitors to discriminate between cancerous and normal cell types, which is primarily linked to increased organ toxicity, a lack of cell selectivity, and a discernible propensity to cause the target cells to become resistant. Discovering harmless and effective VEGFR-2 targeted chemotherapeutic agents that prevent cancer growth is still a challenging area for medicinal chemist researchers.</p>
<p>For years, our research journey continued to discover new VEGFR-2 inhibitors as potent and safe anticancer agents. Our team utilized different scaffolds, including quinoxalines,<sup><a href="#cit26" class="usa-link" aria-describedby="cit26">26,27</a></sup> benzoxazoles,<sup><a href="#cit13" class="usa-link" aria-describedby="cit13">13,28</a></sup> thiazolidines,<sup><a href="#cit29" class="usa-link" aria-describedby="cit29">29,30</a></sup> and nicotinamides<sup><a href="#cit31" class="usa-link" aria-describedby="cit31">31–33</a></sup> for the synthesis of several VEGFR-2 inhibitors that showed promising anticancer activities.</p>
<p>Furthermore, the quinazoline nucleus represents the backbone of AZD-2932 VI (<a href="#fig2" class="usa-link">Fig. 2</a>)<sup><a href="#cit20" class="usa-link" aria-describedby="cit20">20</a></sup> and many other reported VEGFR-2 inhibitors.<sup><a href="#cit34" class="usa-link" aria-describedby="cit34">34–36</a></sup> It highlights how important the quinazoline nucleus is as a flat hetero aromatic moiety in inhibitors of VEGFR-2.</p>
<figure class="fig xbox font-sm" id="fig2"><h3 class="obj_head">Fig. 2. The proposed design of the target compounds.</h3>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=12377202_d5ra03829d-f2.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/83ca/12377202/bcadcb2f27a4/d5ra03829d-f2.jpg" loading="lazy" height="890" width="775" alt="Fig. 2"></a></p>
<div class="p text-right font-secondary"><a href="figure/fig2/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div></figure><p>In 2021,<sup><a href="#cit37" class="usa-link" aria-describedby="cit37">37</a></sup> considering AZD-2932 VI, a quinazoline-based VEGFR-2 inhibitor, as the lead molecule, we developed a number of quinazoline-based derivatives that function as VEGFR-2 inhibitors. Among the synthesized derivatives, compound VII was the most potent candidate, showing an IC<sub>50</sub> value of 4.6 ± 0.06 μM against VEGFR-2 kinase. Such a derivative presented strong cytotoxic activity, having IC<sub>50</sub> values of 17.23, 26.10, and 30.85 μg mL<sup>−1</sup> against HepG2, PC3, and MCF-7, respectively. It showed a significantly higher IC<sub>50</sub> against normal WI-38 cells (145.9 μM) than the IC<sub>50</sub><em>versus</em> cancer cell lines, exhibiting selectivity indices of 8.47, 5.59, and 4.73 to cell lines, respectively.</p>
<p>After that, in 2022, we simplified the previous derivative VII, designing a new series of quinazoline derivatives as anticancer agents that inhibit VEGFR-2 kinase. Compound VIII was the most active member, showing strong VEGFR-2 inhibition activity (IC<sub>50</sub> = 60.00 Nm). This compound demonstrated IC<sub>50</sub> values of 24.10, 40.90, and 33.40 μg mL<sup>−1</sup> against HepG2, PC3, and MCF-7 cancer cells, respectively. It showed selectivity indices of 9.22, 5.53, and 6.92 to cell lines, respectively, in comparison to normal cell WI-38 (IC<sub>50</sub> = 145.9 μM).<sup><a href="#cit2" class="usa-link" aria-describedby="cit2">2</a></sup></p>
<p>Depending on these promising results, and in continuation of our work for the development of new VEGFR-2 inhibitors having potent and selective anti-tumor activity, we utilized the encouraging lead compounds (VII and VIII) for the design and synthesis of a new series of quinazoline-based derivatives to act as VEGFR-2 inhibitors. The developed compounds were evaluated <em>in vitro</em> for their VEGFR-2 inhibitory properties and anti-proliferative effects against definite cancer cell lines. Also, the cytotoxicity against normal cells was evaluated to ensure the safety of the synthesized compounds. In addition, the apoptotic efficacy of the target compounds has been investigated by deep biological investigations, which found the expression levels of apoptotic proteins (caspase-3, caspase-9, BAX, Bcl-2, TNF-α, and IL-6R). Finally, the synthesized derivatives were tested <em>in silico via</em> molecular docking simulation to assess their VEGFR-2 inhibitory activities.</p>
<section id="sec2"><h3 class="pmc_sec_title">1.1. Rationale of molecular design</h3>
<p>An important pharmacophoric characteristics were reported for VEGFR-2 inhibitors,<sup><a href="#cit38" class="usa-link" aria-describedby="cit38">38–43</a></sup><a href="#fig1" class="usa-link">Fig. 1</a>. These features comprise: (i) a flat hetero aromatic ring that fits at the hinge region of the ATP domain and forms an essential hydrogen bond with Cys917,<sup><a href="#cit39" class="usa-link" aria-describedby="cit39">39</a></sup> (ii) linker group that spans the gap between the DFG domain and the hinge region and has a length of three to five carbon atoms,<sup><a href="#cit44" class="usa-link" aria-describedby="cit44">44</a></sup> (iii) a pharmacophore moiety functions as an H-bond donor and acceptor; this modulatory group was stabilized at the DFG motif area, generating at least two hydrogen bonds with the essential amino acid (Glu883 and Asp1044),<sup><a href="#cit45" class="usa-link" aria-describedby="cit45">45</a></sup> and lastly, (iv) a terminal hydrophobic moiety that forms tight hydrophobic contacts inside the allosteric hydrophobic pocket.<sup><a href="#cit46" class="usa-link" aria-describedby="cit46">46</a></sup></p>
<figure class="fig xbox font-sm" id="fig1"><h4 class="obj_head">Fig. 1. Sorafenib, as an FDA-approved anti-VEGFR-2, has the pharmacophoric features of VEGFR-2 inhibitors.</h4>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=12377202_d5ra03829d-f1.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/83ca/12377202/6f1dc13c119f/d5ra03829d-f1.jpg" loading="lazy" height="380" width="732" alt="Fig. 1"></a></p>
<div class="p text-right font-secondary"><a href="figure/fig1/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div></figure><p>In this current work, we modified the previous lead candidates (VII and VIII) in hopes of finding novel VEGFR-2 inhibitors. The modification of our lead compounds was carried out based on the outlined four VEGFR-2 pharmacophoric features, as follows: firstly, we maintain quinazoline-4(3<em>H</em>)-one as a heteroaromatic moiety. Utilizing the quinazoline nucleus in the strong AZD-2932 and other reported VEGFR-2 inhibitors indicates the importance and efficacy of such a nucleus as a head heteroaromatic ring. The selection of this moiety was predicated on bio-isosteric considerations. Quinazoline is a bicyclic heterocycle consisting of two fused six-membered rings, benzene, and pyrimidine, which is convenient to the large space of the ATP binding region.<sup><a href="#cit47" class="usa-link" aria-describedby="cit47">47</a></sup> Due to the presence of two nitrogen atoms, it mimics the function of the pyridine ring in sorafenib that fits into the adenine binding site, facilitating H-bonding in the hinge region. In addition, we made two different substitutions (nitro and/or chloro groups) at position-7 of quinazoline-4(3<em>H</em>)-one nucleus to explore the preference of the two substituents, establishing a reliable SAR. Secondly, we selected the amide group to be the pharmacophore moiety in the designed compounds; the amide pharmacophore functioned as an H-bond donor and acceptor in AZD-2932 VI, sunitinib II, and lucitanib IV. Thirdly, to establish hydrophobic interactions with the allosteric pocket, substituted and unsubstituted phenyl rings were intended as terminal hydrophobic groups. To illustrate how both substitution and electron density affect biological activity, various substituents were selected for the terminal phenyl ring. <a href="#fig2" class="usa-link">Fig. 2</a>.</p></section></section><section id="sec3"><h2 class="pmc_sec_title">2. Findings and discussion</h2>
<section id="sec4"><h3 class="pmc_sec_title">2.1. Chemistry</h3>
<p>The target compounds were synthesized following to methods demonstrated in <a href="#sch1" class="usa-link">Scheme 1</a>. Initially, 4-chloro(or 4-nitro)-2-amino-benzoic acid 1a,b was heated with formamide 2 to obtain substituted quinazoline-4(3<em>H</em>)-one 3a,b according to the reported procedure.<sup><a href="#cit48" class="usa-link" aria-describedby="cit48">48</a></sup> The obtained starting materials 3a,b were subsequently treated with potassium hydroxide to get the corresponding key potassium salts 4a,b.<sup><a href="#cit49" class="usa-link" aria-describedby="cit49">49</a></sup> On the other hand, following the reported procedure,<sup><a href="#cit43" class="usa-link" aria-describedby="cit43">43,50</a></sup> the un/-substituted aniline derivatives 5a–e were allowed to react with the commercially available chloroacetyl chloride 6 in DMF at cold conditions to produce the corresponding 2-chloro-<em>N</em>-phenylacetamide intermediates 7a–e, respectively. Finally, the potassium salts 4a,b; each separately, were heated in DMF with the appropriate phenylacetamide intermediates 7a–e to obtain the final target compounds 8a–e and 9a–e, respectively.</p>
<figure class="fig xbox font-sm" id="sch1"><h4 class="obj_head">Scheme 1. Synthetic pathways for the target compounds.</h4>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=12377202_d5ra03829d-s1.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/83ca/12377202/32af279ede43/d5ra03829d-s1.jpg" loading="lazy" height="979" width="788" alt="Scheme 1"></a></p>
<div class="p text-right font-secondary"><a href="figure/sch1/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div></figure><p>Spectral data verified the structures of final compounds 8a–e and 9a–e. These compounds displayed prominent bands in their IR spectra about 3992–3200 cm<sup>−1</sup>, which corresponded to NHs. Furthermore, the NMR spectra supported the assigned structures of the titled compounds, revealing the presence of a singlet peak identical to NH of the amide group at a range of <em>δ</em> 10.73–10.10 ppm and a sharp singlet peak at 4.86–5.03 ppm equivalent to the aliphatic CH<sub>2</sub> group. Increased integration of the aromatic protons, which corresponded to the extra phenyl ring, was also shown in NMR charts of the synthesized compounds. Moreover, <sup>13</sup>C NMR spectra of these derivatives revealed the appearance of a single peak at 48.17 to 49.50 ppm corresponding to the introduced CH<sub>2</sub> group of the 2-chloro-<em>N</em>-phenylacetamide moiety.</p></section><section id="sec5"><h3 class="pmc_sec_title">2.2. Biological testing</h3>
<section id="sec6"><h4 class="pmc_sec_title">2.2.1. 
<em>In vitro</em> anti-proliferative activities</h4>
<p>To evaluate the anti-proliferative properties of the produced compounds, three human cancer cell lines (MCF-7, breast cancer, HepG-2, hepatocellular carcinoma, and K-562, myelogenous leukemia) were used. Based on their VEGF overexpression,<sup><a href="#cit51" class="usa-link" aria-describedby="cit51">51–53</a></sup> the cell lines investigated were carefully selected. MTT assay was utilized in this test using sorafenib as a standard cytotoxic drug.<sup><a href="#cit42" class="usa-link" aria-describedby="cit42">42</a></sup> The results of cytotoxic activity recorded in <a href="#tab1" class="usa-link">Table 1</a> revealed that all synthesized compounds were very sensitive to all three tested cell lines.</p>
<section class="tw xbox font-sm" id="tab1"><h5 class="obj_head">Table 1. 
<em>In vitro</em> anti-proliferative activities of the synthesized compounds against cancerous MCF-7, HepG-2, K-562, and normal HEK-293 cell lines compared to sorafenib<a href="#tab1fna" class="usa-link"><sup>a</sup></a>.</h5>
<div class="tbl-box p" tabindex="0"><table class="content" frame="hsides" rules="groups">
<colgroup span="1">
<col span="1">
<col span="1">
<col span="1">
<col span="1">
<col span="1">
<col span="1">
<col span="1">
</colgroup>
<thead>
<tr><th colspan="7" rowspan="1">
<img class="graphic" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/83ca/12377202/416843a56036/d5ra03829d-u1.jpg" loading="lazy" id="ugr1" alt="graphic file with name d5ra03829d-u1.jpg">
</th></tr>
<tr>
<th rowspan="2" colspan="1">Comp.</th>
<th rowspan="2" colspan="1">R</th>
<th rowspan="2" colspan="1">R1</th>
<th colspan="3" rowspan="1">Cytotoxicity against cancer cells IC<sub>50</sub> (μM)</th>
<th rowspan="1" colspan="1">Cytotoxicity against normal cell IC<sub>50</sub> (μM)</th>
</tr>
<tr>
<th rowspan="1" colspan="1">MCF-7</th>
<th rowspan="1" colspan="1">HepG-2</th>
<th rowspan="1" colspan="1">K-562</th>
<th rowspan="1" colspan="1">HEK-293</th>
</tr>
</thead>
<tbody>
<tr>
<td rowspan="1" colspan="1">8a</td>
<td rowspan="1" colspan="1">7-Cl</td>
<td rowspan="1" colspan="1">H</td>
<td align="center" rowspan="1" colspan="1">0.6955 ± 0.0051</td>
<td align="center" rowspan="1" colspan="1">0.1871 ± 0.0018</td>
<td align="center" rowspan="1" colspan="1">0.1884 ± 0.0017</td>
<td rowspan="1" colspan="1">NTb</td>
</tr>
<tr>
<td rowspan="1" colspan="1">8b</td>
<td rowspan="1" colspan="1">7-Cl</td>
<td rowspan="1" colspan="1">2-Cl</td>
<td align="center" rowspan="1" colspan="1">0.1908 ± 0.0040</td>
<td align="center" rowspan="1" colspan="1">0.2242 ± 0.0017</td>
<td align="center" rowspan="1" colspan="1">0.4642 ± 0.003</td>
<td rowspan="1" colspan="1">NTb</td>
</tr>
<tr>
<td rowspan="1" colspan="1">8c</td>
<td rowspan="1" colspan="1">7-Cl</td>
<td rowspan="1" colspan="1">4-Cl</td>
<td align="center" rowspan="1" colspan="1">0.1875 ± 0.0026</td>
<td align="center" rowspan="1" colspan="1">0.7344 ± 0.0023</td>
<td align="center" rowspan="1" colspan="1">0.5444 ± 0.0032</td>
<td rowspan="1" colspan="1">NTb</td>
</tr>
<tr>
<td rowspan="1" colspan="1">8d</td>
<td rowspan="1" colspan="1">7-Cl</td>
<td rowspan="1" colspan="1">2,5-Di-Cl</td>
<td align="center" rowspan="1" colspan="1">0.7462 ± 0.0024</td>
<td align="center" rowspan="1" colspan="1">0.6358 ± 0.0060</td>
<td align="center" rowspan="1" colspan="1">1.6713 ± 0.1872</td>
<td rowspan="1" colspan="1">NTb</td>
</tr>
<tr>
<td rowspan="1" colspan="1">8e</td>
<td rowspan="1" colspan="1">7-Cl</td>
<td rowspan="1" colspan="1">3-Cl-4-F</td>
<td align="center" rowspan="1" colspan="1">0.5523 ± 0.0017</td>
<td align="center" rowspan="1" colspan="1">1.4357 ± 0.0073</td>
<td align="center" rowspan="1" colspan="1">0.2664 ± 0.0017</td>
<td rowspan="1" colspan="1">NTb</td>
</tr>
<tr>
<td rowspan="1" colspan="1">9a</td>
<td rowspan="1" colspan="1">7-NO<sub>2</sub>
</td>
<td rowspan="1" colspan="1">H</td>
<td align="center" rowspan="1" colspan="1">0.2824 ± 0.0014</td>
<td align="center" rowspan="1" colspan="1">0.1871 ± 0.0017</td>
<td align="center" rowspan="1" colspan="1">0.3858 ± 0.0032</td>
<td rowspan="1" colspan="1">NTb</td>
</tr>
<tr>
<td rowspan="1" colspan="1">9b</td>
<td rowspan="1" colspan="1">7-NO<sub>2</sub>
</td>
<td rowspan="1" colspan="1">2-Cl</td>
<td align="center" rowspan="1" colspan="1">0.2090 ± 0.0037</td>
<td align="center" rowspan="1" colspan="1">0.1944 ± 0.0066</td>
<td align="center" rowspan="1" colspan="1">0.1902 ± 0.0037</td>
<td align="center" rowspan="1" colspan="1">1.7468 ± 0.0026</td>
</tr>
<tr>
<td rowspan="1" colspan="1">9c</td>
<td rowspan="1" colspan="1">7-NO<sub>2</sub>
</td>
<td rowspan="1" colspan="1">4-Cl</td>
<td align="center" rowspan="1" colspan="1">0.6724 ± 0.0049</td>
<td align="center" rowspan="1" colspan="1">1.0001 ± 0.0049</td>
<td align="center" rowspan="1" colspan="1">0.5388 ± 0.0017</td>
<td rowspan="1" colspan="1">NTb</td>
</tr>
<tr>
<td rowspan="1" colspan="1">9d</td>
<td rowspan="1" colspan="1">7-NO<sub>2</sub>
</td>
<td rowspan="1" colspan="1">2,5-Di-Cl</td>
<td align="center" rowspan="1" colspan="1">0.2042 ± 0.0026</td>
<td align="center" rowspan="1" colspan="1">0.3227 ± 0.0029</td>
<td align="center" rowspan="1" colspan="1">2.2742 ± 0.0035</td>
<td rowspan="1" colspan="1">NTb</td>
</tr>
<tr>
<td rowspan="1" colspan="1">9e</td>
<td rowspan="1" colspan="1">7-NO<sub>2</sub>
</td>
<td rowspan="1" colspan="1">3-Cl-4-F</td>
<td align="center" rowspan="1" colspan="1">0.2314 ± 0.0023</td>
<td align="center" rowspan="1" colspan="1">1.5103 ± 0.0020</td>
<td align="center" rowspan="1" colspan="1">0.3469 ± 0.0029</td>
<td rowspan="1" colspan="1">NTb</td>
</tr>
<tr>
<td rowspan="1" colspan="1">Sorafenib</td>
<td rowspan="1" colspan="1">—</td>
<td rowspan="1" colspan="1">—</td>
<td align="center" rowspan="1" colspan="1">0.1283 ± 0.0031</td>
<td align="center" rowspan="1" colspan="1">0.0844 ± 0.0020</td>
<td align="center" rowspan="1" colspan="1">0.0606 ± 0.0026</td>
<td align="center" rowspan="1" colspan="1">0.1310 ± 0.0032</td>
</tr>
</tbody>
</table></div>
<div class="p text-right font-secondary"><a href="table/tab1/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<div class="tw-foot p"><div class="fn" id="tab1fna">
<sup>a</sup><p class="display-inline">NTb: not tested.</p>
</div></div></section><p>In detail, for anti-proliferative activity against MCF-7 cells, the results indicated that compounds 8b (IC<sub>50</sub> = 0.1908 μM) and 8c (IC<sub>50</sub> = 0.1875 μM), 9b (IC<sub>50</sub> = 0.2090 μM), and 9d (IC<sub>50</sub> = 0.2042 μM) were the most active members, showing strong anti-proliferative activity very close to that of sorafenib (IC<sub>50</sub> = 0.1283 μM). Besides, compounds 9a (IC<sub>50</sub> = 0.2824 μM) and 9e (IC<sub>50</sub> = 0.2314 μM) showed moderate anti-proliferative activities compared to sorafenib. However, compounds 8a (IC<sub>50</sub> = 0.6955 μM), 8d (IC<sub>50</sub> = 0.7462 μM), 8e (IC<sub>50</sub> = 0.5523 μM), and 9c (IC<sub>50</sub> = 0.6724 μM) showed the lowest cytotoxic activities against the MCF-7 cell line.</p>
<p>Concerning anti-proliferative activity against HepG-2 cells, the synthesized compounds showed less sensitivity compared to MCF-7 cells. Compounds 8a (IC<sub>50</sub> = 0.1871 μM), 8b (IC<sub>50</sub> = 0.2242 μM), 9a (IC<sub>50</sub> = 0.1871 μM), 9b (IC<sub>50</sub> = 0.1944 μM), and 9d (IC<sub>50</sub> = 0.3227 μM) were the most active members against the tested cell line compared to sorafenib (IC<sub>50</sub> = 0.0844 μM). Compounds 8c (IC<sub>50</sub> = 0.7344 μM) and 8d (IC<sub>50</sub> = 0.6358 μM), on the other hand, exhibited moderate activity against the HepG-2 cell line. Compounds 8e (IC<sub>50</sub> = 1.4357 μM), 9c (IC<sub>50</sub> = 1.0001 μM), and 9e (IC<sub>50</sub> = 1.5103 μM) appeared to be weak or inactive against the HepG-2 cell line.</p>
<p>With respect to anti-proliferative activity against leukemia cancer cells, K-562, the synthesized compounds showed sensitivity comparable to that of the MCF-7 cells. Particularly, compounds 8a (IC<sub>50</sub> = 0.1884 μM), 8e (IC<sub>50</sub> = 0.2664 μM), 9a (IC<sub>50</sub> = 0.3858 μM), 9b (IC<sub>50</sub> = 0.1902 μM), and 9e (IC<sub>50</sub> = 0.3469 μM) were the most anti-proliferative derivatives compared to sorafenib (IC<sub>50</sub> = 0.0606 μM). Moreover, compounds 8b (IC<sub>50</sub> = 0.4642 μM), 8c (IC<sub>50</sub> = 0.5444 μM), and 9c (IC<sub>50</sub> = 0.5388 μM) displayed modest cytotoxic effects. Finally, compounds 8d (IC<sub>50</sub> = 1.6713 μM) and 9d (IC<sub>50</sub> = 2.2742 μM) appeared to show no significant activity against K-562 cells.</p></section><section id="sec7"><h4 class="pmc_sec_title">2.2.2. Evaluation of cytotoxic action against normal cells</h4>
<p>One of the main requirements for anticancer drugs is to be safe and have the least side effects on normal cells. The cytotoxic activity of the most potent anti-proliferative candidate, 9b, was tested <em>in vitro</em> against Human Embryonic Kidney 293 cells (HEK-293) in order to determine the compounds' selectivity against cancer cells as opposed to healthy ones, referring to sorafenib.<sup><a href="#cit54" class="usa-link" aria-describedby="cit54">54</a></sup></p>
<p>The selectivity index (SI) was calculated as a ratio that measures the window between cytotoxicity (TOX) and anticancer activity (ACA) by dividing the given ACA value into the TOX value (ACA/TOX). The resulting IC<sub>50</sub> value (1.7468 μM, <a href="#tab1" class="usa-link">Table 1</a>) showed more cytotoxic activity against cancer cell lines MCF-7 (8.4-fold), HepG-2 (10-fold), and K-562 (9-fold) than against normal human kidney cells when compared to sorafenib (the corresponding IC<sub>50</sub> value was 0.1310 μM, 1-, 1.5-, and 2-fold against MCF-7, HepG-2, and K-562 respectively).</p></section><section id="sec8"><h4 class="pmc_sec_title">2.2.3. 
<em>In vitro</em> VEGFR-2 inhibitory assay</h4>
<p>Among the most cytotoxic compounds (8a, 8b, 8c, 8e, 9a, 9b, 9d, and 9e), five compounds 8a, 8b, 9a, 9b, and 9d were selected to be assayed for their inhibitory activity against VEGFR-2 kinase in the examined three cell lines (MCF-7, HepG-2, and K-562). This was accomplished to validate the proposed design of the synthesized compounds and to predict the possible mechanism responsible for their induced cytotoxicity.<sup><a href="#cit6" class="usa-link" aria-describedby="cit6">6</a></sup></p>
<p>Essentially, the results of the VEGFR-2 inhibitory assay (<a href="#tab2" class="usa-link">Table 2</a>) greatly matched those of cytotoxicity, confirming the cytotoxic mechanism of the designed compounds. The results indicated that all the target compounds conferred excellent VEGFR-2 inhibitory activities with IC<sub>50</sub> values exceeding that of the positive control sorafenib. Of all the prepared compounds, compound 9b was the most effective VEGFR-2 inhibitor; such derivative demonstrated strong VEGFR-2 inhibitory activity toward all examined cell lines MCF-7, HepG-2, and K-562 having IC<sub>50</sub> values of (19.320, 66.436, 43.052 nM) respectively, that far exceeding that of sorafenib (IC<sub>50</sub> = 87.993, 92.775, 95.735 nM). Compound 9d came second, displaying very strong VEGFR-2 inhibitory activity against MCF-7 and K-562 cells (IC<sub>50</sub> = 47.042 and 58.752 nM, respectively) and less activity against the HepG-2 cell line (IC<sub>50</sub> = 80.182 nM). Compound 8a was the third; such a compound revealed robust VEGFR-2 inhibitory activity against MCF-7, HepG-2, and K-562 with IC<sub>50</sub> values equal to (67.623, 74.864, 62.505 nM), respectively. The fourth order was for compound 9a, which showed strong inhibitory action against VEGFR-2 with IC<sub>50</sub> values of (80.036, 85.240, 64.017 nM) against MCF-7, HepG-2, and K-562, respectively. Finally, the last compound was 8b, which showed the least activity with IC<sub>50s</sub> of 80.740, 88.327, and 78.668 nM, against MCF-7, HepG-2, and K-562, respectively.</p>
<section class="tw xbox font-sm" id="tab2"><h5 class="obj_head">Table 2. Inhibitory effects of the most cytotoxic candidates and sorafenib on VEGFR-2.</h5>
<div class="tbl-box p" tabindex="0"><table class="content" frame="hsides" rules="groups">
<colgroup span="1">
<col span="1">
<col span="1">
<col span="1">
<col span="1">
</colgroup>
<thead>
<tr>
<th rowspan="2" colspan="1">Comp.</th>
<th colspan="3" rowspan="1">IC<sub>50</sub> (nM) VEGFR-2</th>
</tr>
<tr>
<th rowspan="1" colspan="1">MCF-7</th>
<th rowspan="1" colspan="1">HepG-2</th>
<th rowspan="1" colspan="1">K-562</th>
</tr>
</thead>
<tbody>
<tr>
<td rowspan="1" colspan="1">8a</td>
<td align="center" rowspan="1" colspan="1">67.623 ± 1.55</td>
<td align="center" rowspan="1" colspan="1">74.864 ± 1.22</td>
<td align="center" rowspan="1" colspan="1">62.505 ± 1.45</td>
</tr>
<tr>
<td rowspan="1" colspan="1">8b</td>
<td align="center" rowspan="1" colspan="1">80.740 ± 1.24</td>
<td align="center" rowspan="1" colspan="1">88.327 ± 138</td>
<td align="center" rowspan="1" colspan="1">78.668 ± 1.24</td>
</tr>
<tr>
<td rowspan="1" colspan="1">9a</td>
<td align="center" rowspan="1" colspan="1">80.036 ± 1.21</td>
<td align="center" rowspan="1" colspan="1">85.240 ± 1.34</td>
<td align="center" rowspan="1" colspan="1">64.017 ± 1.13</td>
</tr>
<tr>
<td rowspan="1" colspan="1">9b</td>
<td align="center" rowspan="1" colspan="1">19.320 ± 1.14</td>
<td align="center" rowspan="1" colspan="1">66.436 ± 1.12</td>
<td align="center" rowspan="1" colspan="1">43.052 ± 1.38</td>
</tr>
<tr>
<td rowspan="1" colspan="1">9d</td>
<td align="center" rowspan="1" colspan="1">47.042 ± 1.35</td>
<td align="center" rowspan="1" colspan="1">80.182 ± 1.35</td>
<td align="center" rowspan="1" colspan="1">58.752 ± 1.44</td>
</tr>
<tr>
<td rowspan="1" colspan="1">Sorafenib</td>
<td align="center" rowspan="1" colspan="1">87.993 ± 1.17</td>
<td align="center" rowspan="1" colspan="1">92.775 ± 1.29</td>
<td align="center" rowspan="1" colspan="1">95.735 ± 1.06</td>
</tr>
</tbody>
</table></div>
<div class="p text-right font-secondary"><a href="table/tab2/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div></section></section><section id="sec9"><h4 class="pmc_sec_title">2.2.4. Comparative study for EGFR kinase activity</h4>
<p>It is reported that overexpression of the receptor tyrosine kinase (RTK) proteins or functional alterations result in the expression of dysregulated cell growth and cancer.<sup><a href="#cit55" class="usa-link" aria-describedby="cit55">55</a></sup> Receptor tyrosine kinase (RTK) comprises subtypes, including growth factors (EGFR, VEGFR, PDGFR, FGFR, and ILGFR).<sup><a href="#cit39" class="usa-link" aria-describedby="cit39">39</a></sup> Due to the deep structure similarity of receptor tyrosine kinase subtypes, the anti-cancer drug can have several targets. To identify the inhibition of VEGFR-2 kinase activity as the major mechanism of action correlated to the cytotoxic effect of the synthesized compounds, further enzyme assay was performed for the most related enzymes exhibiting kinase activity, epidermal growth factor receptor (EGFR).</p>
<p>EGFR, the quintessential growth factor receptor tyrosine kinase (RTK), is a crucial component in the development of numerous deadly malignancies worldwide.<sup><a href="#cit56" class="usa-link" aria-describedby="cit56">56,57</a></sup> It is overexpressed in approximately 43–89% of many solid tumors, including hepatocellular, breast, colorectal, and ovarian malignancies.<sup><a href="#cit58" class="usa-link" aria-describedby="cit58">58</a></sup></p>
<p>Assaying the inhibition activity against EGFR kinase was conducted as a comparative study to specify the mechanism and measure the sensitivity of the synthesized compounds to the VEGFR-2 enzyme rather than other kinases comprising the EGFR enzyme.</p>
<p>From <a href="#tab3" class="usa-link">Table 3</a>, it is indicated that all selected compounds exhibited high IC<sub>50</sub> values in comparison to erlotinib as a standard EGFR inhibitor; however, they showed low IC<sub>50</sub> values very close to or may exceed that of sorafenib as a standard VEGFR inhibitor. We can infer from these findings that the prepared compounds were more sensitive to VEGFR kinase rather than EGFR kinase, so that VEGFR-2 inhibition activity may be the main possible mechanism for the cytotoxicity induced by the synthesized compounds.</p>
<section class="tw xbox font-sm" id="tab3"><h5 class="obj_head">Table 3. Comparative analysis of EGFR inhibitory activities of the most active compounds against sorafenib and erlotinib.</h5>
<div class="tbl-box p" tabindex="0"><table class="content" frame="hsides" rules="groups">
<colgroup span="1">
<col span="1">
<col span="1">
<col span="1">
<col span="1">
</colgroup>
<thead>
<tr>
<th rowspan="2" colspan="1">Comp.</th>
<th colspan="3" rowspan="1">IC<sub>50</sub> (nM) EGFR</th>
</tr>
<tr>
<th rowspan="1" colspan="1">MCF-7</th>
<th rowspan="1" colspan="1">HepG-2</th>
<th rowspan="1" colspan="1">K-562</th>
</tr>
</thead>
<tbody>
<tr>
<td rowspan="1" colspan="1">8a</td>
<td align="center" rowspan="1" colspan="1">79.758 ± 1.07</td>
<td align="center" rowspan="1" colspan="1">83.210 ± 1.38</td>
<td align="center" rowspan="1" colspan="1">66.098 ± 1.75</td>
</tr>
<tr>
<td rowspan="1" colspan="1">8b</td>
<td align="center" rowspan="1" colspan="1">81.264 ± 1.53</td>
<td align="center" rowspan="1" colspan="1">83.722 ± 1.82</td>
<td align="center" rowspan="1" colspan="1">82.695 ± 1.54</td>
</tr>
<tr>
<td rowspan="1" colspan="1">9a</td>
<td align="center" rowspan="1" colspan="1">80.437 ± 1.59</td>
<td align="center" rowspan="1" colspan="1">83.703 ± 1.57</td>
<td align="center" rowspan="1" colspan="1">78.046 ± 1.57</td>
</tr>
<tr>
<td rowspan="1" colspan="1">9b</td>
<td align="center" rowspan="1" colspan="1">74.708 ± 1.76</td>
<td align="center" rowspan="1" colspan="1">47.738 ± 2.25</td>
<td align="center" rowspan="1" colspan="1">52.544 ± 2.50</td>
</tr>
<tr>
<td rowspan="1" colspan="1">9d</td>
<td align="center" rowspan="1" colspan="1">69.774 ± 1.36</td>
<td align="center" rowspan="1" colspan="1">81.572 ± 2.83</td>
<td align="center" rowspan="1" colspan="1">83.362 ± 1.16</td>
</tr>
<tr>
<td rowspan="1" colspan="1">Erlotinib</td>
<td align="center" rowspan="1" colspan="1">33.671 ± 1.34</td>
<td align="center" rowspan="1" colspan="1">42.927 ± 1.68</td>
<td align="center" rowspan="1" colspan="1">42.238 ± 1.10</td>
</tr>
<tr>
<td rowspan="1" colspan="1">Sorafenib</td>
<td align="center" rowspan="1" colspan="1">84.190 ± 1.40</td>
<td align="center" rowspan="1" colspan="1">89.177 ± 1.32</td>
<td align="center" rowspan="1" colspan="1">92.484 ± 1.51</td>
</tr>
</tbody>
</table></div>
<div class="p text-right font-secondary"><a href="table/tab3/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div></section></section><section id="sec10"><h4 class="pmc_sec_title">2.2.5. Examination of the cell cycle</h4>
<p>In order to cause cytotoxicity, anticancer medicines must stop cell division at specific checkpoints, which are discrete stages of the cell cycle. Disturbing these phases leads to the loss of cellular functions, which significantly assured the great connection between the cell cycle and apoptosis.<sup><a href="#cit59" class="usa-link" aria-describedby="cit59">59</a></sup> To explore the phase at which the synthesized compounds terminate cell proliferation, cell cycle analysis was investigated for the most active compounds 8a and 9b on HepG-2 cells.</p>
<p>From <a href="#tab4" class="usa-link">Table 4</a>, it can be detected that compounds 8a and 9b stimulated a substantial increase in the cell population at the sub-G1 phase from 68.12% (in control cells) to 96.13% (for 8a) and 94.68% (for 9b). These compounds also caused a marked decrease in the population of HepG-2 cells at the phases G1, S, and G2/M. These results indicated that both compounds 8a and 9b were able to arrest the HepG-2 cells at the sub-G1 phase. <a href="#fig3" class="usa-link">Fig. 3</a>.</p>
<section class="tw xbox font-sm" id="tab4"><h5 class="obj_head">Table 4. Impact of compounds 8a and 9b on HepG-2 cell cycle progression.</h5>
<div class="tbl-box p" tabindex="0"><table class="content" frame="hsides" rules="groups">
<colgroup span="1">
<col span="1">
<col span="1">
<col span="1">
<col span="1">
<col span="1">
</colgroup>
<thead>
<tr>
<th rowspan="2" colspan="1">Sample</th>
<th colspan="4" rowspan="1">Cell cycle phases as a percentage</th>
</tr>
<tr>
<th rowspan="1" colspan="1">% Sub-G1</th>
<th rowspan="1" colspan="1">% G1</th>
<th rowspan="1" colspan="1">% S</th>
<th rowspan="1" colspan="1">% G2/M</th>
</tr>
</thead>
<tbody>
<tr>
<td rowspan="1" colspan="1">HepG-2 (control)</td>
<td align="center" rowspan="1" colspan="1">68.12</td>
<td align="center" rowspan="1" colspan="1">23.14</td>
<td align="center" rowspan="1" colspan="1">2.23</td>
<td align="center" rowspan="1" colspan="1">6.52</td>
</tr>
<tr>
<td rowspan="1" colspan="1">8a</td>
<td align="center" rowspan="1" colspan="1">96.13</td>
<td align="center" rowspan="1" colspan="1">3.19</td>
<td align="center" rowspan="1" colspan="1">0.52</td>
<td align="center" rowspan="1" colspan="1">0.16</td>
</tr>
<tr>
<td rowspan="1" colspan="1">9b</td>
<td align="center" rowspan="1" colspan="1">94.68</td>
<td align="center" rowspan="1" colspan="1">4.89</td>
<td align="center" rowspan="1" colspan="1">0.19</td>
<td align="center" rowspan="1" colspan="1">0.24</td>
</tr>
</tbody>
</table></div>
<div class="p text-right font-secondary"><a href="table/tab4/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div></section><figure class="fig xbox font-sm" id="fig3"><h5 class="obj_head">Fig. 3. Analysis of cell cycle phases in HepG-2 cells after compounds 8a (left) and 9b (right) treatment.</h5>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=12377202_d5ra03829d-f3.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/83ca/12377202/afc4b6ce4c39/d5ra03829d-f3.jpg" loading="lazy" height="1417" width="758" alt="Fig. 3"></a></p>
<div class="p text-right font-secondary"><a href="figure/fig3/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div></figure></section><section id="sec11"><h4 class="pmc_sec_title">2.2.6. Gene expression analysis for caspase-3, caspase-9, BAX, Bcl-2, TNF-a, and IL-6R</h4>
<p>Numerous mediators regulate the induction of apoptosis in cells. Protease caspases, particularly caspase-3 and caspase-9, which are important apoptosis regulators, are among these mediators.<sup><a href="#cit60" class="usa-link" aria-describedby="cit60">60</a></sup> Caspase-3 initiates extrinsic apoptosis execution, such as protease, leading to the disintegration of specific regulatory proteins required for the survival and upkeep of cells.<sup><a href="#cit61" class="usa-link" aria-describedby="cit61">61</a></sup> Caspase-9 triggers apoptosis by activating other executioner caspases, including caspase-3, -6, and -7, which cleave multiple additional cellular targets.<sup><a href="#cit62" class="usa-link" aria-describedby="cit62">62</a></sup> The apoptotic process is also mediated by BAX and Bcl-2, two mediators with conflicting functions. While BAX has a pro-apoptotic effect, Bcl-2 has an anti-apoptotic effect.<sup><a href="#cit63" class="usa-link" aria-describedby="cit63">63,64</a></sup> Cell fate is controlled by the ratio of pro-apoptotic to anti-apoptotic proteins (BAX/Bcl-2).<sup><a href="#cit6" class="usa-link" aria-describedby="cit6">6,65</a></sup> Moreover, the cytokine tumor necrosis factor-a (TNF-a) and interleukin-6 receptor (IL-6R) were reported to have pro-apoptotic effects.<sup><a href="#cit66" class="usa-link" aria-describedby="cit66">66,67</a></sup> The blockade of such mediators (TNF-a &amp; IL-6R) induced tumor cell apoptosis.<sup><a href="#cit67" class="usa-link" aria-describedby="cit67">67</a></sup></p>
<p>All synthesized compounds were tested at their cytotoxic concentrations in HepG-2 cells for analysis of gene expression levels of apoptotic markers caspase-3, caspase-9, TNF-α, and IL-6 proteins, and only two active compounds were tested for BAX and Bcl-2 proteins.</p>
<section id="sec12"><h5 class="pmc_sec_title">2.2.6.1. Impacts on the levels of the apoptotic markers (caspase-3 and caspase-9)</h5>
<p>In comparison to control cells, the results listed in <a href="#tab5" class="usa-link">Table 5</a> revealed that the synthesized compounds induced a marked increase in the gene expression levels of both caspase-3 and caspase-9 (<a href="#fig4" class="usa-link">Fig. 4</a>), indicating the significant apoptotic effect of the tested compounds. For activity toward caspase-3, compounds 8a, 8b, 8c, 8d, 8e, 9a, 9b, and 9c showed the highest expression level of the practiced protein with great folds of (3.30, 2.40, 2.72, 3.40, 3.35, 2.1, 2.35, and 3.85) respectively, while compounds 9d and 9e showed low-fold increase of (1.5, and 1.6-folds) respectively. Concerning activity against caspase-9, compounds 8a, 8b, 8c, 8d, 8e, 9a, 9c, 9d, and 9e were the most active members, causing an exceptional increase in caspase-9 expression levels with very high-folds of (6.72, 7.5, 2.5, 4.6, 4.4, 2.77, 6.37, 3.95, and 2.29) respectively. In contrast, compound 9b showed no apoptotic effect, opposing the caspase-9 protein.</p>
<section class="tw xbox font-sm" id="tab5"><h6 class="obj_head">Table 5. The effects of the synthesized compounds on levels of caspase-3, caspase-9, TNF-alpha, and IL-6R gene expression in HepG-2 cells.</h6>
<div class="tbl-box p" tabindex="0"><table class="content" frame="hsides" rules="groups">
<colgroup span="1">
<col span="1">
<col span="1">
<col span="1">
<col span="1">
<col span="1">
</colgroup>
<thead><tr>
<th rowspan="1" colspan="1">Sample</th>
<th rowspan="1" colspan="1">Caspase-3 (ng ml<sup>−1</sup>) ± SE</th>
<th rowspan="1" colspan="1">Caspase-9 (ng L<sup>−1</sup>) ± SE</th>
<th rowspan="1" colspan="1">TNF-alpha (ng L<sup>−1</sup>) ± SE</th>
<th rowspan="1" colspan="1">IL-6R (ng L<sup>−1</sup>) ± SE</th>
</tr></thead>
<tbody>
<tr>
<td rowspan="1" colspan="1">8a</td>
<td align="center" rowspan="1" colspan="1">1.52 ± 0.017</td>
<td align="center" rowspan="1" colspan="1">74.01 ± 3.92</td>
<td align="center" rowspan="1" colspan="1">14.37 ± 0.45</td>
<td align="center" rowspan="1" colspan="1">19.54 ± 1.62</td>
</tr>
<tr>
<td rowspan="1" colspan="1">8b</td>
<td align="center" rowspan="1" colspan="1">1.10 ± 0.046</td>
<td align="center" rowspan="1" colspan="1">83.31 ± 1.28</td>
<td align="center" rowspan="1" colspan="1">23.47 ± 0.56</td>
<td align="center" rowspan="1" colspan="1">24.59 ± 0.95</td>
</tr>
<tr>
<td rowspan="1" colspan="1">8c</td>
<td align="center" rowspan="1" colspan="1">1.25 ± 0.090</td>
<td align="center" rowspan="1" colspan="1">26.98 ± 1.30</td>
<td align="center" rowspan="1" colspan="1">9.13 ± 0.37</td>
<td align="center" rowspan="1" colspan="1">14.73 ± 1.06</td>
</tr>
<tr>
<td rowspan="1" colspan="1">8d</td>
<td align="center" rowspan="1" colspan="1">1.82 ± 0.047</td>
<td align="center" rowspan="1" colspan="1">50.58 ± 4.19</td>
<td align="center" rowspan="1" colspan="1">16.01 ± 1.33</td>
<td align="center" rowspan="1" colspan="1">10.13 ± 2.40</td>
</tr>
<tr>
<td rowspan="1" colspan="1">8e</td>
<td align="center" rowspan="1" colspan="1">1.54 ± 0.11</td>
<td align="center" rowspan="1" colspan="1">48.44 ± 1.24</td>
<td align="center" rowspan="1" colspan="1">32.07 ± 2.32</td>
<td align="center" rowspan="1" colspan="1">11.93 ± 0.25</td>
</tr>
<tr>
<td rowspan="1" colspan="1">9a</td>
<td align="center" rowspan="1" colspan="1">0.98 ± 0.04</td>
<td align="center" rowspan="1" colspan="1">30.57 ± 3.39</td>
<td align="center" rowspan="1" colspan="1">23.6 ± 1.35</td>
<td align="center" rowspan="1" colspan="1">26.0 ± 0.97</td>
</tr>
<tr>
<td rowspan="1" colspan="1">9b</td>
<td align="center" rowspan="1" colspan="1">1.08 ± 0.028</td>
<td align="center" rowspan="1" colspan="1">7.31 ± 0.93</td>
<td align="center" rowspan="1" colspan="1">27.34 ± 1.95</td>
<td align="center" rowspan="1" colspan="1">28.78 ± 1.23</td>
</tr>
<tr>
<td rowspan="1" colspan="1">9c</td>
<td align="center" rowspan="1" colspan="1">1.77 ± 0.08</td>
<td align="center" rowspan="1" colspan="1">70.03 ± 0.47</td>
<td align="center" rowspan="1" colspan="1">16.86 ± 2.39</td>
<td align="center" rowspan="1" colspan="1">11.87 ± 0.80</td>
</tr>
<tr>
<td rowspan="1" colspan="1">9d</td>
<td align="center" rowspan="1" colspan="1">0.68 ± 0.013</td>
<td align="center" rowspan="1" colspan="1">43.52 ± 3.69</td>
<td align="center" rowspan="1" colspan="1">10.2 ± 1.53</td>
<td align="center" rowspan="1" colspan="1">16.64 ± 0.83</td>
</tr>
<tr>
<td rowspan="1" colspan="1">9e</td>
<td align="center" rowspan="1" colspan="1">0.77 ± 0.069</td>
<td align="center" rowspan="1" colspan="1">25.20 ± 1.27</td>
<td align="center" rowspan="1" colspan="1">34.27 ± 1.94</td>
<td align="center" rowspan="1" colspan="1">25.25 ± 0.16</td>
</tr>
<tr>
<td rowspan="1" colspan="1">Control (HepG-2)</td>
<td align="center" rowspan="1" colspan="1">0.460 ± 0.013</td>
<td align="center" rowspan="1" colspan="1">11.01 ± 5.42</td>
<td align="center" rowspan="1" colspan="1">43.48 ± 0.67</td>
<td align="center" rowspan="1" colspan="1">44.10 ± 2.57</td>
</tr>
</tbody>
</table></div>
<div class="p text-right font-secondary"><a href="table/tab5/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div></section><figure class="fig xbox font-sm" id="fig4"><h6 class="obj_head">Fig. 4. The impact of the synthesized compounds on the levels of caspase-3, caspase-9, TNF-alpha, and IL-6R gene expression in HepG-2 cells.</h6>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=12377202_d5ra03829d-f4.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/83ca/12377202/9c88afff86ea/d5ra03829d-f4.jpg" loading="lazy" height="338" width="738" alt="Fig. 4"></a></p>
<div class="p text-right font-secondary"><a href="figure/fig4/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div></figure></section><section id="sec13"><h5 class="pmc_sec_title">2.2.6.2. Impacts on immunomodulatory protein levels (TNF-α and IL-6R)</h5>
<p>The examination of the <a href="#tab5" class="usa-link">Table 5</a> data indicated that the immunomodulatory proteins, TNF-α, and IL-6R were markedly inhibited by the synthesized compounds. Compounds 8a, 8b, 8c, 8d, 9a, 9b, 9c, and 9d were found to cause a marked inhibition of TNF-α expression levels down to (14.37%, 23.47%, 9.13%, 16.01%, 23.6%, 27.34%, 16.86%, and 10.2%) respectively comparing to the control (43.48%). Whereas compounds 8e and 9e caused mild inhibition to a percentage of (32.07% and 34.27%) respectively, <a href="#fig4" class="usa-link">Fig. 4</a>. On the other hand, the effect on IL-6R protein was demonstrated by compounds, 8a, 8c, 8d, 8e, 9c, and 9d as these compounds offered significant inhibition of IL-6R protein to the levels of (19.54%, 14.73%, 10.13%, 11.93%, 11.87%, and 16.64%) respectively comparing the control (44.10%). Other compounds 8b, 9a, 9b, and 9c exerted mild inhibition of IL-6R protein with level values of (24.59%, 26.05%, 28.78%, and 25.25%), respectively. <a href="#fig4" class="usa-link">Fig. 4</a>.</p></section><section id="sec14"><h5 class="pmc_sec_title">2.2.6.3. Effects on the BAX and Bcl-2 protein levels (BAX/Bcl-2 ratio)</h5>
<p>The listed data in <a href="#tab6" class="usa-link">Table 6</a> of studying the effect of the synthesized compounds 8a and 9a on the expression levels of the BAX and Bcl-2 proteins showed that the selected compound 9a triggered a great fold increase in BAX expression levels (6-fold) from 0.44 (control) to 2.65% in the treated cell. However, compound 8a produced a less-fold increase (3.8-fold) from 0.44 to 1.67%. In a related context, compound 9a stimulated a marked reduction in Bcl-2 expression level (2.8-fold) from 3.49 (control) to 1.23% thus BAX/Bcl-2 ratio will be elevated to 2.15% in comparison to the control 0.12% however compound 8a produced much reduction in Bcl-2 level (3.75-fold) from 3.49 (control) to 0.93 increasing the BAX/Bcl-2 ratio much less to be 1.77. <a href="#fig5" class="usa-link">Fig. 5</a>.</p>
<section class="tw xbox font-sm" id="tab6"><h6 class="obj_head">Table 6. The effects of compounds 8a and 9a on levels of BAX and Bcl-2 gene expression in HepG-2 cells.</h6>
<div class="tbl-box p" tabindex="0"><table class="content" frame="hsides" rules="groups">
<colgroup span="1">
<col span="1">
<col span="1">
<col span="1">
<col span="1">
</colgroup>
<thead>
<tr>
<th rowspan="2" colspan="1">Sample</th>
<th colspan="3" rowspan="1">Gene expression (fold change)</th>
</tr>
<tr>
<th rowspan="1" colspan="1">BAX</th>
<th rowspan="1" colspan="1">Bcl-2</th>
<th rowspan="1" colspan="1">BAX/Bcl-2 ratio</th>
</tr>
</thead>
<tbody>
<tr>
<td rowspan="1" colspan="1">8a</td>
<td align="center" rowspan="1" colspan="1">1.6792 ± 0.74</td>
<td align="center" rowspan="1" colspan="1">0.9352 ± 0.09</td>
<td align="center" rowspan="1" colspan="1">1.7777 ± 0.11</td>
</tr>
<tr>
<td rowspan="1" colspan="1">9a</td>
<td align="center" rowspan="1" colspan="1">2.6533 ± 0.40</td>
<td align="center" rowspan="1" colspan="1">1.2368 ± 0.30</td>
<td align="center" rowspan="1" colspan="1">2.1544 ± 0.96</td>
</tr>
<tr>
<td rowspan="1" colspan="1">Control (HepG-2)</td>
<td align="center" rowspan="1" colspan="1">0.4448 ± 0.16</td>
<td align="center" rowspan="1" colspan="1">3.4983 ± 0.80</td>
<td align="center" rowspan="1" colspan="1">0.1260 ± 0.17</td>
</tr>
</tbody>
</table></div>
<div class="p text-right font-secondary"><a href="table/tab6/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div></section><figure class="fig xbox font-sm" id="fig5"><h6 class="obj_head">Fig. 5. The impact of compounds 8a and 9a on HepG-2 cell expression levels of the BAX and Bcl-2 genes.</h6>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=12377202_d5ra03829d-f5.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/83ca/12377202/a35889278184/d5ra03829d-f5.jpg" loading="lazy" height="343" width="738" alt="Fig. 5"></a></p>
<div class="p text-right font-secondary"><a href="figure/fig5/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div></figure></section></section><section id="sec15"><h4 class="pmc_sec_title">2.2.7. Structure–activity relationship</h4>
<p>The favorable outcomes of the cytotoxicity and well-matched VEGFR-2 inhibition experiment provided a useful structure–activity relationship for the synthesized compounds. The SAR of the synthesized compounds was principally built on the results of cytotoxicity and thoroughly examined in conjunction with the pharmacophoric features described in the rational design of the target compounds as VEGFR-2 inhibitors. Concerning the first feature of selecting a hetero aromatic ring to fit the hinge region, we can categorize the synthesized compounds into two scaffolds, scaffold-1 for compounds bearing 7-Cl-quinazolin-4(3<em>H</em>)-one moiety, and scaffold-2 for compounds containing 7-NO<sub>2</sub>-quinazolin-4(3<em>H</em>)-one moiety. The other defined features, including the linker and pharmacophore moiety (HBA + HBD), were kept unchanged for all synthesized compounds. Next, there is a reliable SAR of the synthesized compounds that can be established based on different substitutions at the hydrophobic tail moiety. So, as an assumption, the SAR of the target compounds can be instituted based on modification carried out on the hydrophobic tail in relation to substitutions of quinazoline-4(3<em>H</em>)-one moiety at 7-position with NO<sub>2</sub> and/or Cl groups.</p>
<p>In exploring the effect of the hydrophobic tail as a key parameter affecting the activity of the synthesized compounds, it was primarily found that the activity fluctuated or was nearly more active than for the derivatives tailed with un-substituted terminal phenyl ring than those with substituted ones, this was achieved for the two scaffolds of our designed compounds, as example compounds 8a (scaffold-1) and compound 9a (scaffold-2) appeared to be more active than other derivatives. Then we studied the effect of substitution on the terminal phenyl ring; the activity depended on the nature of substituents as well as the site of the substitution as follows: Upon fixing the nature of the substituents (to be electron withdrawing group in all designed compounds) while changing the site of substitution, we can assume mainly that the activity fluctuated for mono and di-substitution with difficulty to determine the predominance of one compound over another. Then, by comparing the cytotoxicity of di-substituent derivatives as compounds 8d and 8e (scaffold-1) with that of their corresponding compounds 9d and 9e (in scaffold-2), we can conclude that 7-NO<sub>2</sub>-quinazolin-4(3<em>H</em>)-one moiety containing derivatives were more favorable than compounds with 7-Cl-quinazolin-4(3<em>H</em>)-one moiety. Within the di-substitutions category, the cytotoxic efficacy oscillated between similar and dissimilar substituents, which was confirmed by observing the IC<sub>50</sub> values of compounds 9d and 9e against the examined cell lines. For mono substations with the same group (Cl-group, it was found that substitutions at ortho-position and para-position were with equal potency for scaffold-1(compounds 8b and 8c); however, with priority for <em>para</em>-position over <em>ortho</em>-position for scaffold-2 (9c more active than 9b).</p></section></section><section id="sec16"><h3 class="pmc_sec_title">2.3. Molecular docking studies</h3>
<p>Molecular docking modeling sheds light on the drug–receptor interactions and its affinity to a specific target.<sup><a href="#cit68" class="usa-link" aria-describedby="cit68">68</a></sup> Higher binding energy and a binding manner similar to the reference ligand are indicative of promising biological activity.<sup><a href="#cit68" class="usa-link" aria-describedby="cit68">68</a></sup> Docking investigations of the recently synthesized derivatives were implemented to identify the orientations of these compounds and their suggested binding mode at the ATP binding site of the VEGFR-2 kinase enzyme (PDB ID: 4ASD).<sup><a href="#cit14" class="usa-link" aria-describedby="cit14">14</a></sup> Sorafenib was utilized as a reference compound.</p>
<p>Initially, the validation procedure was carried out to confirm the docking algorithm's legitimacy. This was succeeded by re-docking the co-crystallized ligand inside the active pocket of the target protein. Achieving a low root mean square deviation (RMSD = 0.79), together with a proportionate superimposition in orientation between the native and re-docked poses, guaranteed the efficient operation of the employed protocol for the intended docking of molecules (Fig. S1 in the SI).</p>
<p>After the validation step, the proposed docking protocol was initially run to obtain the reported binding mode of the sorafenib.<sup><a href="#cit2" class="usa-link" aria-describedby="cit2">2,69</a></sup> Such a binding pattern showed an ideal and tight interaction of sorafenib as a standard VEGFR-2 inhibitor within the active site of the VEGFR-2 (<em>S</em> score = −25.17 kcal mol<sup>−1</sup>). The binding mode of sorafenib presented the essential three hydrogen bonds for binding inside the VEGFR-2 active pocket. It formed one H-bond with amino acid Cys917 at the hinge region and another two with Glu883 &amp; Asp1044 in the DFG-binding domain. In addition, it facilitated various hydrophobic interactions at the hinge region, spacer region, and terminal allosteric site, forming strong interactions with the target protein (Fig. S2 in the SI).</p>
<p>The newly synthesized compounds were then docked into the VEGFR-2 active pocket to estimate their binding modes and interactions in comparison to sorafenib. <a href="#tab7" class="usa-link">Table 7</a> summarizes the binding scores of the tested ligands, and their binding characteristics within the target protein's active region are illustrated.</p>
<section class="tw xbox font-sm" id="tab7"><h4 class="obj_head">Table 7. The binding scores of the target compounds and sorafenib against VEGFR-2 (4ASD) (computed as Δ<em>G</em> in kcal mol<sup>−1</sup>).</h4>
<div class="tbl-box p" tabindex="0"><table class="content" frame="hsides" rules="groups">
<colgroup span="1">
<col span="1">
<col span="1">
<col span="1">
<col span="1">
</colgroup>
<thead><tr>
<th rowspan="1" colspan="1">Comp.</th>
<th rowspan="1" colspan="1">Δ<em>G</em> [kcal mol<sup>−1</sup>]</th>
<th rowspan="1" colspan="1">Comp.</th>
<th rowspan="1" colspan="1">Δ<em>G</em> [kcal mol<sup>−1</sup>]</th>
</tr></thead>
<tbody>
<tr>
<td rowspan="1" colspan="1">8a</td>
<td align="center" rowspan="1" colspan="1">−18.40</td>
<td rowspan="1" colspan="1">9a</td>
<td align="center" rowspan="1" colspan="1">−14.53</td>
</tr>
<tr>
<td rowspan="1" colspan="1">8b</td>
<td align="center" rowspan="1" colspan="1">−17.89</td>
<td rowspan="1" colspan="1">9b</td>
<td align="center" rowspan="1" colspan="1">−14.82</td>
</tr>
<tr>
<td rowspan="1" colspan="1">8c</td>
<td align="center" rowspan="1" colspan="1">−17.25</td>
<td rowspan="1" colspan="1">9c</td>
<td align="center" rowspan="1" colspan="1">−16.49</td>
</tr>
<tr>
<td rowspan="1" colspan="1">8d</td>
<td align="center" rowspan="1" colspan="1">−10.69</td>
<td rowspan="1" colspan="1">9d</td>
<td align="center" rowspan="1" colspan="1">−13.39</td>
</tr>
<tr>
<td rowspan="1" colspan="1">8e</td>
<td align="center" rowspan="1" colspan="1">−14.25</td>
<td rowspan="1" colspan="1">9e</td>
<td align="center" rowspan="1" colspan="1">−16.08</td>
</tr>
<tr>
<td rowspan="1" colspan="1">Sorafenib</td>
<td align="center" rowspan="1" colspan="1">−25.17</td>
<td rowspan="1" colspan="1">—</td>
<td rowspan="1" colspan="1">—</td>
</tr>
</tbody>
</table></div>
<div class="p text-right font-secondary"><a href="table/tab7/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div></section><p>According to the docking studies, the proposed compounds interacted with crucial amino acids similarly to sorafenib and exhibited a high affinity toward the VEGFR-2 active site. The most cytotoxic derivatives (8a, 8b, 9a, and 9b) were chosen for examination.</p>
<p>Investigation of the highest-scoring pose of compound 8a revealed that it had a promising binding pattern similar to sorafenib, with an affinity value of −18.40 kcal mol<sup>−1</sup>. This compound interacts closely with the ATP binding domain of VEGFR-2 at the DFG region, establishing two hydrogen bonds with the essential amino acids Glu885 and Asp1046. In addition to the amide moiety achieving its required job as a pharmacophore, it also formed an extra hydrophobic interaction with Cys1045. Furthermore, the quinazoline ring fits the hinge region quite well. It stabilized at this head <em>via</em> two hydrophobic interactions with Asp1046, even though it lost interaction with the essential amino acid Cys919. Finally, the terminal phenyl ring traveled to the allosteric site, and it strongly bonded <em>via</em> hydrophobic interactions with Val916, Val899, and Lys868 <a href="#fig6" class="usa-link">Fig. 6</a>.</p>
<figure class="fig xbox font-sm" id="fig6"><h4 class="obj_head">Fig. 6. (A) 3D binding mode of compound 8a into VEGFR-2. (B) 2D binding mode of compound 8a into VEGFR-2.</h4>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=12377202_d5ra03829d-f6.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/83ca/12377202/b743c8208710/d5ra03829d-f6.jpg" loading="lazy" height="968" width="787" alt="Fig. 6"></a></p>
<div class="p text-right font-secondary"><a href="figure/fig6/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div></figure><p>Concerning the binding mode of compound 8b, such a derivative has significant docking scores of −17.89 kcal mol; it fits well into the enzyme active pocket in a way like sorafenib. The hinge area was occupied by the quinazoline moiety, which created hydrophobic contacts with Cys1045 and Asp1046 while losing hydrogen bond formation with Cys919. Additionally, the amide moiety was delivered to the DFG region, forming the two essential hydrogen bonds with Glu885 and Asp1046 amino acids. Finally, the terminal allosteric binding area was efficiently captured by the 2-chlorophenyl moiety of the designed compound, this hydrophobic tail created strong hydrophobic interactions with Val899, Ile890, Lys868, Val914, Val916, and Leu889 <a href="#fig7" class="usa-link">Fig. 7</a>.</p>
<figure class="fig xbox font-sm" id="fig7"><h4 class="obj_head">Fig. 7. (A) 3D binding mode of compound 8b into VEGFR-2. (B) 2D binding mode of compound 8b into VEGFR-2.</h4>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=12377202_d5ra03829d-f7.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/83ca/12377202/2beee7c159df/d5ra03829d-f7.jpg" loading="lazy" height="864" width="787" alt="Fig. 7"></a></p>
<div class="p text-right font-secondary"><a href="figure/fig7/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div></figure><p>Similar to the co-crystallized ligand, the proposed molecule 9a replicated the essential interactions. Such a compound could tightly bind to the receptor with a binding affinity value of −14.53 kcal mol<sup>−1</sup>. In the way that it is binding, the quinazoline head occupied the hinge region and was well bound through hydrophobic interaction with Asp1046, Asp814, and His1026 in addition to electrostatic attraction with Arg1027 and Asp814. Moreover, the amide group acted as an H-bond donor and acceptor and formed two hydrogen bonds, one with Glu885 and another with Asp1046. An unsubstituted phenyl ring interacted hydrophobically with Val899, lys868, and Val916 to engage the terminal allosteric hydrophobic site <a href="#fig8" class="usa-link">Fig. 8</a>.</p>
<figure class="fig xbox font-sm" id="fig8"><h4 class="obj_head">Fig. 8. (A) 3D binding mode of compound 9a into VEGFR-2. (B) 2D binding mode of compound 9a into VEGFR-2.</h4>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=12377202_d5ra03829d-f8.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/83ca/12377202/a65829a6c91a/d5ra03829d-f8.jpg" loading="lazy" height="855" width="787" alt="Fig. 8"></a></p>
<div class="p text-right font-secondary"><a href="figure/fig8/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div></figure><p>Finally, the binding affinity of component 9b was −14.82 (kcal mol<sup>−1</sup>). It interacted with a receptor in a binding manner like that of sorafenib. The quinazoline head of this compound was attached to the hinge region and stabilized through electrostatic attraction between the oxygen atom of the NO<sub>2</sub> group and Arg1027. In addition, the amide group was involved in hydrogen bonding interactions with Glu885 and Asp1046 at the DGF motif. The terminal tail, the 2-chloro phenyl ring, was well tailored in the allosteric site by the formation of several hydrophobic interactions with Val899, Lys868, Val916, and Cys1045 <a href="#fig9" class="usa-link">Fig. 9</a>.</p>
<figure class="fig xbox font-sm" id="fig9"><h4 class="obj_head">Fig. 9. (A) 3D binding mode of compound 9b into VEGFR-2. (B) 2D binding mode of compound 9b into VEGFR-2.</h4>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=12377202_d5ra03829d-f9.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/83ca/12377202/756ca3f8df1e/d5ra03829d-f9.jpg" loading="lazy" height="929" width="795" alt="Fig. 9"></a></p>
<div class="p text-right font-secondary"><a href="figure/fig9/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div></figure></section></section><section id="sec17"><h2 class="pmc_sec_title">3. Conclusion</h2>
<p>In this work, new quinazoline-based series were synthesized as modified analogues of our previously prepared VEGFR-2 inhibitors. The synthesized derivatives were designed to have the basic pharmacophoric features of the reported VEGFR-2 inhibitors and then evaluated for their anticancer activities as well as their inhibition actions against VEGFR-2 kinase. All synthesized derivatives displayed promising antiproliferative activities against three human tumor cell lines (MCF-7, HepG-2, and K-562). Particularly, compounds 8a, 8b, 8c, 8e, 9a, 9b, 9d, and 9e were the most active cytotoxic members compared to sorafenib. Correspondingly, the synthesized candidates displayed strong inhibition effects toward VEGFR-2 kinase activity; compounds 8a, 8b, 9a, 9b, and 9d were the most potent VEGFR-2 inhibitors. In addition, a definite comparative study was performed against EGFR kinase activity, which specifies the VEGFR-2 inhibition activity as the foremost mechanism for the cytotoxicities of the synthesized compounds. Furthermore, deep biological studies were conducted for the synthesized compounds to confirm their substantial apoptotic effect. This includes cell cycle analysis that demonstrated the ability of compounds 8a and 9b to arrest the HepG-2 cells with a high population at the sub-G1 phase. Also, the synthesized compounds induced a marked increase in the gene expression levels of caspase-3, caspase-9, and BAX, with a significant reduction in Bcl-2 expression level as well as marked inhibition of TNF-α and IL-6R proteins. Furthermore, the docking results assured high affinity of the synthesized compounds for VEGFR-2 kinase enzyme, exhibiting a binding mode like that of sorafenib. These biological and <em>in silico</em> results greatly supported the accessibility of the work design that represents the quinazoline-based derivatives as a chemical scaffold that may be used to develop novel VEGFR-2 inhibitors with effective anticancer properties. In the future development of this work, we must overcome the limitations of this study, which include improving the design of the target compound to be completely matched with the assigned features of the reported VEGFR-2 inhibitors. This can be achieved through maintaining the quinazoline scaffold while elongating the designed compounds by inserting a linker moiety. Also, extra biological studies concerning VEGFR-2 inhibition must be included in the future study to further confirm the approachability of the quinazoline-based derivatives to act as good VEGFR-2 inhibitors.</p></section><section id="sec18"><h2 class="pmc_sec_title">4. Experimental</h2>
<section id="sec19"><h3 class="pmc_sec_title">4.1. Chemistry and materials</h3>
<p>The solvents and equipment used in the synthesis and characterization of the target compounds are shown in the Supplementary data. Utilizing the reported methods, compounds 3a,b,<sup><a href="#cit48" class="usa-link" aria-describedby="cit48">48</a></sup>4a,b,<sup><a href="#cit70" class="usa-link" aria-describedby="cit70">70</a></sup> and 7a–e (ref. <a href="#cit43" class="usa-link" aria-describedby="cit43">43</a>) were prepared.</p>
<section id="sec20"><h4 class="pmc_sec_title">4.1.1. General procedure for the synthesis of target compounds 8a–e and 9a–e</h4>
<p>A proper amount of 2-chloro-<em>N</em>-phenylacetamide intermediates 7a–e, each was added to a mixture containing an equimolar amount of every potassium salt 4a and 4b separately (0.5 g, 0.0022 mol) dissolved in DMF (10 mL) with the presence of a catalytic amount of KI (0.5 g). The reaction mixture was heated for 2 h, then poured into cold water after the reaction was finished. The resulting precipitate was filtered and crystallized from ethanol to provide the corresponding final target compounds 8a–e and 9a–e, respectively.</p>
<section id="sec21"><h5 class="pmc_sec_title">4.1.1.1. 2-(7-Chloro-4-oxoquinazolin-3(4<em>H</em>)-yl)-<em>N</em>-phenylacetamide (8a)</h5>
<p>Pale yellow crystal (yield, 85%); m.p. = 265–268 °C; IR (KBr) <em>ν</em> cm<sup>−1</sup>: 3322, 3267 (NH), 3042 (CH aromatic), 2977 (CH aliphatic), 1668, 1631 (C<span aria-roledescription="private character" aria-label="DOUBLE BOND, LENGTH AS M-DASH" aria-description="double bond, length as m-dash">

<svg xmlns="http://www.w3.org/2000/svg" version="1.0" width="13.200000pt" height="16.000000pt" viewBox="0 0 13.200000 16.000000" preserveAspectRatio="xMidYMid meet"><metadata>
Created by potrace 1.16, written by Peter Selinger 2001-2019
</metadata><g transform="translate(1.000000,15.000000) scale(0.017500,-0.017500)" fill="currentColor" stroke="none"><path d="M0 440 l0 -40 320 0 320 0 0 40 0 40 -320 0 -320 0 0 -40z M0 280 l0 -40 320 0 320 0 0 40 0 40 -320 0 -320 0 0 -40z"/></g></svg>

</span>O), 1584 (C<span aria-roledescription="private character" aria-label="DOUBLE BOND, LENGTH AS M-DASH" aria-description="double bond, length as m-dash">

<svg xmlns="http://www.w3.org/2000/svg" version="1.0" width="13.200000pt" height="16.000000pt" viewBox="0 0 13.200000 16.000000" preserveAspectRatio="xMidYMid meet"><metadata>
Created by potrace 1.16, written by Peter Selinger 2001-2019
</metadata><g transform="translate(1.000000,15.000000) scale(0.017500,-0.017500)" fill="currentColor" stroke="none"><path d="M0 440 l0 -40 320 0 320 0 0 40 0 40 -320 0 -320 0 0 -40z M0 280 l0 -40 320 0 320 0 0 40 0 40 -320 0 -320 0 0 -40z"/></g></svg>

</span>N); <sup>1</sup>H NMR (400 MHz, DMSO-<em>d</em><sub>6</sub>) <em>δ</em> 10.44 (s, 1H, NH), 8.42 (s, 1H, N<span aria-roledescription="private character" aria-label="DOUBLE BOND, LENGTH AS M-DASH" aria-description="double bond, length as m-dash">

<svg xmlns="http://www.w3.org/2000/svg" version="1.0" width="13.200000pt" height="16.000000pt" viewBox="0 0 13.200000 16.000000" preserveAspectRatio="xMidYMid meet"><metadata>
Created by potrace 1.16, written by Peter Selinger 2001-2019
</metadata><g transform="translate(1.000000,15.000000) scale(0.017500,-0.017500)" fill="currentColor" stroke="none"><path d="M0 440 l0 -40 320 0 320 0 0 40 0 40 -320 0 -320 0 0 -40z M0 280 l0 -40 320 0 320 0 0 40 0 40 -320 0 -320 0 0 -40z"/></g></svg>

</span>CH–N), 8.15 (d, <em>J</em> = 8.6 Hz, 1H, CH quinaz.), 7.80 (d, <em>J</em> = 2.1 Hz, 1H, CH quinaz.), 7.59 (m, 3H, CH aromatic), 7.35–7.30 (m, 2H, CH quinaz.), 7.07 (m, <em>J</em> = 7.3, 1.2 Hz, 1H, CH aromatic), 4.87 (s, 2H, CH<sub>2</sub>); <sup>13</sup>C NMR (101 MHz, DMSO-<em>d</em><sub>6</sub>) <em>δ</em> 165.69, 160.19, 150.65, 150.41, 149.67, 139.66, 139.05, 129.42, 128.71, 127.95, 126.97, 124.17, 120.74, 119.55 (2C), 49.30; anal. calcd for C<sub>16</sub>H<sub>12</sub>ClN<sub>3</sub>O<sub>2</sub> (313.74): C, 61.25; H, 3.86; N, 13.39; found C, 61.13; H, 4.05; N, 13.62%.</p></section><section id="sec22"><h5 class="pmc_sec_title">4.1.1.2. 2-(7-Chloro-4-oxoquinazolin-3(4<em>H</em>)-yl)-<em>N</em>-(2-chlorophenyl)acetamide (8b)</h5>
<p>Off-white crystal (yield, 73%); m.p. = 290–292 °C; IR (KBr) <em>ν</em> cm<sup>−1</sup>: 3328 (NH), 3066 (CH aromatic), 2917 (CH aliphatic), 1692, 1651 (C<span aria-roledescription="private character" aria-label="DOUBLE BOND, LENGTH AS M-DASH" aria-description="double bond, length as m-dash">

<svg xmlns="http://www.w3.org/2000/svg" version="1.0" width="13.200000pt" height="16.000000pt" viewBox="0 0 13.200000 16.000000" preserveAspectRatio="xMidYMid meet"><metadata>
Created by potrace 1.16, written by Peter Selinger 2001-2019
</metadata><g transform="translate(1.000000,15.000000) scale(0.017500,-0.017500)" fill="currentColor" stroke="none"><path d="M0 440 l0 -40 320 0 320 0 0 40 0 40 -320 0 -320 0 0 -40z M0 280 l0 -40 320 0 320 0 0 40 0 40 -320 0 -320 0 0 -40z"/></g></svg>

</span>O), 1598 (C<span aria-roledescription="private character" aria-label="DOUBLE BOND, LENGTH AS M-DASH" aria-description="double bond, length as m-dash">

<svg xmlns="http://www.w3.org/2000/svg" version="1.0" width="13.200000pt" height="16.000000pt" viewBox="0 0 13.200000 16.000000" preserveAspectRatio="xMidYMid meet"><metadata>
Created by potrace 1.16, written by Peter Selinger 2001-2019
</metadata><g transform="translate(1.000000,15.000000) scale(0.017500,-0.017500)" fill="currentColor" stroke="none"><path d="M0 440 l0 -40 320 0 320 0 0 40 0 40 -320 0 -320 0 0 -40z M0 280 l0 -40 320 0 320 0 0 40 0 40 -320 0 -320 0 0 -40z"/></g></svg>

</span>N); <sup>1</sup>H NMR (400 MHz, DMSO-<em>d</em><sub>6</sub>) <em>δ</em> 10.10 (s, 1H, NH), 8.45 (s, 1H, N<span aria-roledescription="private character" aria-label="DOUBLE BOND, LENGTH AS M-DASH" aria-description="double bond, length as m-dash">

<svg xmlns="http://www.w3.org/2000/svg" version="1.0" width="13.200000pt" height="16.000000pt" viewBox="0 0 13.200000 16.000000" preserveAspectRatio="xMidYMid meet"><metadata>
Created by potrace 1.16, written by Peter Selinger 2001-2019
</metadata><g transform="translate(1.000000,15.000000) scale(0.017500,-0.017500)" fill="currentColor" stroke="none"><path d="M0 440 l0 -40 320 0 320 0 0 40 0 40 -320 0 -320 0 0 -40z M0 280 l0 -40 320 0 320 0 0 40 0 40 -320 0 -320 0 0 -40z"/></g></svg>

</span>CH–N), 8.16 (d, <em>J</em> = 8.6 Hz, 1H, CH quinaz.), 7.79 (d, <em>J</em> = 2.1 Hz, 1H, CH quinaz.), 7.74 (dd, <em>J</em> = 8.1, 1.6 Hz, 1H, CH quinaz.), 7.61 (dd, <em>J</em> = 8.6, 2.1 Hz, 1H, CH aromatic), 7.52 (dd, <em>J</em> = 8.0, 1.5 Hz, 1H, CH aromatic), 7.33 (dd, <em>J</em> = 7.7, 1.5 Hz, 1H, CH aromatic), 7.21(dd, <em>J</em> = 7.7, 1.6 Hz, 1H, CH aromatic), 4.99 (s, 2H, CH<sub>2</sub>); <sup>13</sup>C NMR (101 MHz, DMSO-<em>d</em><sub>6</sub>) <em>δ</em> 166.44, 160.15, 150.50, 149.64, 139.64, 134.82, 130.08, 128.64, 127.97, 127.93, 127.00, 126.92, 126.60, 126.35, 120.74, 49.09; anal. calcd for C<sub>16</sub>H<sub>11</sub>Cl<sub>2</sub>N<sub>3</sub>O<sub>2</sub> (348.18): C, 55.19; H, 3.18; N, 12.07; found C, 55.40; H, 3.29; N, 12.25%.</p></section><section id="sec23"><h5 class="pmc_sec_title">4.1.1.3. 2-(7-Chloro-4-oxoquinazolin-3(4<em>H</em>)-yl)-<em>N</em>-(4-chlorophenyl)acetamide (8c)</h5>
<p>Yellow crystal (yield, 82%); m.p. = 280–282 °C; IR (KBr) <em>ν</em> cm<sup>−1</sup>: 3310 (NH), 3077 (CH aromatic), 2959 (CH aliphatic), 1651 (C<span aria-roledescription="private character" aria-label="DOUBLE BOND, LENGTH AS M-DASH" aria-description="double bond, length as m-dash">

<svg xmlns="http://www.w3.org/2000/svg" version="1.0" width="13.200000pt" height="16.000000pt" viewBox="0 0 13.200000 16.000000" preserveAspectRatio="xMidYMid meet"><metadata>
Created by potrace 1.16, written by Peter Selinger 2001-2019
</metadata><g transform="translate(1.000000,15.000000) scale(0.017500,-0.017500)" fill="currentColor" stroke="none"><path d="M0 440 l0 -40 320 0 320 0 0 40 0 40 -320 0 -320 0 0 -40z M0 280 l0 -40 320 0 320 0 0 40 0 40 -320 0 -320 0 0 -40z"/></g></svg>

</span>O), 1599 (C<span aria-roledescription="private character" aria-label="DOUBLE BOND, LENGTH AS M-DASH" aria-description="double bond, length as m-dash">

<svg xmlns="http://www.w3.org/2000/svg" version="1.0" width="13.200000pt" height="16.000000pt" viewBox="0 0 13.200000 16.000000" preserveAspectRatio="xMidYMid meet"><metadata>
Created by potrace 1.16, written by Peter Selinger 2001-2019
</metadata><g transform="translate(1.000000,15.000000) scale(0.017500,-0.017500)" fill="currentColor" stroke="none"><path d="M0 440 l0 -40 320 0 320 0 0 40 0 40 -320 0 -320 0 0 -40z M0 280 l0 -40 320 0 320 0 0 40 0 40 -320 0 -320 0 0 -40z"/></g></svg>

</span>N); <sup>1</sup>H NMR (400 MHz, DMSO-<em>d</em><sub>6</sub>) <em>δ</em> 10.59 (s, 1H, NH), 8.42 (s, 1H, N<span aria-roledescription="private character" aria-label="DOUBLE BOND, LENGTH AS M-DASH" aria-description="double bond, length as m-dash">

<svg xmlns="http://www.w3.org/2000/svg" version="1.0" width="13.200000pt" height="16.000000pt" viewBox="0 0 13.200000 16.000000" preserveAspectRatio="xMidYMid meet"><metadata>
Created by potrace 1.16, written by Peter Selinger 2001-2019
</metadata><g transform="translate(1.000000,15.000000) scale(0.017500,-0.017500)" fill="currentColor" stroke="none"><path d="M0 440 l0 -40 320 0 320 0 0 40 0 40 -320 0 -320 0 0 -40z M0 280 l0 -40 320 0 320 0 0 40 0 40 -320 0 -320 0 0 -40z"/></g></svg>

</span>CH–N), 8.14 (d, <em>J</em> = 8.5 Hz, 1H, CH quinaz.), 7.80 (d, <em>J</em> = 2.0 Hz, 1H, CH quinaz.), 7.63–7.59 (m, 3H, CH aromatic &amp; CH quinaz.), 7.40–7.36 (m, 2H, CH aromatic), 4.86 (s, 2H, CH<sub>2</sub>); <sup>13</sup>C NMR (101 MHz, DMSO-<em>d</em><sub>6</sub>) <em>δ</em> 165.40, 159.69, 149.98, 149.17, 139.20, 137.49, 128.81 (2C) 128.14, 127.49, 127.18, 126.46, 120.65 (2C), 120.23, 48.84; anal. calcd for C<sub>16</sub>H<sub>11</sub>Cl<sub>2</sub>N<sub>3</sub>O<sub>2</sub> (348.18): C, 55.19; H, 3.18; N, 12.07; found C, 55.37; H, 3.40; N, 12.31%.</p></section><section id="sec24"><h5 class="pmc_sec_title">4.1.1.4. 2-(7-Chloro-4-oxoquinazolin-3(4<em>H</em>)-yl)-<em>N</em>-(2,6-dichlorophenyl)acetamide (8d)</h5>
<p>White crystal (yield, 87%); m.p. = 260–263 °C; IR (KBr) <em>ν</em> cm<sup>−1</sup>: 3313, 3200 (NH), 3082 (CH aromatic), 2947 (CH aliphatic), 1690, 1670 (C<span aria-roledescription="private character" aria-label="DOUBLE BOND, LENGTH AS M-DASH" aria-description="double bond, length as m-dash">

<svg xmlns="http://www.w3.org/2000/svg" version="1.0" width="13.200000pt" height="16.000000pt" viewBox="0 0 13.200000 16.000000" preserveAspectRatio="xMidYMid meet"><metadata>
Created by potrace 1.16, written by Peter Selinger 2001-2019
</metadata><g transform="translate(1.000000,15.000000) scale(0.017500,-0.017500)" fill="currentColor" stroke="none"><path d="M0 440 l0 -40 320 0 320 0 0 40 0 40 -320 0 -320 0 0 -40z M0 280 l0 -40 320 0 320 0 0 40 0 40 -320 0 -320 0 0 -40z"/></g></svg>

</span>O), 1602 (C<span aria-roledescription="private character" aria-label="DOUBLE BOND, LENGTH AS M-DASH" aria-description="double bond, length as m-dash">

<svg xmlns="http://www.w3.org/2000/svg" version="1.0" width="13.200000pt" height="16.000000pt" viewBox="0 0 13.200000 16.000000" preserveAspectRatio="xMidYMid meet"><metadata>
Created by potrace 1.16, written by Peter Selinger 2001-2019
</metadata><g transform="translate(1.000000,15.000000) scale(0.017500,-0.017500)" fill="currentColor" stroke="none"><path d="M0 440 l0 -40 320 0 320 0 0 40 0 40 -320 0 -320 0 0 -40z M0 280 l0 -40 320 0 320 0 0 40 0 40 -320 0 -320 0 0 -40z"/></g></svg>

</span>N); <sup>1</sup>H NMR (400 MHz, DMSO-<em>d</em><sub>6</sub>) <em>δ</em> 10.39 (s, 1H, NH), 8.44 (s, 1H, N<span aria-roledescription="private character" aria-label="DOUBLE BOND, LENGTH AS M-DASH" aria-description="double bond, length as m-dash">

<svg xmlns="http://www.w3.org/2000/svg" version="1.0" width="13.200000pt" height="16.000000pt" viewBox="0 0 13.200000 16.000000" preserveAspectRatio="xMidYMid meet"><metadata>
Created by potrace 1.16, written by Peter Selinger 2001-2019
</metadata><g transform="translate(1.000000,15.000000) scale(0.017500,-0.017500)" fill="currentColor" stroke="none"><path d="M0 440 l0 -40 320 0 320 0 0 40 0 40 -320 0 -320 0 0 -40z M0 280 l0 -40 320 0 320 0 0 40 0 40 -320 0 -320 0 0 -40z"/></g></svg>

</span>CH–N), 8.17 (d, <em>J</em> = 8.5 Hz, 1H, CH quinaz.), 7.79 (d, <em>J</em> = 2.1 Hz, 1H, CH quinaz.), 7.62–7.53 (m, 3H, CH aromatic &amp; CH quinaz.), 7.39–7.33 (m, 1H, CH aromatic), 4.96 (s, 2H, CH<sub>2</sub>); <sup>13</sup>C NMR (101 MHz, DMSO-<em>d</em><sub>6</sub>) <em>δ</em> 166.09, 160.01, 150.41, 150.32, 149.61, 139.62, 133.95 (2C), 132.74, 129.89, 129.05 (2C), 127.93, 126.92, 120.78, 48.39; anal. aalcd for C<sub>16</sub>H<sub>10</sub>Cl<sub>3</sub>N<sub>3</sub>O<sub>2</sub> (382.63): C, 50.23; H, 2.63; N, 10.98; found C, 50.41; H, 2.89; N, 11.20%.</p></section><section id="sec25"><h5 class="pmc_sec_title">4.1.1.5. 
<em>N</em>-(3-Chloro-4-fluorophenyl)-2-(7-chloro-4-oxoquinazolin-3(4<em>H</em>)-yl)acetamide (8e)</h5>
<p>Pale yellow crystal (yield, 85%); m.p. = 175–177 °C; IR (KBr) <em>ν</em> cm<sup>−1</sup>: 3353, 3322 (NH), 3067 (CH aromatic), 2954 (CH aliphatic), 1692, 1674 (C<span aria-roledescription="private character" aria-label="DOUBLE BOND, LENGTH AS M-DASH" aria-description="double bond, length as m-dash">

<svg xmlns="http://www.w3.org/2000/svg" version="1.0" width="13.200000pt" height="16.000000pt" viewBox="0 0 13.200000 16.000000" preserveAspectRatio="xMidYMid meet"><metadata>
Created by potrace 1.16, written by Peter Selinger 2001-2019
</metadata><g transform="translate(1.000000,15.000000) scale(0.017500,-0.017500)" fill="currentColor" stroke="none"><path d="M0 440 l0 -40 320 0 320 0 0 40 0 40 -320 0 -320 0 0 -40z M0 280 l0 -40 320 0 320 0 0 40 0 40 -320 0 -320 0 0 -40z"/></g></svg>

</span>O), 1600 (C<span aria-roledescription="private character" aria-label="DOUBLE BOND, LENGTH AS M-DASH" aria-description="double bond, length as m-dash">

<svg xmlns="http://www.w3.org/2000/svg" version="1.0" width="13.200000pt" height="16.000000pt" viewBox="0 0 13.200000 16.000000" preserveAspectRatio="xMidYMid meet"><metadata>
Created by potrace 1.16, written by Peter Selinger 2001-2019
</metadata><g transform="translate(1.000000,15.000000) scale(0.017500,-0.017500)" fill="currentColor" stroke="none"><path d="M0 440 l0 -40 320 0 320 0 0 40 0 40 -320 0 -320 0 0 -40z M0 280 l0 -40 320 0 320 0 0 40 0 40 -320 0 -320 0 0 -40z"/></g></svg>

</span>N); <sup>1</sup>H NMR (400 MHz, DMSO-<em>d</em><sub>6</sub>) <em>δ</em> 10.69 (s, 1H, NH), 8.43 (s, 1H, N<span aria-roledescription="private character" aria-label="DOUBLE BOND, LENGTH AS M-DASH" aria-description="double bond, length as m-dash">

<svg xmlns="http://www.w3.org/2000/svg" version="1.0" width="13.200000pt" height="16.000000pt" viewBox="0 0 13.200000 16.000000" preserveAspectRatio="xMidYMid meet"><metadata>
Created by potrace 1.16, written by Peter Selinger 2001-2019
</metadata><g transform="translate(1.000000,15.000000) scale(0.017500,-0.017500)" fill="currentColor" stroke="none"><path d="M0 440 l0 -40 320 0 320 0 0 40 0 40 -320 0 -320 0 0 -40z M0 280 l0 -40 320 0 320 0 0 40 0 40 -320 0 -320 0 0 -40z"/></g></svg>

</span>CH–N), 8.15 (d, <em>J</em> = 8.6 Hz, 1H, CH quinaz.), 7.89 (dd, <em>J</em> = 6.8, 2.5 Hz, 1H, CH quinaz.), 7.80 (d, <em>J</em> = 2.0 Hz, 1H, CH quinaz.), 7.61 (dd, <em>J</em> = 8.6, 2.1 Hz, 1H, CH aromatic), 7.48–7.38 (m, 1H, CH aromatic), 7.40 (m, <em>J</em> = 9.1 Hz, 1H, CH aromatic), 4.87 (s, 2H, CH<sub>2</sub>); <sup>13</sup>C NMR (101 MHz, DMSO-<em>d</em><sub>6</sub>) <em>δ</em> 166.07, 160.18, 150.41, 149.63, 139.70, 136.25, 128.61, 127.99, 126.95, 121.02, 120.69, 119.93, 119.86, 117.73, 117.52, 49.31; anal. calcd for C<sub>16</sub>H<sub>10</sub>Cl<sub>2</sub>FN<sub>3</sub>O<sub>2</sub> (366.17): C, 52.48; H, 2.75; N, 11.48; found C, 52.67; H, 2.98; N, 11.75%.</p></section><section id="sec26"><h5 class="pmc_sec_title">4.1.1.6. 2-(7-Nitro-4-oxoquinazolin-3(4<em>H</em>)-yl)-<em>N</em>-phenylacetamide (9a)</h5>
<p>Off-white crystal (yield, 74%); m.p. = 245–248 °C; IR (KBr) <em>ν</em> cm<sup>−1</sup>: 3459 (NH), 3061 (CH aromatic), 2977 (CH aliphatic), 1701, 1664 (C<span aria-roledescription="private character" aria-label="DOUBLE BOND, LENGTH AS M-DASH" aria-description="double bond, length as m-dash">

<svg xmlns="http://www.w3.org/2000/svg" version="1.0" width="13.200000pt" height="16.000000pt" viewBox="0 0 13.200000 16.000000" preserveAspectRatio="xMidYMid meet"><metadata>
Created by potrace 1.16, written by Peter Selinger 2001-2019
</metadata><g transform="translate(1.000000,15.000000) scale(0.017500,-0.017500)" fill="currentColor" stroke="none"><path d="M0 440 l0 -40 320 0 320 0 0 40 0 40 -320 0 -320 0 0 -40z M0 280 l0 -40 320 0 320 0 0 40 0 40 -320 0 -320 0 0 -40z"/></g></svg>

</span>O), 1619 (C<span aria-roledescription="private character" aria-label="DOUBLE BOND, LENGTH AS M-DASH" aria-description="double bond, length as m-dash">

<svg xmlns="http://www.w3.org/2000/svg" version="1.0" width="13.200000pt" height="16.000000pt" viewBox="0 0 13.200000 16.000000" preserveAspectRatio="xMidYMid meet"><metadata>
Created by potrace 1.16, written by Peter Selinger 2001-2019
</metadata><g transform="translate(1.000000,15.000000) scale(0.017500,-0.017500)" fill="currentColor" stroke="none"><path d="M0 440 l0 -40 320 0 320 0 0 40 0 40 -320 0 -320 0 0 -40z M0 280 l0 -40 320 0 320 0 0 40 0 40 -320 0 -320 0 0 -40z"/></g></svg>

</span>N); <sup>1</sup>H NMR (400 MHz, DMSO-<em>d</em><sub>6</sub>) <em>δ</em> 10.48 (s, 1H, NH), 8.56 (s, 1H, N<span aria-roledescription="private character" aria-label="DOUBLE BOND, LENGTH AS M-DASH" aria-description="double bond, length as m-dash">

<svg xmlns="http://www.w3.org/2000/svg" version="1.0" width="13.200000pt" height="16.000000pt" viewBox="0 0 13.200000 16.000000" preserveAspectRatio="xMidYMid meet"><metadata>
Created by potrace 1.16, written by Peter Selinger 2001-2019
</metadata><g transform="translate(1.000000,15.000000) scale(0.017500,-0.017500)" fill="currentColor" stroke="none"><path d="M0 440 l0 -40 320 0 320 0 0 40 0 40 -320 0 -320 0 0 -40z M0 280 l0 -40 320 0 320 0 0 40 0 40 -320 0 -320 0 0 -40z"/></g></svg>

</span>CH–N), 8.45 (d, <em>J</em> = 2.2 Hz, 1H, CH quinaz.), 8.39 (d, <em>J</em> = 8.7 Hz, 1H, CH quinaz.), 8.30 (dd, <em>J</em> = 8.8, 2.3 Hz, 1H, CH quinaz.), 7.59 (d, <em>J</em> = 8.0 Hz, 2H, CH aromatic), 7.33 (m, <em>J</em> = 7.7 Hz, 2H, CH aromatic), 7.08 (m, <em>J</em> = 7.4 Hz, 1H, CH aromatic), 4.93 (s, 2H, CH<sub>2</sub>); <sup>13</sup>C NMR (101 MHz, DMSO-<em>d</em><sub>6</sub>) <em>δ</em> 165.45, 159.86, 151.70, 151.13, 148.91, 139.00, 129.43, 129.38, 129.32, 126.10, 122.94, 122.76, 121.24, 119.58 (2C), 49.50; anal. calcd for C<sub>16</sub>H<sub>12</sub>N<sub>4</sub>O<sub>4</sub> (324.30): C, 59.26; H, 3.73; N, 17.28; found C, 59.37; H, 3.96; N, 17.46%.</p></section><section id="sec27"><h5 class="pmc_sec_title">4.1.1.7. 
<em>N</em>-(2-Chlorophenyl)-2-(7-nitro-4-oxoquinazolin-3(4<em>H</em>)-yl)acetamide (9b)</h5>
<p>Greenish white crystal (yield, 65%); m.p. = 265–266 °C; IR (KBr) <em>ν</em> cm<sup>−1</sup>: 3992 (CH aromatic), 2892 (CH aliphatic), 1696, 1658 (C<span aria-roledescription="private character" aria-label="DOUBLE BOND, LENGTH AS M-DASH" aria-description="double bond, length as m-dash">

<svg xmlns="http://www.w3.org/2000/svg" version="1.0" width="13.200000pt" height="16.000000pt" viewBox="0 0 13.200000 16.000000" preserveAspectRatio="xMidYMid meet"><metadata>
Created by potrace 1.16, written by Peter Selinger 2001-2019
</metadata><g transform="translate(1.000000,15.000000) scale(0.017500,-0.017500)" fill="currentColor" stroke="none"><path d="M0 440 l0 -40 320 0 320 0 0 40 0 40 -320 0 -320 0 0 -40z M0 280 l0 -40 320 0 320 0 0 40 0 40 -320 0 -320 0 0 -40z"/></g></svg>

</span>O), 1586 (C<span aria-roledescription="private character" aria-label="DOUBLE BOND, LENGTH AS M-DASH" aria-description="double bond, length as m-dash">

<svg xmlns="http://www.w3.org/2000/svg" version="1.0" width="13.200000pt" height="16.000000pt" viewBox="0 0 13.200000 16.000000" preserveAspectRatio="xMidYMid meet"><metadata>
Created by potrace 1.16, written by Peter Selinger 2001-2019
</metadata><g transform="translate(1.000000,15.000000) scale(0.017500,-0.017500)" fill="currentColor" stroke="none"><path d="M0 440 l0 -40 320 0 320 0 0 40 0 40 -320 0 -320 0 0 -40z M0 280 l0 -40 320 0 320 0 0 40 0 40 -320 0 -320 0 0 -40z"/></g></svg>

</span>N); <sup>1</sup>H NMR (400 MHz, DMSO-<em>d</em><sub>6</sub>) <em>δ</em> 10.13 (s, 1H, NH), 8.57 (s, 1H, N<span aria-roledescription="private character" aria-label="DOUBLE BOND, LENGTH AS M-DASH" aria-description="double bond, length as m-dash">

<svg xmlns="http://www.w3.org/2000/svg" version="1.0" width="13.200000pt" height="16.000000pt" viewBox="0 0 13.200000 16.000000" preserveAspectRatio="xMidYMid meet"><metadata>
Created by potrace 1.16, written by Peter Selinger 2001-2019
</metadata><g transform="translate(1.000000,15.000000) scale(0.017500,-0.017500)" fill="currentColor" stroke="none"><path d="M0 440 l0 -40 320 0 320 0 0 40 0 40 -320 0 -320 0 0 -40z M0 280 l0 -40 320 0 320 0 0 40 0 40 -320 0 -320 0 0 -40z"/></g></svg>

</span>CH–N), 8.50–8.35 (m, 2H, CH aromatic), 8.30 (dd, <em>J</em> = 8.8, 2.3 Hz, 1H, CH quinaz.), 7.73 (d, <em>J</em> = 8.1 Hz, 1H, CH quinaz.), 7.53 (d, <em>J</em> = 8.0 Hz, 1H, CH quinaz.), 7.34 (m, <em>J</em> = 7.6 Hz, 1H, CH aromatic), 7.22 (m, <em>J</em> = 7.8 Hz, 1H, CH aromatic), 5.03 (s, 2H, CH<sub>2</sub>); <sup>13</sup>C NMR (101 MHz, DMSO-<em>d</em><sub>6</sub>) <em>δ</em> 166.21, 159.83, 151.69, 151.22, 148.89, 134.77, 130.10, 128.92, 127.99, 127.07, 126.64, 126.39, 126.12, 122.85, 121.35, 49.31; anal. calcd for C<sub>16</sub>H<sub>11</sub>ClN<sub>4</sub>O<sub>4</sub> (358.74): C, 53.57; H, 3.09; N, 15.62; found C, 53.81; H, 3.26; N, 15.84%.</p></section><section id="sec28"><h5 class="pmc_sec_title">4.1.1.8. 
<em>N</em>-(4-Chlorophenyl)-2-(7-nitro-4-oxoquinazolin-3(4<em>H</em>)-yl)acetamide (9c)</h5>
<p>Pale yellow crystal (yield, 95%); m.p. = 255–258 °C; IR (KBr) <em>ν</em> cm<sup>−1</sup>: 3302 (NH), 3069 (CH aromatic), 2981(CH aliphatic), 1643 (C<span aria-roledescription="private character" aria-label="DOUBLE BOND, LENGTH AS M-DASH" aria-description="double bond, length as m-dash">

<svg xmlns="http://www.w3.org/2000/svg" version="1.0" width="13.200000pt" height="16.000000pt" viewBox="0 0 13.200000 16.000000" preserveAspectRatio="xMidYMid meet"><metadata>
Created by potrace 1.16, written by Peter Selinger 2001-2019
</metadata><g transform="translate(1.000000,15.000000) scale(0.017500,-0.017500)" fill="currentColor" stroke="none"><path d="M0 440 l0 -40 320 0 320 0 0 40 0 40 -320 0 -320 0 0 -40z M0 280 l0 -40 320 0 320 0 0 40 0 40 -320 0 -320 0 0 -40z"/></g></svg>

</span>O), 1599 (C<span aria-roledescription="private character" aria-label="DOUBLE BOND, LENGTH AS M-DASH" aria-description="double bond, length as m-dash">

<svg xmlns="http://www.w3.org/2000/svg" version="1.0" width="13.200000pt" height="16.000000pt" viewBox="0 0 13.200000 16.000000" preserveAspectRatio="xMidYMid meet"><metadata>
Created by potrace 1.16, written by Peter Selinger 2001-2019
</metadata><g transform="translate(1.000000,15.000000) scale(0.017500,-0.017500)" fill="currentColor" stroke="none"><path d="M0 440 l0 -40 320 0 320 0 0 40 0 40 -320 0 -320 0 0 -40z M0 280 l0 -40 320 0 320 0 0 40 0 40 -320 0 -320 0 0 -40z"/></g></svg>

</span>N); <sup>1</sup>H NMR (400 MHz, DMSO-<em>d</em><sub>6</sub>) <em>δ</em> 10.63 (s, 1H, NH), 8.55 (s, 1H, N<span aria-roledescription="private character" aria-label="DOUBLE BOND, LENGTH AS M-DASH" aria-description="double bond, length as m-dash">

<svg xmlns="http://www.w3.org/2000/svg" version="1.0" width="13.200000pt" height="16.000000pt" viewBox="0 0 13.200000 16.000000" preserveAspectRatio="xMidYMid meet"><metadata>
Created by potrace 1.16, written by Peter Selinger 2001-2019
</metadata><g transform="translate(1.000000,15.000000) scale(0.017500,-0.017500)" fill="currentColor" stroke="none"><path d="M0 440 l0 -40 320 0 320 0 0 40 0 40 -320 0 -320 0 0 -40z M0 280 l0 -40 320 0 320 0 0 40 0 40 -320 0 -320 0 0 -40z"/></g></svg>

</span>CH–N), 8.46 (d, <em>J</em> = 2.3 Hz, 1H, CH quinaz.), 8.39 (d, <em>J</em> = 8.8 Hz, 1H, CH quinaz.), 8.30 (dd, <em>J</em> = 8.7, 2.3 Hz, 1H, CH quinaz.), 7.65–7.58 (m, 2H, CH aromatic), 7.41–7.38 (m, 2H, CH aromatic), 4.92 (s, 2H, CH<sub>2</sub>); <sup>13</sup>C NMR (101 MHz, DMSO-<em>d</em><sub>6</sub>) <em>δ</em> 165.65, 159.86, 151.72, 151.18, 148.90, 137.93, 129.31 (2C), 128.91, 127.72, 126.08, 122.87, 121.39, 121.15 (2C), 49.54; anal. calcd for C<sub>16</sub>H<sub>11</sub>ClN<sub>4</sub>O<sub>4</sub> (358.74): C, 53.57; H, 3.09; N, 15.62; found C, 53.71; H, 3.32; N, 15.89%.</p></section><section id="sec29"><h5 class="pmc_sec_title">4.1.1.9. 
<em>N</em>-(2,6-Dichlorophenyl)-2-(7-nitro-4-oxoquinazolin-3(4<em>H</em>)-yl)acetamide (9d)</h5>
<p>Off-white crystal (yield, 96%); m.p. = 285–287 °C; IR (KBr) <em>ν</em> cm<sup>−1</sup>: 3364, 3290 (NH), 3086 (CH aromatic), 2962 (CH aliphatic), 1684, 1643 (C<span aria-roledescription="private character" aria-label="DOUBLE BOND, LENGTH AS M-DASH" aria-description="double bond, length as m-dash">

<svg xmlns="http://www.w3.org/2000/svg" version="1.0" width="13.200000pt" height="16.000000pt" viewBox="0 0 13.200000 16.000000" preserveAspectRatio="xMidYMid meet"><metadata>
Created by potrace 1.16, written by Peter Selinger 2001-2019
</metadata><g transform="translate(1.000000,15.000000) scale(0.017500,-0.017500)" fill="currentColor" stroke="none"><path d="M0 440 l0 -40 320 0 320 0 0 40 0 40 -320 0 -320 0 0 -40z M0 280 l0 -40 320 0 320 0 0 40 0 40 -320 0 -320 0 0 -40z"/></g></svg>

</span>O), 1599 (C<span aria-roledescription="private character" aria-label="DOUBLE BOND, LENGTH AS M-DASH" aria-description="double bond, length as m-dash">

<svg xmlns="http://www.w3.org/2000/svg" version="1.0" width="13.200000pt" height="16.000000pt" viewBox="0 0 13.200000 16.000000" preserveAspectRatio="xMidYMid meet"><metadata>
Created by potrace 1.16, written by Peter Selinger 2001-2019
</metadata><g transform="translate(1.000000,15.000000) scale(0.017500,-0.017500)" fill="currentColor" stroke="none"><path d="M0 440 l0 -40 320 0 320 0 0 40 0 40 -320 0 -320 0 0 -40z M0 280 l0 -40 320 0 320 0 0 40 0 40 -320 0 -320 0 0 -40z"/></g></svg>

</span>N); <sup>1</sup>H NMR (400 MHz, DMSO-<em>d</em><sub>6</sub>) <em>δ</em> 10.43 (s, 1H, NH), 8.39 (m, 3H, N<span aria-roledescription="private character" aria-label="DOUBLE BOND, LENGTH AS M-DASH" aria-description="double bond, length as m-dash">

<svg xmlns="http://www.w3.org/2000/svg" version="1.0" width="13.200000pt" height="16.000000pt" viewBox="0 0 13.200000 16.000000" preserveAspectRatio="xMidYMid meet"><metadata>
Created by potrace 1.16, written by Peter Selinger 2001-2019
</metadata><g transform="translate(1.000000,15.000000) scale(0.017500,-0.017500)" fill="currentColor" stroke="none"><path d="M0 440 l0 -40 320 0 320 0 0 40 0 40 -320 0 -320 0 0 -40z M0 280 l0 -40 320 0 320 0 0 40 0 40 -320 0 -320 0 0 -40z"/></g></svg>

</span>CH–N &amp; CH quinaz.), 7.45 (m, 4H, CH quinaz. &amp; CH aromatic), 5.00 (s, 2H, CH<sub>2</sub>); <sup>13</sup>C NMR (101 MHz, DMSO-<em>d</em><sub>6</sub>) <em>δ</em> 165.39, 159.18, 151.15, 150.61, 148.36, 133.46 (2C), 132.21, 129.41, 128.56 (2C), 128.45, 125.68, 122.32, 120.81, 48.17; anal. calcd for C<sub>16</sub>H<sub>10</sub>Cl<sub>2</sub>N<sub>4</sub>O<sub>4</sub> (393.18): C, 48.88; H, 2.56; N, 14.25; found C, 49.09; H, 2.70; N, 14.51%.</p></section><section id="sec30"><h5 class="pmc_sec_title">4.1.1.10. 
<em>N</em>-(3-Chloro-4-fluorophenyl)-2-(7-nitro-4-oxoquinazolin-3(4<em>H</em>)-yl)acetamide (9e)</h5>
<p>White crystal (yield, 85%); m.p. &gt; 300 °C; IR (KBr) <em>ν</em> cm<sup>−1</sup>:, 3074 (CH aromatic), 2923 (CH aliphatic), 1626 (C<span aria-roledescription="private character" aria-label="DOUBLE BOND, LENGTH AS M-DASH" aria-description="double bond, length as m-dash">

<svg xmlns="http://www.w3.org/2000/svg" version="1.0" width="13.200000pt" height="16.000000pt" viewBox="0 0 13.200000 16.000000" preserveAspectRatio="xMidYMid meet"><metadata>
Created by potrace 1.16, written by Peter Selinger 2001-2019
</metadata><g transform="translate(1.000000,15.000000) scale(0.017500,-0.017500)" fill="currentColor" stroke="none"><path d="M0 440 l0 -40 320 0 320 0 0 40 0 40 -320 0 -320 0 0 -40z M0 280 l0 -40 320 0 320 0 0 40 0 40 -320 0 -320 0 0 -40z"/></g></svg>

</span>O), 1603 (C<span aria-roledescription="private character" aria-label="DOUBLE BOND, LENGTH AS M-DASH" aria-description="double bond, length as m-dash">

<svg xmlns="http://www.w3.org/2000/svg" version="1.0" width="13.200000pt" height="16.000000pt" viewBox="0 0 13.200000 16.000000" preserveAspectRatio="xMidYMid meet"><metadata>
Created by potrace 1.16, written by Peter Selinger 2001-2019
</metadata><g transform="translate(1.000000,15.000000) scale(0.017500,-0.017500)" fill="currentColor" stroke="none"><path d="M0 440 l0 -40 320 0 320 0 0 40 0 40 -320 0 -320 0 0 -40z M0 280 l0 -40 320 0 320 0 0 40 0 40 -320 0 -320 0 0 -40z"/></g></svg>

</span>N); <sup>1</sup>H NMR (400 MHz, DMSO-<em>d</em><sub>6</sub>) <em>δ</em> 10.73 (s, 1H, NH), 8.60–8.23 (m, 4H, N<span aria-roledescription="private character" aria-label="DOUBLE BOND, LENGTH AS M-DASH" aria-description="double bond, length as m-dash">

<svg xmlns="http://www.w3.org/2000/svg" version="1.0" width="13.200000pt" height="16.000000pt" viewBox="0 0 13.200000 16.000000" preserveAspectRatio="xMidYMid meet"><metadata>
Created by potrace 1.16, written by Peter Selinger 2001-2019
</metadata><g transform="translate(1.000000,15.000000) scale(0.017500,-0.017500)" fill="currentColor" stroke="none"><path d="M0 440 l0 -40 320 0 320 0 0 40 0 40 -320 0 -320 0 0 -40z M0 280 l0 -40 320 0 320 0 0 40 0 40 -320 0 -320 0 0 -40z"/></g></svg>

</span>CH–N &amp; CH quinaz.), 7.81–7.66 (m, 1H, CH aromatic), 7.46–7.25 (m, 2H, CH aromatic), 4.91 (s, 2H, CH<sub>2</sub>); <sup>13</sup>C NMR (101 MHz, DMSO-<em>d</em><sub>6</sub>) <em>δ</em> 165.33, 159.37, 151.24, 150.65, 148.41, 135.46, 128.41, 125.57, 122.38, 120.91, 117.77, 117.59, 115.46, 108.30, 108.09, 49.01; anal. calcd for C<sub>16</sub>H<sub>10</sub>ClFN<sub>4</sub>O<sub>4</sub> (376.73): C, 51.01; H, 2.68; N, 14.87; found C, 51.27; H, 2.89; N, 15.06%.</p></section></section></section><section id="sec31"><h3 class="pmc_sec_title">4.2. Biological testing</h3>
<section id="sec32"><h4 class="pmc_sec_title">4.2.1. 
<em>In vitro</em> anti-proliferative activity</h4>
<p>Anti-proliferative activities of the synthesized compounds were assessed against cancer cell lines (MCF-7, breast cancer, HepG-2, hepatocellular carcinoma, and K-562, myelogenous leukemia), and normal cell line (HEK-293, Human Embryonic Kidney 293 cells) using the MTT assay protocol<sup><a href="#cit71" class="usa-link" aria-describedby="cit71">71,72</a></sup> as described in the SI.</p></section><section id="sec33"><h4 class="pmc_sec_title">4.2.2. 
<em>In vitro</em> VEGFR-2 and EGFR kinases assay</h4>
<p>An ELISA kit was used to test the VEGFR-2 and EGFR inhibitory activities of the most cytotoxic compounds in accordance with the reported technique<sup><a href="#cit73" class="usa-link" aria-describedby="cit73">73</a></sup> as detailed in the SI.</p></section><section id="sec34"><h4 class="pmc_sec_title">4.2.3. Analysis of cell cycle</h4>
<p>Propidium iodide (PI) staining and flow cytometry analysis<sup><a href="#cit74" class="usa-link" aria-describedby="cit74">74,75</a></sup> were used to analyze the cell cycle for derivatives 8a and 9a, as illustrated in the SI.</p></section><section id="sec35"><h4 class="pmc_sec_title">4.2.4. Gene expression analysis for caspase-3, caspase-9, BAX, Bcl-2, TNF-a, and IL-6R</h4>
<p>The effect of the synthesized compounds on the expression of cleaved caspase-3, caspase-9, BAX, Bcl-2, TNF-α, and IL-6R proteins was determined using qRT-PCR<sup><a href="#cit76" class="usa-link" aria-describedby="cit76">76–78</a></sup> as designated in the SI.</p></section></section><section id="sec36"><h3 class="pmc_sec_title">4.3. Molecular docking studies</h3>
<p>The docking studies were performed against the crystal structure of VEGFR-2 [PDB ID: 4ASD] utilizing MOE.14 software<sup><a href="#cit31" class="usa-link" aria-describedby="cit31">31,33,79</a></sup> as described in the Supplementary data. The final figures were visualized using Discovery Studio 4.0.<sup><a href="#cit80" class="usa-link" aria-describedby="cit80">80</a></sup></p></section></section><section id="sec37"><h2 class="pmc_sec_title">Conflicts of interest</h2>
<p>There is no conflict of interest.</p></section><section id="sec38"><h2 class="pmc_sec_title">Supplementary Material</h2>
<section class="sm xbox font-sm" id="RA-015-D5RA03829D-s001"><div class="caption p"><span>RA-015-D5RA03829D-s001</span></div>
<div class="media p" id="d67e2459"><div class="caption">
<a href="/articles/instance/12377202/bin/RA-015-D5RA03829D-s001.pdf" data-ga-action="click_feat_suppl" class="usa-link">RA-015-D5RA03829D-s001.pdf</a><sup> (5.5MB, pdf) </sup>
</div></div></section></section><section id="ack1" class="ack"><h2 class="pmc_sec_title">Acknowledgments</h2>
<p>This work was funded by the Deanship of Graduate Studies and Scientific Research at Jouf University under grant no. (DGSSR-2024-01-02143).</p></section><section id="sec39"><h2 class="pmc_sec_title">Data availability</h2>
<p>Supplementary data related to this manuscript are found in a separate file. See DOI: <a href="https://doi.org/10.1039/d5ra03829d" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://doi.org/10.1039/d5ra03829d</a>.</p></section><section id="ref-list1" class="ref-list"><h2 class="pmc_sec_title">References</h2>
<section id="ref-list1_sec2"><ol class="ref-list font-sm">
<li id="cit1">
<cite>Siegel R. L. Miller K. D. Jemal A. Cancer statistics. Ca-Cancer J. Clin. 2020;70(1):7–30. doi: 10.3322/caac.21590.</cite> [<a href="https://doi.org/10.3322/caac.21590" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31912902/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Ca-Cancer%20J.%20Clin.&amp;title=Cancer%20statistics&amp;author=R.%20L.%20Siegel&amp;author=K.%20D.%20Miller&amp;author=A.%20Jemal&amp;volume=70&amp;issue=1&amp;publication_year=2020&amp;pages=7-30&amp;pmid=31912902&amp;doi=10.3322/caac.21590&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="cit2">
<cite>Abdallah A. E. Mabrouk R. R. Al Ward M. M. S. Eissa S. I. Elkaeed E. B. Mehany A. B. Abo-Saif M. A. El-Feky O. A. Alesawy M. S. El-Zahabi M. A. Synthesis, biological evaluation, and molecular docking of new series of antitumor and apoptosis inducers designed as VEGFR-2 inhibitors. J. Enzyme Inhib. Med. Chem. 2022;37(1):573–591. doi: 10.1080/14756366.2021.2017911.</cite> [<a href="https://doi.org/10.1080/14756366.2021.2017911" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8757611/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35012403/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J.%20Enzyme%20Inhib.%20Med.%20Chem.&amp;title=Synthesis,%20biological%20evaluation,%20and%20molecular%20docking%20of%20new%20series%20of%20antitumor%20and%20apoptosis%20inducers%20designed%20as%20VEGFR-2%20inhibitors&amp;author=A.%20E.%20Abdallah&amp;author=R.%20R.%20Mabrouk&amp;author=M.%20M.%20S.%20Al%20Ward&amp;author=S.%20I.%20Eissa&amp;author=E.%20B.%20Elkaeed&amp;volume=37&amp;issue=1&amp;publication_year=2022&amp;pages=573-591&amp;pmid=35012403&amp;doi=10.1080/14756366.2021.2017911&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="cit3">
<cite>Lugano R. Ramachandran M. Dimberg A. Tumor angiogenesis: causes, consequences, challenges and opportunities. Cell. Mol. Life Sci. 2020;77(9):1745–1770. doi: 10.1007/s00018-019-03351-7.</cite> [<a href="https://doi.org/10.1007/s00018-019-03351-7" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7190605/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31690961/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cell.%20Mol.%20Life%20Sci.&amp;title=Tumor%20angiogenesis:%20causes,%20consequences,%20challenges%20and%20opportunities&amp;author=R.%20Lugano&amp;author=M.%20Ramachandran&amp;author=A.%20Dimberg&amp;volume=77&amp;issue=9&amp;publication_year=2020&amp;pages=1745-1770&amp;pmid=31690961&amp;doi=10.1007/s00018-019-03351-7&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="cit4">
<cite>Scott E. N. Meinhardt G. Jacques C. Laurent D. Thomas A. L. Vatalanib: the clinical development of a tyrosine kinase inhibitor of angiogenesis in solid tumours. Expert Opin. Invest. Drugs. 2007;16(3):367–379. doi: 10.1517/13543784.16.3.367.</cite> [<a href="https://doi.org/10.1517/13543784.16.3.367" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/17302531/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Expert%20Opin.%20Invest.%20Drugs&amp;title=Vatalanib:%20the%20clinical%20development%20of%20a%20tyrosine%20kinase%20inhibitor%20of%20angiogenesis%20in%20solid%20tumours&amp;author=E.%20N.%20Scott&amp;author=G.%20Meinhardt&amp;author=C.%20Jacques&amp;author=D.%20Laurent&amp;author=A.%20L.%20Thomas&amp;volume=16&amp;issue=3&amp;publication_year=2007&amp;pages=367-379&amp;pmid=17302531&amp;doi=10.1517/13543784.16.3.367&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="cit5">
<cite>Dragovich T. Laheru D. Dayyani F. Bolejack V. Smith L. Seng J. Burris H. Rosen P. Hidalgo M. Ritch P. Phase II trial of vatalanib in patients with advanced or metastatic pancreatic adenocarcinoma after first-line gemcitabine therapy (PCRT O4-001) Cancer Chemother. Pharmacol. 2014;74:379–387. doi: 10.1007/s00280-014-2499-4.</cite> [<a href="https://doi.org/10.1007/s00280-014-2499-4" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4461053/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/24939212/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cancer%20Chemother.%20Pharmacol.&amp;title=Phase%20II%20trial%20of%20vatalanib%20in%20patients%20with%20advanced%20or%20metastatic%20pancreatic%20adenocarcinoma%20after%20first-line%20gemcitabine%20therapy%20(PCRT%20O4-001)&amp;author=T.%20Dragovich&amp;author=D.%20Laheru&amp;author=F.%20Dayyani&amp;author=V.%20Bolejack&amp;author=L.%20Smith&amp;volume=74&amp;publication_year=2014&amp;pages=379-387&amp;pmid=24939212&amp;doi=10.1007/s00280-014-2499-4&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="cit6">
<cite>Alanazi M. M. Eissa I. H. Alsaif N. A. Obaidullah A. J. Alanazi W. A. Alasmari A. F. Albassam H. Elkady H. Elwan A. Design, synthesis, docking, ADMET studies, and anticancer evaluation of new 3-methylquinoxaline derivatives as VEGFR-2 inhibitors and apoptosis inducers. J. Enzyme Inhib. Med. Chem. 2021;36(1):1760–1782. doi: 10.1080/14756366.2021.1956488.</cite> [<a href="https://doi.org/10.1080/14756366.2021.1956488" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8344243/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34340610/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J.%20Enzyme%20Inhib.%20Med.%20Chem.&amp;title=Design,%20synthesis,%20docking,%20ADMET%20studies,%20and%20anticancer%20evaluation%20of%20new%203-methylquinoxaline%20derivatives%20as%20VEGFR-2%20inhibitors%20and%20apoptosis%20inducers&amp;author=M.%20M.%20Alanazi&amp;author=I.%20H.%20Eissa&amp;author=N.%20A.%20Alsaif&amp;author=A.%20J.%20Obaidullah&amp;author=W.%20A.%20Alanazi&amp;volume=36&amp;issue=1&amp;publication_year=2021&amp;pages=1760-1782&amp;pmid=34340610&amp;doi=10.1080/14756366.2021.1956488&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="cit7">
<cite>Patel H. M. Bari P. Karpoormath R. Noolvi M. Thapliyal N. Surana S. Jain P. Design and synthesis of VEGFR-2 tyrosine kinase inhibitors as potential anticancer agents by virtual based screening. RSC Adv. 2015;5(70):56724–56771. doi: 10.1039/d5ra90070k.</cite> [<a href="https://doi.org/10.1039/d5ra90070k" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC12135165/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/40476244/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=RSC%20Adv.&amp;title=Design%20and%20synthesis%20of%20VEGFR-2%20tyrosine%20kinase%20inhibitors%20as%20potential%20anticancer%20agents%20by%20virtual%20based%20screening&amp;author=H.%20M.%20Patel&amp;author=P.%20Bari&amp;author=R.%20Karpoormath&amp;author=M.%20Noolvi&amp;author=N.%20Thapliyal&amp;volume=5&amp;issue=70&amp;publication_year=2015&amp;pages=56724-56771&amp;pmid=40476244&amp;doi=10.1039/d5ra90070k&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="cit8">
<cite>Alsaif N. A. Elwan A. Alanazi M. M. Obaidullah A. J. Alanazi W. A. Alasmari A. F. Albassam H. Mahdy H. A. Taghour M. S. Design, synthesis and molecular docking of new [1, 2, 4] triazolo [4, 3-a] quinoxaline derivatives as anticancer agents targeting VEGFR-2 kinase. Mol. Diversity. 2022;26(4):1915–1932. doi: 10.1007/s11030-021-10303-6.</cite> [<a href="https://doi.org/10.1007/s11030-021-10303-6" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34460053/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Mol.%20Diversity&amp;title=Design,%20synthesis%20and%20molecular%20docking%20of%20new%20%5B1,%202,%204%5D%20triazolo%20%5B4,%203-a%5D%20quinoxaline%20derivatives%20as%20anticancer%20agents%20targeting%20VEGFR-2%20kinase&amp;author=N.%20A.%20Alsaif&amp;author=A.%20Elwan&amp;author=M.%20M.%20Alanazi&amp;author=A.%20J.%20Obaidullah&amp;author=W.%20A.%20Alanazi&amp;volume=26&amp;issue=4&amp;publication_year=2022&amp;pages=1915-1932&amp;pmid=34460053&amp;doi=10.1007/s11030-021-10303-6&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="cit9">
<cite>Arora A. Scholar E. M. Role of tyrosine kinase inhibitors in cancer therapy. J. Pharmacol. Exp. Ther. 2005;315(3):971–979. doi: 10.1124/jpet.105.084145.</cite> [<a href="https://doi.org/10.1124/jpet.105.084145" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/16002463/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J.%20Pharmacol.%20Exp.%20Ther.&amp;title=Role%20of%20tyrosine%20kinase%20inhibitors%20in%20cancer%20therapy&amp;author=A.%20Arora&amp;author=E.%20M.%20Scholar&amp;volume=315&amp;issue=3&amp;publication_year=2005&amp;pages=971-979&amp;pmid=16002463&amp;doi=10.1124/jpet.105.084145&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="cit10">
<cite>Yousef R. G. Eldehna W. M. Elwan A. Abdelaziz A. S. Mehany A. B. Gobaara I. M. Alsfouk B. A. Elkaeed E. B. Metwaly A. M. Eissa I. H. Design, synthesis, in silico and in vitro studies of new immunomodulatory anticancer nicotinamide derivatives targeting VEGFR-2. Molecules. 2022;27(13):4079. doi: 10.3390/molecules27134079.</cite> [<a href="https://doi.org/10.3390/molecules27134079" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9268560/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35807326/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Molecules&amp;title=Design,%20synthesis,%20in%20silico%20and%20in%20vitro%20studies%20of%20new%20immunomodulatory%20anticancer%20nicotinamide%20derivatives%20targeting%20VEGFR-2&amp;author=R.%20G.%20Yousef&amp;author=W.%20M.%20Eldehna&amp;author=A.%20Elwan&amp;author=A.%20S.%20Abdelaziz&amp;author=A.%20B.%20Mehany&amp;volume=27&amp;issue=13&amp;publication_year=2022&amp;pages=4079&amp;pmid=35807326&amp;doi=10.3390/molecules27134079&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="cit11">
<cite>Shahin M. I. Abou El Ella D. A. Ismail N. S. Abouzid K. A. Design, synthesis and biological evaluation of type-II VEGFR-2 inhibitors based on quinoxaline scaffold. Bioorg. Chem. 2014;56:16–26. doi: 10.1016/j.bioorg.2014.05.010.</cite> [<a href="https://doi.org/10.1016/j.bioorg.2014.05.010" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/24922538/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Bioorg.%20Chem.&amp;title=Design,%20synthesis%20and%20biological%20evaluation%20of%20type-II%20VEGFR-2%20inhibitors%20based%20on%20quinoxaline%20scaffold&amp;author=M.%20I.%20Shahin&amp;author=D.%20A.%20Abou%20El%20Ella&amp;author=N.%20S.%20Ismail&amp;author=K.%20A.%20Abouzid&amp;volume=56&amp;publication_year=2014&amp;pages=16-26&amp;pmid=24922538&amp;doi=10.1016/j.bioorg.2014.05.010&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="cit12">
<cite>
Green D. R., Means to an End: Apoptosis and Other Cell Death Mechanisms, Cold Spring Harbor Laboratory Press, 2011</cite> [<a href="https://scholar.google.com/scholar_lookup?title=Means%20to%20an%20End:%20Apoptosis%20and%20Other%20Cell%20Death%20Mechanisms&amp;author=D.%20R.%20Green&amp;publication_year=2011&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="cit13">
<cite>Eissa I. H. El-Haggar R. Dahab M. A. Ahmed M. F. Mahdy H. A. Alsantali R. I. Elwan A. Masurier N. Fatahala S. S. Design, synthesis, molecular modeling and biological evaluation of novel Benzoxazole-Benzamide conjugates via a 2-Thioacetamido linker as potential anti-proliferative agents, VEGFR-2 inhibitors and apoptotic inducers. J. Enzyme Inhib. Med. Chem. 2022;37(1):1587–1599. doi: 10.1080/14756366.2022.2081844.</cite> [<a href="https://doi.org/10.1080/14756366.2022.2081844" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9176662/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35637622/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J.%20Enzyme%20Inhib.%20Med.%20Chem.&amp;title=Design,%20synthesis,%20molecular%20modeling%20and%20biological%20evaluation%20of%20novel%20Benzoxazole-Benzamide%20conjugates%20via%20a%202-Thioacetamido%20linker%20as%20potential%20anti-proliferative%20agents,%20VEGFR-2%20inhibitors%20and%20apoptotic%20inducers&amp;author=I.%20H.%20Eissa&amp;author=R.%20El-Haggar&amp;author=M.%20A.%20Dahab&amp;author=M.%20F.%20Ahmed&amp;author=H.%20A.%20Mahdy&amp;volume=37&amp;issue=1&amp;publication_year=2022&amp;pages=1587-1599&amp;pmid=35637622&amp;doi=10.1080/14756366.2022.2081844&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="cit14">
<cite>Zeidan M. A. Mostafa A. S. Gomaa R. M. Abou-Zeid L. A. El-Mesery M. Magda A.-A. Selim K. B. Design, synthesis and docking study of novel
picolinamide derivatives as anticancer agents and VEGFR-2 inhibitors. Eur. J. Med. Chem. 2019;168:315–329. doi: 10.1016/j.ejmech.2019.02.050.</cite> [<a href="https://doi.org/10.1016/j.ejmech.2019.02.050" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30826508/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Eur.%20J.%20Med.%20Chem.&amp;title=Design,%20synthesis%20and%20docking%20study%20of%20novel%20picolinamide%20derivatives%20as%20anticancer%20agents%20and%20VEGFR-2%20inhibitors&amp;author=M.%20A.%20Zeidan&amp;author=A.%20S.%20Mostafa&amp;author=R.%20M.%20Gomaa&amp;author=L.%20A.%20Abou-Zeid&amp;author=M.%20El-Mesery&amp;volume=168&amp;publication_year=2019&amp;pages=315-329&amp;pmid=30826508&amp;doi=10.1016/j.ejmech.2019.02.050&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="cit15">
<cite>Morabito A. De Maio E. Di Maio M. Normanno N. Perrone F. Tyrosine kinase inhibitors of vascular endothelial growth factor receptors in clinical trials: current status and future directions. Oncologist. 2006;11(7):753–764. doi: 10.1634/theoncologist.11-7-753.</cite> [<a href="https://doi.org/10.1634/theoncologist.11-7-753" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/16880234/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Oncologist&amp;title=Tyrosine%20kinase%20inhibitors%20of%20vascular%20endothelial%20growth%20factor%20receptors%20in%20clinical%20trials:%20current%20status%20and%20future%20directions&amp;author=A.%20Morabito&amp;author=E.%20De%20Maio&amp;author=M.%20Di%20Maio&amp;author=N.%20Normanno&amp;author=F.%20Perrone&amp;volume=11&amp;issue=7&amp;publication_year=2006&amp;pages=753-764&amp;pmid=16880234&amp;doi=10.1634/theoncologist.11-7-753&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="cit16">
<cite>Chow L. Q. Eckhardt S. G. Sunitinib: from rational design to clinical efficacy. J. Clin. Oncol. 2007;25(7):884–896. doi: 10.1200/JCO.2006.06.3602.</cite> [<a href="https://doi.org/10.1200/JCO.2006.06.3602" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/17327610/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J.%20Clin.%20Oncol.&amp;title=Sunitinib:%20from%20rational%20design%20to%20clinical%20efficacy&amp;author=L.%20Q.%20Chow&amp;author=S.%20G.%20Eckhardt&amp;volume=25&amp;issue=7&amp;publication_year=2007&amp;pages=884-896&amp;pmid=17327610&amp;doi=10.1200/JCO.2006.06.3602&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="cit17">
<cite>De Luca A. Normanno N. Tivozanib, a pan-VEGFR tyrosine kinase inhibitor for the potential treatment of solid tumors. IDrugs. 2010;13(9):636–645.</cite> [<a href="https://pubmed.ncbi.nlm.nih.gov/20799147/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=IDrugs&amp;title=Tivozanib,%20a%20pan-VEGFR%20tyrosine%20kinase%20inhibitor%20for%20the%20potential%20treatment%20of%20solid%20tumors&amp;author=A.%20De%20Luca&amp;author=N.%20Normanno&amp;volume=13&amp;issue=9&amp;publication_year=2010&amp;pages=636-645&amp;pmid=20799147&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="cit18">
<cite>Hui R. Pearson A. Cortes J. Campbell C. Poirot C. Azim H. A. Fumagalli D. Lambertini M. Daly F. Arahmani R. Perez-Garcia J. Aftimos P. Bedard P. L. Xuereb L. Lucitanib for the treatment of HR+/HER2− metastatic breast cancer: results from the multicohort phase II FINESSE study. Clin. Cancer Res. 2020;26(2):354–363. doi: 10.1158/1078-0432.CCR-19-1164.</cite> [<a href="https://doi.org/10.1158/1078-0432.CCR-19-1164" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31619444/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Clin.%20Cancer%20Res.&amp;title=Lucitanib%20for%20the%20treatment%20of%20HR+/HER2%E2%88%92%20metastatic%20breast%20cancer:%20results%20from%20the%20multicohort%20phase%20II%20FINESSE%20study&amp;author=R.%20Hui&amp;author=A.%20Pearson&amp;author=J.%20Cortes&amp;author=C.%20Campbell&amp;author=C.%20Poirot&amp;volume=26&amp;issue=2&amp;publication_year=2020&amp;pages=354-363&amp;pmid=31619444&amp;doi=10.1158/1078-0432.CCR-19-1164&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="cit19">
<cite>Roviello G. Corona S. P. Bozza G. Aieta M. Generali D. Rodriquenz M. G. Mileo A. M. Imperatori M. Ianza A. Conca R. Lenvatinib for the treatment of renal cell carcinoma. Expert Opin. Invest. Drugs. 2018;27(5):507–512. doi: 10.1080/13543784.2018.1472235.</cite> [<a href="https://doi.org/10.1080/13543784.2018.1472235" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29718721/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Expert%20Opin.%20Invest.%20Drugs&amp;title=Lenvatinib%20for%20the%20treatment%20of%20renal%20cell%20carcinoma&amp;author=G.%20Roviello&amp;author=S.%20P.%20Corona&amp;author=G.%20Bozza&amp;author=M.%20Aieta&amp;author=D.%20Generali&amp;volume=27&amp;issue=5&amp;publication_year=2018&amp;pages=507-512&amp;pmid=29718721&amp;doi=10.1080/13543784.2018.1472235&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="cit20">
<cite>Plé P. A. Jung F. Ashton S. Hennequin L. Laine R. Morgentin R. Pasquet G. Taylor S. Discovery of AZD2932, a new Quinazoline Ether Inhibitor with high affinity for VEGFR-2 and PDGFR tyrosine kinases. Bioorg. Med. Chem. Lett. 2012;22(1):262–266. doi: 10.1016/j.bmcl.2011.11.019.</cite> [<a href="https://doi.org/10.1016/j.bmcl.2011.11.019" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/22153662/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Bioorg.%20Med.%20Chem.%20Lett&amp;title=Discovery%20of%20AZD2932,%20a%20new%20Quinazoline%20Ether%20Inhibitor%20with%20high%20affinity%20for%20VEGFR-2%20and%20PDGFR%20tyrosine%20kinases&amp;author=P.%20A.%20Pl%C3%A9&amp;author=F.%20Jung&amp;author=S.%20Ashton&amp;author=L.%20Hennequin&amp;author=R.%20Laine&amp;volume=22&amp;issue=1&amp;publication_year=2012&amp;pages=262-266&amp;pmid=22153662&amp;doi=10.1016/j.bmcl.2011.11.019&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="cit21">
<cite>Rübsam K. Flaig M. J. Ruzicka T. Prinz J. C. Erythema marginatum hemorrhagicum: a unique cutaneous side effect of sorafenib. J. Am. Acad. Dermatol. 2011;64(6):1194–1196. doi: 10.1016/j.jaad.2009.08.035.</cite> [<a href="https://doi.org/10.1016/j.jaad.2009.08.035" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/21571189/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J.%20Am.%20Acad.%20Dermatol.&amp;title=Erythema%20marginatum%20hemorrhagicum:%20a%20unique%20cutaneous%20side%20effect%20of%20sorafenib&amp;author=K.%20R%C3%BCbsam&amp;author=M.%20J.%20Flaig&amp;author=T.%20Ruzicka&amp;author=J.%20C.%20Prinz&amp;volume=64&amp;issue=6&amp;publication_year=2011&amp;pages=1194-1196&amp;pmid=21571189&amp;doi=10.1016/j.jaad.2009.08.035&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="cit22">
<cite>Shu M. Zai X. Zhang B. Wang R. Lin Z. Hypothyroidism side effect in patients treated with sunitinib or sorafenib: clinical and structural analyses. PLoS One. 2016;11(1):e0147048. doi: 10.1371/journal.pone.0147048.</cite> [<a href="https://doi.org/10.1371/journal.pone.0147048" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4718448/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/26784451/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=PLoS%20One&amp;title=Hypothyroidism%20side%20effect%20in%20patients%20treated%20with%20sunitinib%20or%20sorafenib:%20clinical%20and%20structural%20analyses&amp;author=M.%20Shu&amp;author=X.%20Zai&amp;author=B.%20Zhang&amp;author=R.%20Wang&amp;author=Z.%20Lin&amp;volume=11&amp;issue=1&amp;publication_year=2016&amp;pages=e0147048&amp;pmid=26784451&amp;doi=10.1371/journal.pone.0147048&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="cit23">
<cite>Hahn O. Stadler W. Sorafenib. Curr. Opin. Oncol. 2006;18(6):615–621. doi: 10.1097/01.cco.0000245316.82391.52.</cite> [<a href="https://doi.org/10.1097/01.cco.0000245316.82391.52" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/16988583/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Curr.%20Opin.%20Oncol.&amp;title=Sorafenib&amp;author=O.%20Hahn&amp;author=W.%20Stadler&amp;volume=18&amp;issue=6&amp;publication_year=2006&amp;pages=615-621&amp;pmid=16988583&amp;doi=10.1097/01.cco.0000245316.82391.52&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="cit24">
<cite>Kollmannsberger C. Soulieres D. Wong R. Scalera A. Gaspo R. Bjarnason G. Sunitinib therapy for metastatic renal cell carcinoma: recommendations for management of side. Can. Urol. Assoc. J. 2007;1(2):S41. doi: 10.5489/cuaj.67.</cite> [<a href="https://doi.org/10.5489/cuaj.67" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC2422945/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/18542784/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Can.%20Urol.%20Assoc.%20J.&amp;title=Sunitinib%20therapy%20for%20metastatic%20renal%20cell%20carcinoma:%20recommendations%20for%20management%20of%20side&amp;author=C.%20Kollmannsberger&amp;author=D.%20Soulieres&amp;author=R.%20Wong&amp;author=A.%20Scalera&amp;author=R.%20Gaspo&amp;volume=1&amp;issue=2&amp;publication_year=2007&amp;pages=S41&amp;pmid=18542784&amp;doi=10.5489/cuaj.67&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="cit25">
<cite>Sproat M. Tivozanib (Fotivda®) Oncol. Times. 2021;43(16):14–20.</cite> [<a href="https://scholar.google.com/scholar_lookup?journal=Oncol.%20Times&amp;title=Tivozanib%20(Fotivda%C2%AE)&amp;author=M.%20Sproat&amp;volume=43&amp;issue=16&amp;publication_year=2021&amp;pages=14-20&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="cit26">
<cite>Alanazi M. M. Elwan A. Alsaif N. A. Obaidullah A. J. Alkahtani H. M. Al-Mehizia A. A. Alsubaie S. M. Taghour M. S. Eissa I. H. Discovery of new 3-methylquinoxalines as potential anti-cancer agents and apoptosis inducers targeting VEGFR-2: Design, synthesis, and in silico studies. J. Enzyme Inhib. Med. Chem. 2021;36(1):1732–1750. doi: 10.1080/14756366.2021.1945591.</cite> [<a href="https://doi.org/10.1080/14756366.2021.1945591" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8330740/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34325596/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J.%20Enzyme%20Inhib.%20Med.%20Chem.&amp;title=Discovery%20of%20new%203-methylquinoxalines%20as%20potential%20anti-cancer%20agents%20and%20apoptosis%20inducers%20targeting%20VEGFR-2:%20Design,%20synthesis,%20and%20in%20silico%20studies&amp;author=M.%20M.%20Alanazi&amp;author=A.%20Elwan&amp;author=N.%20A.%20Alsaif&amp;author=A.%20J.%20Obaidullah&amp;author=H.%20M.%20Alkahtani&amp;volume=36&amp;issue=1&amp;publication_year=2021&amp;pages=1732-1750&amp;pmid=34325596&amp;doi=10.1080/14756366.2021.1945591&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="cit27">
<cite>Alsaif N. A. Mahdy H. A. Alanazi M. M. Obaidullah A. J. Alkahtani H. M. Al-Hossaini A. M. Al-Mehizi A. A. Elwan A. Taghour M. S. Targeting VEGFR-2 by new quinoxaline derivatives: Design, synthesis, antiproliferative assay, apoptosis induction, and in silico studies. Arch. Pharm. 2022;355(2):2100359. doi: 10.1002/ardp.202100359.</cite> [<a href="https://doi.org/10.1002/ardp.202100359" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34862634/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Arch.%20Pharm.&amp;title=Targeting%20VEGFR-2%20by%20new%20quinoxaline%20derivatives:%20Design,%20synthesis,%20antiproliferative%20assay,%20apoptosis%20induction,%20and%20in%20silico%20studies&amp;author=N.%20A.%20Alsaif&amp;author=H.%20A.%20Mahdy&amp;author=M.%20M.%20Alanazi&amp;author=A.%20J.%20Obaidullah&amp;author=H.%20M.%20Alkahtani&amp;volume=355&amp;issue=2&amp;publication_year=2022&amp;pages=2100359&amp;pmid=34862634&amp;doi=10.1002/ardp.202100359&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="cit28">
<cite>Taghour M. S. Mahdy H. A. Gomaa M. H. Aglan A. Eldeib M. G. Elwan A. Dahab M. A. Elkaeed E. B. Alsfouk A. A. Khalifa M. M. Benzoxazole derivatives as new VEGFR-2 inhibitors and apoptosis inducers: Design, synthesis, in silico studies, and antiproliferative evaluation. J. Enzyme Inhib. Med. Chem. 2022;37(1):2063–2077. doi: 10.1080/14756366.2022.2103552.</cite> [<a href="https://doi.org/10.1080/14756366.2022.2103552" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9327782/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35875937/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J.%20Enzyme%20Inhib.%20Med.%20Chem.&amp;title=Benzoxazole%20derivatives%20as%20new%20VEGFR-2%20inhibitors%20and%20apoptosis%20inducers:%20Design,%20synthesis,%20in%20silico%20studies,%20and%20antiproliferative%20evaluation&amp;author=M.%20S.%20Taghour&amp;author=H.%20A.%20Mahdy&amp;author=M.%20H.%20Gomaa&amp;author=A.%20Aglan&amp;author=M.%20G.%20Eldeib&amp;volume=37&amp;issue=1&amp;publication_year=2022&amp;pages=2063-2077&amp;pmid=35875937&amp;doi=10.1080/14756366.2022.2103552&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="cit29">
<cite>Eissa I. Elkady H. Taghour M. S. Elwan A. Dahab M. A. Hagras M. Elkaeed E. B. Alsfouk B. A. Ibrahim I. M. Husein D. Z. Novel Thiazolidine-2, 4-Dione Derivatives as Potential VEGFR-2 Inhibitors: Synthesis, Biological Testing, and in Silico Studies. ChemistrySelect. 2024;9(11):e202303095.</cite> [<a href="https://scholar.google.com/scholar_lookup?journal=ChemistrySelect&amp;title=Novel%20Thiazolidine-2,%204-Dione%20Derivatives%20as%20Potential%20VEGFR-2%20Inhibitors:%20Synthesis,%20Biological%20Testing,%20and%20in%20Silico%20Studies&amp;author=I.%20Eissa&amp;author=H.%20Elkady&amp;author=M.%20S.%20Taghour&amp;author=A.%20Elwan&amp;author=M.%20A.%20Dahab&amp;volume=9&amp;issue=11&amp;publication_year=2024&amp;pages=e202303095&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="cit30">
<cite>Elkady H. El-Dardir O. A. Elwan A. Taghour M. S. Mahdy H. A. Dahab M. A. Elkaeed E. B. Alsfouk B. A. Ibrahim I. M. Husein D. Z. Synthesis, biological evaluation and computer-aided discovery of new thiazolidine-2, 4-dione derivatives as potential antitumor VEGFR-2 inhibitors. RSC Adv. 2023;13(40):27801–27827. doi: 10.1039/d3ra05689a.</cite> [<a href="https://doi.org/10.1039/d3ra05689a" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10508263/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37731835/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=RSC%20Adv.&amp;title=Synthesis,%20biological%20evaluation%20and%20computer-aided%20discovery%20of%20new%20thiazolidine-2,%204-dione%20derivatives%20as%20potential%20antitumor%20VEGFR-2%20inhibitors&amp;author=H.%20Elkady&amp;author=O.%20A.%20El-Dardir&amp;author=A.%20Elwan&amp;author=M.%20S.%20Taghour&amp;author=H.%20A.%20Mahdy&amp;volume=13&amp;issue=40&amp;publication_year=2023&amp;pages=27801-27827&amp;pmid=37731835&amp;doi=10.1039/d3ra05689a&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="cit31">
<cite>Yousef R. G. Elwan A. Gobaara I. M. Mehany A. B. Eldehna W. M. El-Metwally S. A. Alsfouk B. A. Elkaeed E. B. Metwaly A. M. Eissa I. H. Anti-cancer and immunomodulatory evaluation of new nicotinamide derivatives as potential VEGFR-2 inhibitors and apoptosis inducers: in vitro and in silico studies. J. Enzyme Inhib. Med. Chem. 2022;37(1):2206–2222. doi: 10.1080/14756366.2022.2110868.</cite> [<a href="https://doi.org/10.1080/14756366.2022.2110868" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9466619/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35980113/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J.%20Enzyme%20Inhib.%20Med.%20Chem.&amp;title=Anti-cancer%20and%20immunomodulatory%20evaluation%20of%20new%20nicotinamide%20derivatives%20as%20potential%20VEGFR-2%20inhibitors%20and%20apoptosis%20inducers:%20in%20vitro%20and%20in%20silico%20studies&amp;author=R.%20G.%20Yousef&amp;author=A.%20Elwan&amp;author=I.%20M.%20Gobaara&amp;author=A.%20B.%20Mehany&amp;author=W.%20M.%20Eldehna&amp;volume=37&amp;issue=1&amp;publication_year=2022&amp;pages=2206-2222&amp;pmid=35980113&amp;doi=10.1080/14756366.2022.2110868&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="cit32">
<cite>Yousef R. G. Elwan A. Abdallah A. E. Elkady H. Mehany A. B. Abo-Saif M. A. Radwan M. M. ElSohly M. A. Ibrahim I. M. Elkady M. A. Biological and computational assessment of new synthesized nicotinamides as potential immunomodulatory VEGFR-2 inhibitors. J. Mol. Struct. 2024;1305:137753.</cite> [<a href="https://scholar.google.com/scholar_lookup?journal=J.%20Mol.%20Struct.&amp;title=Biological%20and%20computational%20assessment%20of%20new%20synthesized%20nicotinamides%20as%20potential%20immunomodulatory%20VEGFR-2%20inhibitors&amp;author=R.%20G.%20Yousef&amp;author=A.%20Elwan&amp;author=A.%20E.%20Abdallah&amp;author=H.%20Elkady&amp;author=A.%20B.%20Mehany&amp;volume=1305&amp;publication_year=2024&amp;pages=137753&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="cit33">
<cite>Yousef R. G. Eissa I. H. Elkady H. Eldehna W. M. Mehany A. B. Nabeeh A. Ibrahim I. M. Elwan A. El-Zahabi M. A. New nicotinamide derivatives as potential anticancer agents targeting VEGFR-2: design, synthesis, in vitro, and in silico studies. J. Biomol. Struct. Dyn. 2023:1–18. doi: 10.1080/07391102.2023.2294170.</cite> [<a href="https://doi.org/10.1080/07391102.2023.2294170" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/38100580/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J.%20Biomol.%20Struct.%20Dyn.&amp;title=New%20nicotinamide%20derivatives%20as%20potential%20anticancer%20agents%20targeting%20VEGFR-2:%20design,%20synthesis,%20in%20vitro,%20and%20in%20silico%20studies&amp;author=R.%20G.%20Yousef&amp;author=I.%20H.%20Eissa&amp;author=H.%20Elkady&amp;author=W.%20M.%20Eldehna&amp;author=A.%20B.%20Mehany&amp;publication_year=2023&amp;pages=1-18&amp;pmid=38100580&amp;doi=10.1080/07391102.2023.2294170&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="cit34">
<cite>Commander H. Whiteside G. Perry C. Vandetanib: first global approval. Drugs. 2011;71(10):1355–1365. doi: 10.2165/11595310-000000000-00000.</cite> [<a href="https://doi.org/10.2165/11595310-000000000-00000" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/21770481/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Drugs&amp;title=Vandetanib:%20first%20global%20approval&amp;author=H.%20Commander&amp;author=G.%20Whiteside&amp;author=C.%20Perry&amp;volume=71&amp;issue=10&amp;publication_year=2011&amp;pages=1355-1365&amp;pmid=21770481&amp;doi=10.2165/11595310-000000000-00000&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="cit35">
<cite>Saxenaa A. K. Bhuniab S. S. Development of VEGFR inhibitors as antiangiogenic agents. Med. Chem. Rev. 2016;51:297–310.</cite> [<a href="https://scholar.google.com/scholar_lookup?journal=Med.%20Chem.%20Rev.&amp;title=Development%20of%20VEGFR%20inhibitors%20as%20antiangiogenic%20agents&amp;author=A.%20K.%20Saxenaa&amp;author=S.%20S.%20Bhuniab&amp;volume=51&amp;publication_year=2016&amp;pages=297-310&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="cit36">
<cite>Abd El Hadi S. R. Lasheen D. S. Soliman D. H. Elrazaz E. Z. Abouzid K. A. Scaffold hopping and redesign approaches for quinazoline based urea derivatives as potent VEGFR-2 inhibitors. Bioorg. Chem. 2020;101:103961. doi: 10.1016/j.bioorg.2020.103961.</cite> [<a href="https://doi.org/10.1016/j.bioorg.2020.103961" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32480170/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Bioorg.%20Chem.&amp;title=Scaffold%20hopping%20and%20redesign%20approaches%20for%20quinazoline%20based%20urea%20derivatives%20as%20potent%20VEGFR-2%20inhibitors&amp;author=S.%20R.%20Abd%20El%20Hadi&amp;author=D.%20S.%20Lasheen&amp;author=D.%20H.%20Soliman&amp;author=E.%20Z.%20Elrazaz&amp;author=K.%20A.%20Abouzid&amp;volume=101&amp;publication_year=2020&amp;pages=103961&amp;pmid=32480170&amp;doi=10.1016/j.bioorg.2020.103961&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="cit37">
<cite>Abdallah A. E. Eissa S. I. Al Ward M. M. S. Mabrouk R. R. Mehany A. B. El-Zahabi M. A. Design, synthesis and molecular modeling of new quinazolin-4 (3H)-one based VEGFR-2 kinase inhibitors for potential anticancer evaluation. Bioorg. Chem. 2021;109:104695. doi: 10.1016/j.bioorg.2021.104695.</cite> [<a href="https://doi.org/10.1016/j.bioorg.2021.104695" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33647743/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Bioorg.%20Chem.&amp;title=Design,%20synthesis%20and%20molecular%20modeling%20of%20new%20quinazolin-4%20(3H)-one%20based%20VEGFR-2%20kinase%20inhibitors%20for%20potential%20anticancer%20evaluation&amp;author=A.%20E.%20Abdallah&amp;author=S.%20I.%20Eissa&amp;author=M.%20M.%20S.%20Al%20Ward&amp;author=R.%20R.%20Mabrouk&amp;author=A.%20B.%20Mehany&amp;volume=109&amp;publication_year=2021&amp;pages=104695&amp;pmid=33647743&amp;doi=10.1016/j.bioorg.2021.104695&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="cit38">
<cite>Xie Q.-Q. Xie H.-Z. Ren J.-X. Li L.-L. Yang S.-Y. Pharmacophore modeling studies of type I and type II kinase inhibitors of Tie2. J. Mol. Graphics Modell. 2009;27(6):751–758. doi: 10.1016/j.jmgm.2008.11.008.</cite> [<a href="https://doi.org/10.1016/j.jmgm.2008.11.008" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/19138543/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J.%20Mol.%20Graphics%20Modell.&amp;title=Pharmacophore%20modeling%20studies%20of%20type%20I%20and%20type%20II%20kinase%20inhibitors%20of%20Tie2&amp;author=Q.-Q.%20Xie&amp;author=H.-Z.%20Xie&amp;author=J.-X.%20Ren&amp;author=L.-L.%20Li&amp;author=S.-Y.%20Yang&amp;volume=27&amp;issue=6&amp;publication_year=2009&amp;pages=751-758&amp;pmid=19138543&amp;doi=10.1016/j.jmgm.2008.11.008&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="cit39">
<cite>Lee K. Jeong K.-W. Lee Y. Song J. Y. Kim M. S. Lee G. S. Kim Y. Pharmacophore modeling and virtual screening studies for new VEGFR-2 kinase inhibitors. Eur. J. Med. Chem. 2010;45(11):5420–5427. doi: 10.1016/j.ejmech.2010.09.002.</cite> [<a href="https://doi.org/10.1016/j.ejmech.2010.09.002" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/20869793/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Eur.%20J.%20Med.%20Chem.&amp;title=Pharmacophore%20modeling%20and%20virtual%20screening%20studies%20for%20new%20VEGFR-2%20kinase%20inhibitors&amp;author=K.%20Lee&amp;author=K.-W.%20Jeong&amp;author=Y.%20Lee&amp;author=J.%20Y.%20Song&amp;author=M.%20S.%20Kim&amp;volume=45&amp;issue=11&amp;publication_year=2010&amp;pages=5420-5427&amp;pmid=20869793&amp;doi=10.1016/j.ejmech.2010.09.002&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="cit40">
<cite>Eskander R. N. Tewari K. S. Incorporation of anti-angiogenesis therapy in the management of advanced ovarian carcinoma—mechanistics, review of phase III randomized clinical trials, and regulatory implications. Gynecol. Oncol. 2014;132(2):496–505. doi: 10.1016/j.ygyno.2013.11.029.</cite> [<a href="https://doi.org/10.1016/j.ygyno.2013.11.029" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/24316305/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Gynecol.%20Oncol.&amp;title=Incorporation%20of%20anti-angiogenesis%20therapy%20in%20the%20management%20of%20advanced%20ovarian%20carcinoma%E2%80%94mechanistics,%20review%20of%20phase%20III%20randomized%20clinical%20trials,%20and%20regulatory%20implications&amp;author=R.%20N.%20Eskander&amp;author=K.%20S.%20Tewari&amp;volume=132&amp;issue=2&amp;publication_year=2014&amp;pages=496-505&amp;pmid=24316305&amp;doi=10.1016/j.ygyno.2013.11.029&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="cit41">
<cite>Eissa I. H. Ibrahim M. K. Metwaly A. M. Belal A. Mehany A. B. Abdelhady A. A. Elhendawy M. A. Radwan M. M. ElSohly M. A. Mahdy H. A. Design, molecular docking, in vitro, and in vivo studies of new quinazolin-4 (3H)-ones as VEGFR-2 inhibitors with potential activity against hepatocellular carcinoma. Bioorg. Chem. 2021;107:104532. doi: 10.1016/j.bioorg.2020.104532.</cite> [<a href="https://doi.org/10.1016/j.bioorg.2020.104532" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33334586/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Bioorg.%20Chem.&amp;title=Design,%20molecular%20docking,%20in%20vitro,%20and%20in%20vivo%20studies%20of%20new%20quinazolin-4%20(3H)-ones%20as%20VEGFR-2%20inhibitors%20with%20potential%20activity%20against%20hepatocellular%20carcinoma&amp;author=I.%20H.%20Eissa&amp;author=M.%20K.%20Ibrahim&amp;author=A.%20M.%20Metwaly&amp;author=A.%20Belal&amp;author=A.%20B.%20Mehany&amp;volume=107&amp;publication_year=2021&amp;pages=104532&amp;pmid=33334586&amp;doi=10.1016/j.bioorg.2020.104532&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="cit42">
<cite>El-Metwally S. A. Abou-El-Regal M. M. Eissa I. H. Mehany A. B. Mahdy H. A. Elkady H. Elwan A. Elkaeed E. B. Discovery of thieno [2, 3-d] pyrimidine-based derivatives as potent VEGFR-2 kinase inhibitors and anti-cancer agents. Bioorg. Chem. 2021;112:104947. doi: 10.1016/j.bioorg.2021.104947.</cite> [<a href="https://doi.org/10.1016/j.bioorg.2021.104947" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33964580/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Bioorg.%20Chem.&amp;title=Discovery%20of%20thieno%20%5B2,%203-d%5D%20pyrimidine-based%20derivatives%20as%20potent%20VEGFR-2%20kinase%20inhibitors%20and%20anti-cancer%20agents&amp;author=S.%20A.%20El-Metwally&amp;author=M.%20M.%20Abou-El-Regal&amp;author=I.%20H.%20Eissa&amp;author=A.%20B.%20Mehany&amp;author=H.%20A.%20Mahdy&amp;volume=112&amp;publication_year=2021&amp;pages=104947&amp;pmid=33964580&amp;doi=10.1016/j.bioorg.2021.104947&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="cit43">
<cite>Alsaif N. A. Dahab M. A. Alanazi M. M. Obaidullah A. J. Al-Mehizia A. A. Alanazi M. M. Aldawas S. Mahdy H. A. Elkady H. New quinoxaline derivatives as VEGFR-2 inhibitors with anticancer and apoptotic activity: Design, molecular modeling, and synthesis. Bioorg. Chem. 2021;110:104807. doi: 10.1016/j.bioorg.2021.104807.</cite> [<a href="https://doi.org/10.1016/j.bioorg.2021.104807" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33721808/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Bioorg.%20Chem.&amp;title=New%20quinoxaline%20derivatives%20as%20VEGFR-2%20inhibitors%20with%20anticancer%20and%20apoptotic%20activity:%20Design,%20molecular%20modeling,%20and%20synthesis&amp;author=N.%20A.%20Alsaif&amp;author=M.%20A.%20Dahab&amp;author=M.%20M.%20Alanazi&amp;author=A.%20J.%20Obaidullah&amp;author=A.%20A.%20Al-Mehizia&amp;volume=110&amp;publication_year=2021&amp;pages=104807&amp;pmid=33721808&amp;doi=10.1016/j.bioorg.2021.104807&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="cit44">
<cite>Machado V. A. Peixoto D. Costa R. Froufe H. J. Calhelha R. C. Abreu R. M. Ferreira I. C. Soares R. Queiroz M.-J. R. Synthesis, antiangiogenesis evaluation and molecular docking studies of 1-aryl-3-[(thieno [3, 2-b] pyridin-7-ylthio) phenyl] ureas: Discovery of a new substitution pattern for type II VEGFR-2 Tyr kinase inhibitors. Bioorg. Med. Chem. 2015;23(19):6497–6509. doi: 10.1016/j.bmc.2015.08.010.</cite> [<a href="https://doi.org/10.1016/j.bmc.2015.08.010" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/26344591/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Bioorg.%20Med.%20Chem.&amp;title=Synthesis,%20antiangiogenesis%20evaluation%20and%20molecular%20docking%20studies%20of%201-aryl-3-%5B(thieno%20%5B3,%202-b%5D%20pyridin-7-ylthio)%20phenyl%5D%20ureas:%20Discovery%20of%20a%20new%20substitution%20pattern%20for%20type%20II%20VEGFR-2%20Tyr%20kinase%20inhibitors&amp;author=V.%20A.%20Machado&amp;author=D.%20Peixoto&amp;author=R.%20Costa&amp;author=H.%20J.%20Froufe&amp;author=R.%20C.%20Calhelha&amp;volume=23&amp;issue=19&amp;publication_year=2015&amp;pages=6497-6509&amp;pmid=26344591&amp;doi=10.1016/j.bmc.2015.08.010&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="cit45">
<cite>Wang Z. Wang N. Han S. Wang D. Mo S. Yu L. Huang H. Tsui K. Shen J. Chen J. Dietary compound isoliquiritigenin inhibits breast cancer neoangiogenesis via VEGF/VEGFR-2 signaling pathway. PLoS One. 2013;8(7):e68566. doi: 10.1371/journal.pone.0068566.</cite> [<a href="https://doi.org/10.1371/journal.pone.0068566" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC3702614/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/23861918/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=PLoS%20One&amp;title=Dietary%20compound%20isoliquiritigenin%20inhibits%20breast%20cancer%20neoangiogenesis%20via%20VEGF/VEGFR-2%20signaling%20pathway&amp;author=Z.%20Wang&amp;author=N.%20Wang&amp;author=S.%20Han&amp;author=D.%20Wang&amp;author=S.%20Mo&amp;volume=8&amp;issue=7&amp;publication_year=2013&amp;pages=e68566&amp;pmid=23861918&amp;doi=10.1371/journal.pone.0068566&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="cit46">
<cite>Dietrich J. Hulme C. Hurley L. H. The design, synthesis, and evaluation of 8 hybrid DFG-out allosteric kinase inhibitors: A structural analysis of the binding interactions of Gleevec®, Nexavar®, and BIRB-796. Bioorg. Med. Chem. 2010;18(15):5738–5748. doi: 10.1016/j.bmc.2010.05.063.</cite> [<a href="https://doi.org/10.1016/j.bmc.2010.05.063" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/20621496/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Bioorg.%20Med.%20Chem.&amp;title=The%20design,%20synthesis,%20and%20evaluation%20of%208%20hybrid%20DFG-out%20allosteric%20kinase%20inhibitors:%20A%20structural%20analysis%20of%20the%20binding%20interactions%20of%20Gleevec%C2%AE,%20Nexavar%C2%AE,%20and%20BIRB-796&amp;author=J.%20Dietrich&amp;author=C.%20Hulme&amp;author=L.%20H.%20Hurley&amp;volume=18&amp;issue=15&amp;publication_year=2010&amp;pages=5738-5748&amp;pmid=20621496&amp;doi=10.1016/j.bmc.2010.05.063&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="cit47">
<cite>Hou T. Zhu L. Chen L. Xu X. Mapping the binding site of a large set of quinazoline type EGF-R inhibitors using molecular field analyses and molecular docking studies. J. Chem. Inf. Comput. Sci. 2003;43(1):273–287. doi: 10.1021/ci025552a.</cite> [<a href="https://doi.org/10.1021/ci025552a" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/12546563/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J.%20Chem.%20Inf.%20Comput.%20Sci.&amp;title=Mapping%20the%20binding%20site%20of%20a%20large%20set%20of%20quinazoline%20type%20EGF-R%20inhibitors%20using%20molecular%20field%20analyses%20and%20molecular%20docking%20studies&amp;author=T.%20Hou&amp;author=L.%20Zhu&amp;author=L.%20Chen&amp;author=X.%20Xu&amp;volume=43&amp;issue=1&amp;publication_year=2003&amp;pages=273-287&amp;pmid=12546563&amp;doi=10.1021/ci025552a&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="cit48">
<cite>Kulkarni S. S. Singh S. Shah J. R. Low W.-K. Talele T. T. Synthesis and SAR optimization of quinazolin-4 (3H)-ones as poly (ADP-ribose) polymerase-1 inhibitors. Eur. J. Med. Chem. 2012;50:264–273. doi: 10.1016/j.ejmech.2012.02.001.</cite> [<a href="https://doi.org/10.1016/j.ejmech.2012.02.001" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/22365563/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Eur.%20J.%20Med.%20Chem.&amp;title=Synthesis%20and%20SAR%20optimization%20of%20quinazolin-4%20(3H)-ones%20as%20poly%20(ADP-ribose)%20polymerase-1%20inhibitors&amp;author=S.%20S.%20Kulkarni&amp;author=S.%20Singh&amp;author=J.%20R.%20Shah&amp;author=W.-K.%20Low&amp;author=T.%20T.%20Talele&amp;volume=50&amp;publication_year=2012&amp;pages=264-273&amp;pmid=22365563&amp;doi=10.1016/j.ejmech.2012.02.001&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="cit49">
<cite>Ibrahim M. K. Eissa I. H. Alesawy M. S. Metwaly A. M. Radwan M. M. ElSohly M. A. Design, synthesis, molecular modeling and anti-hyperglycemic evaluation of quinazolin-4 (3H)-one derivatives as potential PPARγ and SUR agonists. Bioorg. Med. Chem. 2017;25(17):4723–4744. doi: 10.1016/j.bmc.2017.07.015.</cite> [<a href="https://doi.org/10.1016/j.bmc.2017.07.015" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28720328/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Bioorg.%20Med.%20Chem.&amp;title=Design,%20synthesis,%20molecular%20modeling%20and%20anti-hyperglycemic%20evaluation%20of%20quinazolin-4%20(3H)-one%20derivatives%20as%20potential%20PPAR%CE%B3%20and%20SUR%20agonists&amp;author=M.%20K.%20Ibrahim&amp;author=I.%20H.%20Eissa&amp;author=M.%20S.%20Alesawy&amp;author=A.%20M.%20Metwaly&amp;author=M.%20M.%20Radwan&amp;volume=25&amp;issue=17&amp;publication_year=2017&amp;pages=4723-4744&amp;pmid=28720328&amp;doi=10.1016/j.bmc.2017.07.015&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="cit50">
<cite>Mohammadhosseini N. Moradi S. Khoobi M. Shafiee A. Synthesis of Novel 6-Mercapto-12-phenethyl-quinazolino [3, 4-a] quinazolinones. J. Heterocycl. Chem. 2016;53(5):1595–1602.</cite> [<a href="https://scholar.google.com/scholar_lookup?journal=J.%20Heterocycl.%20Chem.&amp;title=Synthesis%20of%20Novel%206-Mercapto-12-phenethyl-quinazolino%20%5B3,%204-a%5D%20quinazolinones&amp;author=N.%20Mohammadhosseini&amp;author=S.%20Moradi&amp;author=M.%20Khoobi&amp;author=A.%20Shafiee&amp;volume=53&amp;issue=5&amp;publication_year=2016&amp;pages=1595-1602&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="cit51">
<cite>Guo S. Colbert L. S. Fuller M. Zhang Y. Gonzalez-Perez R. R. Vascular endothelial growth factor receptor-2 in breast cancer. Biochim. Biophys. Acta Rev. Canc. 2010;1806(1):108–121. doi: 10.1016/j.bbcan.2010.04.004.</cite> [<a href="https://doi.org/10.1016/j.bbcan.2010.04.004" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC2885515/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/20462514/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Biochim.%20Biophys.%20Acta%20Rev.%20Canc&amp;title=Vascular%20endothelial%20growth%20factor%20receptor-2%20in%20breast%20cancer&amp;author=S.%20Guo&amp;author=L.%20S.%20Colbert&amp;author=M.%20Fuller&amp;author=Y.%20Zhang&amp;author=R.%20R.%20Gonzalez-Perez&amp;volume=1806&amp;issue=1&amp;publication_year=2010&amp;pages=108-121&amp;pmid=20462514&amp;doi=10.1016/j.bbcan.2010.04.004&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="cit52">
<cite>Kaseb A. O. Hanbali A. Cotant M. Hassan M. M. Wollner I. Philip P. A. Vascular endothelial growth factor in the management of hepatocellular carcinoma: a review of literature, Cancer. Interdisciplinary International Journal of the American Cancer Society. 2009;115(21):4895–4906. doi: 10.1002/cncr.24537.</cite> [<a href="https://doi.org/10.1002/cncr.24537" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/19637355/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Interdisciplinary%20International%20Journal%20of%20the%20American%20Cancer%20Society&amp;title=Vascular%20endothelial%20growth%20factor%20in%20the%20management%20of%20hepatocellular%20carcinoma:%20a%20review%20of%20literature,%20Cancer&amp;author=A.%20O.%20Kaseb&amp;author=A.%20Hanbali&amp;author=M.%20Cotant&amp;author=M.%20M.%20Hassan&amp;author=I.%20Wollner&amp;volume=115&amp;issue=21&amp;publication_year=2009&amp;pages=4895-4906&amp;pmid=19637355&amp;doi=10.1002/cncr.24537&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="cit53">
<cite>Kampen K. R. Ter Elst A. de Bont E. S. Vascular endothelial growth factor signaling in acute myeloid leukemia. Cell. Mol. Life Sci. 2013;70:1307–1317. doi: 10.1007/s00018-012-1085-3.</cite> [<a href="https://doi.org/10.1007/s00018-012-1085-3" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC11113417/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/22833169/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cell.%20Mol.%20Life%20Sci.&amp;title=Vascular%20endothelial%20growth%20factor%20signaling%20in%20acute%20myeloid%20leukemia&amp;author=K.%20R.%20Kampen&amp;author=A.%20Ter%20Elst&amp;author=E.%20S.%20de%20Bont&amp;volume=70&amp;publication_year=2013&amp;pages=1307-1317&amp;pmid=22833169&amp;doi=10.1007/s00018-012-1085-3&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="cit54">
<cite>Zulkarnain N. N. Anuar N. Johari N. A. Abdullah S. R. S. Othman A. R. Cytotoxicity evaluation of ketoprofen found in pharmaceutical wastewater on HEK 293 cell growth and metabolism. Environ. Toxicol. Pharmacol. 2020;80:103498. doi: 10.1016/j.etap.2020.103498.</cite> [<a href="https://doi.org/10.1016/j.etap.2020.103498" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32950717/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Environ.%20Toxicol.%20Pharmacol.&amp;title=Cytotoxicity%20evaluation%20of%20ketoprofen%20found%20in%20pharmaceutical%20wastewater%20on%20HEK%20293%20cell%20growth%20and%20metabolism&amp;author=N.%20N.%20Zulkarnain&amp;author=N.%20Anuar&amp;author=N.%20A.%20Johari&amp;author=S.%20R.%20S.%20Abdullah&amp;author=A.%20R.%20Othman&amp;volume=80&amp;publication_year=2020&amp;pages=103498&amp;pmid=32950717&amp;doi=10.1016/j.etap.2020.103498&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="cit55">
<cite>Zwick E. Bange J. Ullrich A. Receptor tyrosine kinases as targets for anticancer drugs. Trends Mol. Med. 2002;8(1):17–23. doi: 10.1016/s1471-4914(01)02217-1.</cite> [<a href="https://doi.org/10.1016/s1471-4914(01)02217-1" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/11796262/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Trends%20Mol.%20Med.&amp;title=Receptor%20tyrosine%20kinases%20as%20targets%20for%20anticancer%20drugs&amp;author=E.%20Zwick&amp;author=J.%20Bange&amp;author=A.%20Ullrich&amp;volume=8&amp;issue=1&amp;publication_year=2002&amp;pages=17-23&amp;pmid=11796262&amp;doi=10.1016/s1471-4914(01)02217-1&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="cit56">
<cite>Pines G. Köstler W. J. Yarden Y. Oncogenic mutant forms of EGFR: lessons in signal transduction and targets for cancer therapy. FEBS Lett. 2010;584(12):2699–2706. doi: 10.1016/j.febslet.2010.04.019.</cite> [<a href="https://doi.org/10.1016/j.febslet.2010.04.019" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC2892754/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/20388509/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=FEBS%20Lett.&amp;title=Oncogenic%20mutant%20forms%20of%20EGFR:%20lessons%20in%20signal%20transduction%20and%20targets%20for%20cancer%20therapy&amp;author=G.%20Pines&amp;author=W.%20J.%20K%C3%B6stler&amp;author=Y.%20Yarden&amp;volume=584&amp;issue=12&amp;publication_year=2010&amp;pages=2699-2706&amp;pmid=20388509&amp;doi=10.1016/j.febslet.2010.04.019&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="cit57">
<cite>Wee P. Wang Z. Epidermal growth factor receptor cell proliferation signaling pathways. Cancers. 2017;9(5):52. doi: 10.3390/cancers9050052.</cite> [<a href="https://doi.org/10.3390/cancers9050052" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5447962/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28513565/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cancers&amp;title=Epidermal%20growth%20factor%20receptor%20cell%20proliferation%20signaling%20pathways&amp;author=P.%20Wee&amp;author=Z.%20Wang&amp;volume=9&amp;issue=5&amp;publication_year=2017&amp;pages=52&amp;pmid=28513565&amp;doi=10.3390/cancers9050052&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="cit58">
<cite>Abdelsalam E. A. Abd El-Hafeez A. A. Eldehna W. M. El Hassab M. A. Marzouk H. M. M. Elaasser M. M. Abou Taleb N. A. Amin K. M. Abdel-Aziz H. A. Ghosh P. Discovery of novel thiazolyl-pyrazolines as dual EGFR and VEGFR-2 inhibitors endowed with in vitro antitumor activity towards non-small lung cancer. J. Enzyme Inhib. Med. Chem. 2022;37(1):2265–2282. doi: 10.1080/14756366.2022.2104841.</cite> [<a href="https://doi.org/10.1080/14756366.2022.2104841" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9415638/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36000167/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J.%20Enzyme%20Inhib.%20Med.%20Chem.&amp;title=Discovery%20of%20novel%20thiazolyl-pyrazolines%20as%20dual%20EGFR%20and%20VEGFR-2%20inhibitors%20endowed%20with%20in%20vitro%20antitumor%20activity%20towards%20non-small%20lung%20cancer&amp;author=E.%20A.%20Abdelsalam&amp;author=A.%20A.%20Abd%20El-Hafeez&amp;author=W.%20M.%20Eldehna&amp;author=M.%20A.%20El%20Hassab&amp;author=H.%20M.%20M.%20Marzouk&amp;volume=37&amp;issue=1&amp;publication_year=2022&amp;pages=2265-2282&amp;pmid=36000167&amp;doi=10.1080/14756366.2022.2104841&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="cit59">
<cite>Alenzi F. Q. Links between apoptosis, proliferation and the cell cycle. Br. J. Biomed. Sci. 2004;61(2):99–102. doi: 10.1080/09674845.2004.11732652.</cite> [<a href="https://doi.org/10.1080/09674845.2004.11732652" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/15250676/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Br.%20J.%20Biomed.%20Sci.&amp;title=Links%20between%20apoptosis,%20proliferation%20and%20the%20cell%20cycle&amp;author=F.%20Q.%20Alenzi&amp;volume=61&amp;issue=2&amp;publication_year=2004&amp;pages=99-102&amp;pmid=15250676&amp;doi=10.1080/09674845.2004.11732652&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="cit60">
<cite>El-Adl K. Ibrahim M.-K. Alesawy M. S. Eissa I. H. [1, 2, 4] Triazolo [4, 3-c] quinazoline and bis ([1, 2, 4] triazolo)[4, 3-a: 4′, 3′-c] quinazoline derived DNA intercalators: Design, synthesis, in silico ADMET profile, molecular docking and anti-proliferative evaluation studies. Bioorg. Med. Chem. 2021;30:115958. doi: 10.1016/j.bmc.2020.115958.</cite> [<a href="https://doi.org/10.1016/j.bmc.2020.115958" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33360576/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Bioorg.%20Med.%20Chem.&amp;title=%5B1,%202,%204%5D%20Triazolo%20%5B4,%203-c%5D%20quinazoline%20and%20bis%20(%5B1,%202,%204%5D%20triazolo)%5B4,%203-a:%204%E2%80%B2,%203%E2%80%B2-c%5D%20quinazoline%20derived%20DNA%20intercalators:%20Design,%20synthesis,%20in%20silico%20ADMET%20profile,%20molecular%20docking%20and%20anti-proliferative%20evaluation%20studies&amp;author=K.%20El-Adl&amp;author=M.-K.%20Ibrahim&amp;author=M.%20S.%20Alesawy&amp;author=I.%20H.%20Eissa&amp;volume=30&amp;publication_year=2021&amp;pages=115958&amp;pmid=33360576&amp;doi=10.1016/j.bmc.2020.115958&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="cit61">
<cite>Crawford E. D. Wells J. A. Caspase substrates and cellular remodeling. Annu. Rev. Biochem. 2011;80(1):1055–1087. doi: 10.1146/annurev-biochem-061809-121639.</cite> [<a href="https://doi.org/10.1146/annurev-biochem-061809-121639" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/21456965/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Annu.%20Rev.%20Biochem.&amp;title=Caspase%20substrates%20and%20cellular%20remodeling&amp;author=E.%20D.%20Crawford&amp;author=J.%20A.%20Wells&amp;volume=80&amp;issue=1&amp;publication_year=2011&amp;pages=1055-1087&amp;pmid=21456965&amp;doi=10.1146/annurev-biochem-061809-121639&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="cit62">
<cite>Kuida K. Caspase-9. Int. J. Biochem. Cell Biol. 2000;32(2):121–124. doi: 10.1016/s1357-2725(99)00024-2.</cite> [<a href="https://doi.org/10.1016/s1357-2725(99)00024-2" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/10687948/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Int.%20J.%20Biochem.%20Cell%20Biol.&amp;title=Caspase-9&amp;author=K.%20Kuida&amp;volume=32&amp;issue=2&amp;publication_year=2000&amp;pages=121-124&amp;pmid=10687948&amp;doi=10.1016/s1357-2725(99)00024-2&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="cit63">
<cite>Antonsson B. Conti F. Ciavatta A. Montessuit S. Lewis S. Martinou I. Bernasconi L. Bernard A. Mermod J.-J. Mazzei G. Inhibition of Bax channel-forming activity by Bcl-2. Science. 1997;277(5324):370–372. doi: 10.1126/science.277.5324.370.</cite> [<a href="https://doi.org/10.1126/science.277.5324.370" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/9219694/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Science&amp;title=Inhibition%20of%20Bax%20channel-forming%20activity%20by%20Bcl-2&amp;author=B.%20Antonsson&amp;author=F.%20Conti&amp;author=A.%20Ciavatta&amp;author=S.%20Montessuit&amp;author=S.%20Lewis&amp;volume=277&amp;issue=5324&amp;publication_year=1997&amp;pages=370-372&amp;pmid=9219694&amp;doi=10.1126/science.277.5324.370&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="cit64">
<cite>Antonsson B. artinou J.-C. The Bcl-2 protein family. Exp. Cell Res. 2000;256(1):50–57. doi: 10.1006/excr.2000.4839.</cite> [<a href="https://doi.org/10.1006/excr.2000.4839" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/10739651/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Exp.%20Cell%20Res.&amp;title=The%20Bcl-2%20protein%20family&amp;author=B.%20Antonsson&amp;author=J.-C.%20artinou&amp;volume=256&amp;issue=1&amp;publication_year=2000&amp;pages=50-57&amp;pmid=10739651&amp;doi=10.1006/excr.2000.4839&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="cit65">
<cite>Ling Y. Lu N. Gao Y. Chen Y. Wang S. Yang Y. Guo Q. Endostar induces apoptotic effects in HUVECs through activation of caspase-3 and decrease of Bcl-2. Anticancer Res. 2009;29(1):411–417.</cite> [<a href="https://pubmed.ncbi.nlm.nih.gov/19331180/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Anticancer%20Res.&amp;title=Endostar%20induces%20apoptotic%20effects%20in%20HUVECs%20through%20activation%20of%20caspase-3%20and%20decrease%20of%20Bcl-2&amp;author=Y.%20Ling&amp;author=N.%20Lu&amp;author=Y.%20Gao&amp;author=Y.%20Chen&amp;author=S.%20Wang&amp;volume=29&amp;issue=1&amp;publication_year=2009&amp;pages=411-417&amp;pmid=19331180&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="cit66">
<cite>van den Berg J. M. Weyer S. Weening J. J. Roos D. Kuijpers T. W. Divergent effects of tumor necrosis factor α on apoptosis of human neutrophils. J. Leukoc. Biol. 2001;69(3):467–473.</cite> [<a href="https://pubmed.ncbi.nlm.nih.gov/11261795/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J.%20Leukoc.%20Biol.&amp;title=Divergent%20effects%20of%20tumor%20necrosis%20factor%20%CE%B1%20on%20apoptosis%20of%20human%20neutrophils&amp;author=J.%20M.%20van%20den%20Berg&amp;author=S.%20Weyer&amp;author=J.%20J.%20Weening&amp;author=D.%20Roos&amp;author=T.%20W.%20Kuijpers&amp;volume=69&amp;issue=3&amp;publication_year=2001&amp;pages=467-473&amp;pmid=11261795&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="cit67">
<cite>Long K. B. Tooker G. Tooker E. Luque S. L. Lee J. W. Pan X. Beatty G. L. IL6 receptor blockade enhances chemotherapy efficacy in pancreatic ductal adenocarcinoma. Mol. Cancer Therapeut. 2017;16(9):1898–1908. doi: 10.1158/1535-7163.MCT-16-0899.</cite> [<a href="https://doi.org/10.1158/1535-7163.MCT-16-0899" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5587413/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28611107/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Mol.%20Cancer%20Therapeut.&amp;title=IL6%20receptor%20blockade%20enhances%20chemotherapy%20efficacy%20in%20pancreatic%20ductal%20adenocarcinoma&amp;author=K.%20B.%20Long&amp;author=G.%20Tooker&amp;author=E.%20Tooker&amp;author=S.%20L.%20Luque&amp;author=J.%20W.%20Lee&amp;volume=16&amp;issue=9&amp;publication_year=2017&amp;pages=1898-1908&amp;pmid=28611107&amp;doi=10.1158/1535-7163.MCT-16-0899&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="cit68">
<cite>Sobhy M. K. Mowafy S. Lasheen D. S. Farag N. A. Abouzid K. A. 3D-QSAR pharmacophore modelling, virtual screening and docking studies for lead discovery of a novel scaffold for VEGFR 2 inhibitors: Design, synthesis and biological evaluation. Bioorg. Chem. 2019;89:102988. doi: 10.1016/j.bioorg.2019.102988.</cite> [<a href="https://doi.org/10.1016/j.bioorg.2019.102988" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31146197/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Bioorg.%20Chem.&amp;title=3D-QSAR%20pharmacophore%20modelling,%20virtual%20screening%20and%20docking%20studies%20for%20lead%20discovery%20of%20a%20novel%20scaffold%20for%20VEGFR%202%20inhibitors:%20Design,%20synthesis%20and%20biological%20evaluation&amp;author=M.%20K.%20Sobhy&amp;author=S.%20Mowafy&amp;author=D.%20S.%20Lasheen&amp;author=N.%20A.%20Farag&amp;author=K.%20A.%20Abouzid&amp;volume=89&amp;publication_year=2019&amp;pages=102988&amp;pmid=31146197&amp;doi=10.1016/j.bioorg.2019.102988&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="cit69">
<cite>Alesawy M. S. Ibrahim M. K. Eissa I. H. El-Adl K. Design, synthesis, in silico ADMET, docking, and antiproliferative evaluations of [1, 2, 4] triazolo [4, 3-c] quinazolines as classical DNA intercalators. Arch. Pharm. 2022:e2100412. doi: 10.1002/ardp.202100412.</cite> [<a href="https://doi.org/10.1002/ardp.202100412" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35014084/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Arch.%20Pharm.&amp;title=Design,%20synthesis,%20in%20silico%20ADMET,%20docking,%20and%20antiproliferative%20evaluations%20of%20%5B1,%202,%204%5D%20triazolo%20%5B4,%203-c%5D%20quinazolines%20as%20classical%20DNA%20intercalators&amp;author=M.%20S.%20Alesawy&amp;author=M.%20K.%20Ibrahim&amp;author=I.%20H.%20Eissa&amp;author=K.%20El-Adl&amp;publication_year=2022&amp;pages=e2100412&amp;pmid=35014084&amp;doi=10.1002/ardp.202100412&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="cit70">
<cite>Kumar A. Kumari N. Bhattacherjee S. Venugopal U. Parwez S. Siddiqi M. I. Krishnan M. Y. Panda G. Design, synthesis and biological evaluation of (Quinazoline 4-yloxy) acetamide and (4-oxoquinazoline-3 (4H)-yl) acetamide derivatives as inhibitors of Mycobacterium tuberculosis bd oxidase. Eur. J. Med. Chem. 2022;242:114639. doi: 10.1016/j.ejmech.2022.114639.</cite> [<a href="https://doi.org/10.1016/j.ejmech.2022.114639" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35973312/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Eur.%20J.%20Med.%20Chem.&amp;title=Design,%20synthesis%20and%20biological%20evaluation%20of%20(Quinazoline%204-yloxy)%20acetamide%20and%20(4-oxoquinazoline-3%20(4H)-yl)%20acetamide%20derivatives%20as%20inhibitors%20of%20Mycobacterium%20tuberculosis%20bd%20oxidase&amp;author=A.%20Kumar&amp;author=N.%20Kumari&amp;author=S.%20Bhattacherjee&amp;author=U.%20Venugopal&amp;author=S.%20Parwez&amp;volume=242&amp;publication_year=2022&amp;pages=114639&amp;pmid=35973312&amp;doi=10.1016/j.ejmech.2022.114639&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="cit71">
<cite>Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J. Immunol. Methods. 1983;65(1–2):55–63. doi: 10.1016/0022-1759(83)90303-4.</cite> [<a href="https://doi.org/10.1016/0022-1759(83)90303-4" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/6606682/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J.%20Immunol.%20Methods&amp;title=Rapid%20colorimetric%20assay%20for%20cellular%20growth%20and%20survival:%20application%20to%20proliferation%20and%20cytotoxicity%20assays&amp;author=T.%20Mosmann&amp;volume=65&amp;issue=1%E2%80%932&amp;publication_year=1983&amp;pages=55-63&amp;pmid=6606682&amp;doi=10.1016/0022-1759(83)90303-4&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="cit72">
<cite>Eldehna W. M. Salem R. Elsayed Z. M. Al-Warhi T. Knany H. R. Ayyad R. R. Traiki T. B. Abdulla M.-H. Ahmad R. Abdel-Aziz H. A. Development of novel benzofuran-isatin conjugates as potential antiproliferative agents with apoptosis inducing mechanism in Colon
cancer. J. Enzyme Inhib. Med. Chem. 2021;36(1):1423–1434. doi: 10.1080/14756366.2021.1944127.</cite> [<a href="https://doi.org/10.1080/14756366.2021.1944127" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8245078/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34176414/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J.%20Enzyme%20Inhib.%20Med.%20Chem.&amp;title=Development%20of%20novel%20benzofuran-isatin%20conjugates%20as%20potential%20antiproliferative%20agents%20with%20apoptosis%20inducing%20mechanism%20in%20Colon%20cancer&amp;author=W.%20M.%20Eldehna&amp;author=R.%20Salem&amp;author=Z.%20M.%20Elsayed&amp;author=T.%20Al-Warhi&amp;author=H.%20R.%20Knany&amp;volume=36&amp;issue=1&amp;publication_year=2021&amp;pages=1423-1434&amp;pmid=34176414&amp;doi=10.1080/14756366.2021.1944127&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="cit73">
<cite>Abou-Seri S. M. Eldehna W. M. Ali M. M. Abou El Ella D. A. 1-Piperazinylphthalazines as potential VEGFR-2 inhibitors and anticancer agents: synthesis and in vitro biological evaluation. Eur. J. Med. Chem. 2016;107:165–179. doi: 10.1016/j.ejmech.2015.10.053.</cite> [<a href="https://doi.org/10.1016/j.ejmech.2015.10.053" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/26590508/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Eur.%20J.%20Med.%20Chem.&amp;title=1-Piperazinylphthalazines%20as%20potential%20VEGFR-2%20inhibitors%20and%20anticancer%20agents:%20synthesis%20and%20in%20vitro%20biological%20evaluation&amp;author=S.%20M.%20Abou-Seri&amp;author=W.%20M.%20Eldehna&amp;author=M.%20M.%20Ali&amp;author=D.%20A.%20Abou%20El%20Ella&amp;volume=107&amp;publication_year=2016&amp;pages=165-179&amp;pmid=26590508&amp;doi=10.1016/j.ejmech.2015.10.053&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="cit74">
<cite>Ran F. Li W. Qin Y. Yu T. Liu Z. Zhou M. Liu C. Qiao T. Li X. Yousef R. G. Inhibition of vascular smooth muscle and cancer cell proliferation by new VEGFR inhibitors and their immunomodulator effect: Design, synthesis, and biological evaluation. Oxid. Med. Cell. Longev. 2021;2021(1):8321400. doi: 10.1155/2021/8321400.</cite> [<a href="https://doi.org/10.1155/2021/8321400" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8568530/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34745424/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Oxid.%20Med.%20Cell.%20Longev.&amp;title=Inhibition%20of%20vascular%20smooth%20muscle%20and%20cancer%20cell%20proliferation%20by%20new%20VEGFR%20inhibitors%20and%20their%20immunomodulator%20effect:%20Design,%20synthesis,%20and%20biological%20evaluation&amp;author=F.%20Ran&amp;author=W.%20Li&amp;author=Y.%20Qin&amp;author=T.%20Yu&amp;author=Z.%20Liu&amp;volume=2021&amp;issue=1&amp;publication_year=2021&amp;pages=8321400&amp;pmid=34745424&amp;doi=10.1155/2021/8321400&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="cit75">
<cite>Eissa I. H. Dahab M. A. Ibrahim M. K. Alsaif N. A. Alanazi A. Eissa S. I. Mehany A. B. Beauchemin A. M. Design and discovery of new antiproliferative 1, 2, 4-triazin-3 (2H)-ones as tubulin polymerization inhibitors targeting colchicine binding site. Bioorg. Chem. 2021;112:104965. doi: 10.1016/j.bioorg.2021.104965.</cite> [<a href="https://doi.org/10.1016/j.bioorg.2021.104965" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34020238/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Bioorg.%20Chem.&amp;title=Design%20and%20discovery%20of%20new%20antiproliferative%201,%202,%204-triazin-3%20(2H)-ones%20as%20tubulin%20polymerization%20inhibitors%20targeting%20colchicine%20binding%20site&amp;author=I.%20H.%20Eissa&amp;author=M.%20A.%20Dahab&amp;author=M.%20K.%20Ibrahim&amp;author=N.%20A.%20Alsaif&amp;author=A.%20Alanazi&amp;volume=112&amp;publication_year=2021&amp;pages=104965&amp;pmid=34020238&amp;doi=10.1016/j.bioorg.2021.104965&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="cit76">
<cite>Balah A. Ezzat O. Akool E.-S. Vitamin E inhibits cyclosporin A-induced CTGF and TIMP-1 expression by repressing ROS-mediated activation of TGF-β/Smad signaling pathway in rat liver. Int. Immunopharmacol. 2018;65:493–502. doi: 10.1016/j.intimp.2018.09.033.</cite> [<a href="https://doi.org/10.1016/j.intimp.2018.09.033" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30391882/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Int.%20Immunopharmacol.&amp;title=Vitamin%20E%20inhibits%20cyclosporin%20A-induced%20CTGF%20and%20TIMP-1%20expression%20by%20repressing%20ROS-mediated%20activation%20of%20TGF-%CE%B2/Smad%20signaling%20pathway%20in%20rat%20liver&amp;author=A.%20Balah&amp;author=O.%20Ezzat&amp;author=E.-S.%20Akool&amp;volume=65&amp;publication_year=2018&amp;pages=493-502&amp;pmid=30391882&amp;doi=10.1016/j.intimp.2018.09.033&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="cit77">
<cite>Aborehab N. M. Elnagar M. R. Waly N. E. Gallic acid potentiates the apoptotic effect of paclitaxel and carboplatin via overexpression of Bax and P53 on the MCF-7 human breast cancer cell line. J. Biochem. Mol. Toxicol. 2021;35(2):e22638. doi: 10.1002/jbt.22638.</cite> [<a href="https://doi.org/10.1002/jbt.22638" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33002289/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J.%20Biochem.%20Mol.%20Toxicol.&amp;title=Gallic%20acid%20potentiates%20the%20apoptotic%20effect%20of%20paclitaxel%20and%20carboplatin%20via%20overexpression%20of%20Bax%20and%20P53%20on%20the%20MCF-7%20human%20breast%20cancer%20cell%20line&amp;author=N.%20M.%20Aborehab&amp;author=M.%20R.%20Elnagar&amp;author=N.%20E.%20Waly&amp;volume=35&amp;issue=2&amp;publication_year=2021&amp;pages=e22638&amp;pmid=33002289&amp;doi=10.1002/jbt.22638&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="cit78">
<cite>Elnagar M. R. Walls A. B. Helal G. K. Hamada F. M. Thomsen M. S. Jensen A. A. Functional characterization of α7 nicotinic acetylcholine and NMDA receptor signaling in SH-SY5Y neuroblastoma cells in an ERK phosphorylation assay. Eur. J. Pharmacol. 2018;826:106–113. doi: 10.1016/j.ejphar.2018.02.047.</cite> [<a href="https://doi.org/10.1016/j.ejphar.2018.02.047" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29501870/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Eur.%20J.%20Pharmacol.&amp;title=Functional%20characterization%20of%20%CE%B17%20nicotinic%20acetylcholine%20and%20NMDA%20receptor%20signaling%20in%20SH-SY5Y%20neuroblastoma%20cells%20in%20an%20ERK%20phosphorylation%20assay&amp;author=M.%20R.%20Elnagar&amp;author=A.%20B.%20Walls&amp;author=G.%20K.%20Helal&amp;author=F.%20M.%20Hamada&amp;author=M.%20S.%20Thomsen&amp;volume=826&amp;publication_year=2018&amp;pages=106-113&amp;pmid=29501870&amp;doi=10.1016/j.ejphar.2018.02.047&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="cit79">
<cite>Alsaif N. A. Taghour M. S. Alanazi M. M. Obaidullah A. J. Al-Mehizia A. A. Alanazi M. M. Aldawas S. Elwan A. Elkady H. Discovery of new VEGFR-2 inhibitors based on bis ([1, 2, 4] triazolo)[4, 3-a: 3', 4'-c] quinoxaline derivatives as anticancer agents and apoptosis inducers. J. Enzyme Inhib. Med. Chem. 2021;36(1):1093–1114. doi: 10.1080/14756366.2021.1915303.</cite> [<a href="https://doi.org/10.1080/14756366.2021.1915303" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8168755/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34056992/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J.%20Enzyme%20Inhib.%20Med.%20Chem.&amp;title=Discovery%20of%20new%20VEGFR-2%20inhibitors%20based%20on%20bis%20(%5B1,%202,%204%5D%20triazolo)%5B4,%203-a:%203',%204'-c%5D%20quinoxaline%20derivatives%20as%20anticancer%20agents%20and%20apoptosis%20inducers&amp;author=N.%20A.%20Alsaif&amp;author=M.%20S.%20Taghour&amp;author=M.%20M.%20Alanazi&amp;author=A.%20J.%20Obaidullah&amp;author=A.%20A.%20Al-Mehizia&amp;volume=36&amp;issue=1&amp;publication_year=2021&amp;pages=1093-1114&amp;pmid=34056992&amp;doi=10.1080/14756366.2021.1915303&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="cit80">
<cite>El-Naggar A. M. Eissa I. H. Belal A. El-Sayed A. A. Design, eco-friendly synthesis, molecular modeling and anticancer evaluation of thiazol-5 (4 H)-ones as potential tubulin polymerization inhibitors targeting the colchicine binding site. RSC Adv. 2020;10(5):2791–2811. doi: 10.1039/c9ra10094f.</cite> [<a href="https://doi.org/10.1039/c9ra10094f" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9048505/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35496078/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=RSC%20Adv.&amp;title=Design,%20eco-friendly%20synthesis,%20molecular%20modeling%20and%20anticancer%20evaluation%20of%20thiazol-5%20(4%20H)-ones%20as%20potential%20tubulin%20polymerization%20inhibitors%20targeting%20the%20colchicine%20binding%20site&amp;author=A.%20M.%20El-Naggar&amp;author=I.%20H.%20Eissa&amp;author=A.%20Belal&amp;author=A.%20A.%20El-Sayed&amp;volume=10&amp;issue=5&amp;publication_year=2020&amp;pages=2791-2811&amp;pmid=35496078&amp;doi=10.1039/c9ra10094f&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
</ol></section></section><section id="_ad93_" lang="en" class="associated-data"><h2 class="pmc_sec_title">Associated Data</h2>
<p class="font-secondary"><em>This section collects any data citations, data availability statements, or supplementary materials included in this article.</em></p>
<section id="_adsm93_" lang="en" class="supplementary-materials"><h3 class="pmc_sec_title">Supplementary Materials</h3>
<section class="sm xbox font-sm" id="db_ds_supplementary-material1_reqid_"><div class="caption p"><span>RA-015-D5RA03829D-s001</span></div>
<div class="media p"><div class="caption">
<a href="/articles/instance/12377202/bin/RA-015-D5RA03829D-s001.pdf" data-ga-action="click_feat_suppl" class="usa-link">RA-015-D5RA03829D-s001.pdf</a><sup> (5.5MB, pdf) </sup>
</div></div></section></section><section id="_adda93_" lang="en" class="data-availability-statement"><h3 class="pmc_sec_title">Data Availability Statement</h3>
<p>Supplementary data related to this manuscript are found in a separate file. See DOI: <a href="https://doi.org/10.1039/d5ra03829d" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://doi.org/10.1039/d5ra03829d</a>.</p></section></section></section><footer class="p courtesy-note font-secondary font-sm text-center"><hr class="headless">
<p>Articles from RSC Advances are provided here courtesy of <strong>Royal Society of Chemistry</strong></p></footer></section></article>

                      

                    </main>
                </div>
            </div>
        </div>

        



<!-- Secondary navigation placeholder -->
<div class="pmc-sidenav desktop:grid-col-4 display-flex">
    <section class="pmc-sidenav__container" aria-label="Article resources and navigation">
        <button type="button" class="usa-button pmc-sidenav__container__close usa-button--unstyled">
            <img src="/static/img/usa-icons/close.svg" role="img" alt="Close" />
        </button>
    <div class="display-none desktop:display-block">
       <section class="margin-top-4 desktop:margin-top-0">
              <h2 class="margin-top-0">ACTIONS</h2>
           <ul class="usa-list usa-list--unstyled usa-list--actions">
               
               <li>
                     <a
                             href="https://doi.org/10.1039/d5ra03829d"
                             class="usa-button usa-button--outline width-24 font-xs display-inline-flex flex-align-center flex-justify-start padding-left-1"
                             target="_blank"
                             rel="noreferrer noopener"
                             data-ga-category="actions"
                             data-ga-action="click"
                             data-ga-label="publisher_link_desktop"
                     >
                         <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#launch"></use>
                         </svg>
                         <span class="display-inline-flex flex-justify-center flex-1 padding-right-2">View on publisher site</span>
                     </a>
               </li>
               
               
               <li>
                    <a
                            href="pdf/RA-015-D5RA03829D.pdf"
                            class="usa-button usa-button--outline width-24 display-inline-flex flex-align-center flex-justify-start padding-left-1"
                            data-ga-category="actions"
                            data-ga-action="click"
                            data-ga-label="pdf_download_desktop"
                    >
                         <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#file_download"></use>
                        </svg>
                        <span class="display-inline-flex flex-justify-center flex-1">PDF (5.7 MB)</span>
                    </a>
               </li>
               
                
               <li>
                   <button role="button" class="usa-button width-24 citation-dialog-trigger display-inline-flex flex-align-center flex-justify-start padding-left-1"
                        aria-label="Open dialog with citation text in different styles"
                        data-ga-category="actions"
                        data-ga-action="open"
                        data-ga-label="cite_desktop"
                        data-all-citations-url="/resources/citations/12377202/"
                        data-citation-style="nlm"
                        data-download-format-link="/resources/citations/12377202/export/"
                    >
                        <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#format_quote"></use>
                        </svg>
                       <span class="display-inline-flex flex-justify-center flex-1 button-label">Cite</span>
                    </button>
               </li>
                
               <li>

                        <button class="usa-button width-24 collections-dialog-trigger collections-button display-inline-flex flex-align-center flex-justify-start padding-left-1 collections-button-empty"
                              aria-label="Save article in MyNCBI collections."
                              data-ga-category="actions"
                              data-ga-action="click"
                              data-ga-label="collections_button_desktop"
                              data-collections-open-dialog-enabled="false"
                              data-collections-open-dialog-url="https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpmc.ncbi.nlm.nih.gov%2Farticles%2FPMC12377202%2F%3Freport%3Dclassic%23open-collections-dialog"
                              data-in-collections="false">
                            <svg class="usa-icon width-3 height-3 usa-icon--bookmark-full" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-full.svg#icon"></use>
                            </svg>
                            <svg class="usa-icon width-3 height-3 usa-icon--bookmark-empty" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-empty.svg#icon"></use>
                            </svg>
                            <span class="display-inline-flex flex-justify-center flex-1">Collections</span>
                       </button>
               </li>
               <li class="pmc-permalink">
                    <button
                            type="button"
                            class="usa-button width-24 display-inline-flex flex-align-center flex-justify padding-left-1 shadow-none"
                            aria-label="Show article permalink"
                            aria-expanded="false"
                            aria-haspopup="true"
                            data-ga-category="actions"
                            data-ga-action="open"
                            data-ga-label="permalink_desktop"
                    >
                         <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#share"></use>
                        </svg>
                        <span class="display-inline-flex flex-justify-center flex-1 button-label">Permalink</span>
                    </button>
                   

<div class="pmc-permalink__dropdown" hidden>
    <div class="pmc-permalink__dropdown__container">
          <h2 class="usa-modal__heading margin-top-0 margin-bottom-2 text-uppercase font-sans-xs">PERMALINK</h2>
          <div class="pmc-permalink__dropdown__content">
              <input type="text" class="usa-input" value="https://pmc.ncbi.nlm.nih.gov/articles/PMC12377202/" aria-label="Article permalink">
              <button class="usa-button display-inline-flex pmc-permalink__dropdown__copy__btn margin-right-0" title="Copy article permalink" data-ga-category="save_share" data-ga-action="link" data-ga-label="copy_link">
                  <svg class="usa-icon" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#content_copy"></use>
                  </svg>
                  <span class="margin-left-1">Copy</span>
              </button>
          </div>
    </div>
</div>
               </li>
           </ul>
       </section>
     </div>

        <section class="pmc-resources margin-top-6 desktop:margin-top-4" data-page-path="/articles/PMC12377202/">
            <h2 class="margin-top-0">RESOURCES</h2>
            
                <div class="usa-accordion usa-accordion--multiselectable" data-allow-multiple>
                    <h3 class="usa-accordion__heading">
                        <button
                        type="button"
                        class="usa-accordion__button"
                        aria-expanded="false"
                        aria-controls="resources-similar-articles"
                        data-ga-category="resources_accordion"
                        data-ga-action="open_similar_articles"
                        data-ga-label="/articles/PMC12377202/"
                        data-action-open="open_similar_articles"
                        data-action-close="close_similar_articles"
                        >
                            Similar articles
                        </button>
                    </h3>
                    <div
                            id="resources-similar-articles"
                            class="usa-accordion__content usa-prose"
                            
                    >
                        
                    </div>
                    <h3 class="usa-accordion__heading">
                        <button
                        type="button"
                        class="usa-accordion__button"
                        aria-expanded="false"
                        aria-controls="resources-cited-by-other-articles"
                        data-ga-category="resources_accordion"
                        data-ga-action="open_cited_by"
                        data-ga-label="/articles/PMC12377202/"
                        data-action-open="open_cited_by"
                        data-action-close="close_cited_by"
                        >
                             Cited by other articles
                        </button>
                    </h3>
                    <div
                            id="resources-cited-by-other-articles"
                            class="usa-accordion__content usa-prose"
                            
                    >
                          
                    </div>
                    
                        <h3 class="usa-accordion__heading">
                            <button
                            type="button"
                            class="usa-accordion__button"
                            aria-expanded="false"
                            aria-controls="resources-links-to-ncbi-databases"
                            data-ga-category="resources_accordion"
                            data-ga-action="open_NCBI_links"
                            data-ga-label="/articles/PMC12377202/"
                            data-action-open="open_NCBI_links"
                            data-action-close="close_NCBI_link"
                            >
                                 Links to NCBI Databases
                            </button>
                        </h3>
                        <div
                                id="resources-links-to-ncbi-databases"
                                class="usa-accordion__content usa-prose"
                                data-source-url="/resources/db-links/12377202/"
                        >
                        </div>
                    
                    
                </div>
            
        </section>


        <section
        class="usa-in-page-nav usa-in-page-nav--wide margin-top-6 desktop:margin-top-4"
        data-title-text="On this page"
        data-title-heading-level="h2"
        data-scroll-offset="0"
        data-root-margin="-10% 0px -80% 0px"
        data-main-content-selector="main"
        data-threshold="1"
        hidden
        ></section>
    </section>
</div>


        

<div class="overlay" role="dialog" aria-label="Citation Dialog" hidden>
    <div class="dialog citation-dialog" aria-hidden="true">
        <div class="display-inline-flex flex-align-center flex-justify width-full margin-bottom-2">
            <h2 class="usa-modal__heading margin-0">Cite</h2>
             <button type="button" class="usa-button usa-button--unstyled close-overlay text-black width-auto"  tabindex="1">
                <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#close"></use>
                </svg>
             </button>
        </div>

        

<div class="citation-text-block">
  <div class="citation-text margin-bottom-2"></div>
  <ul class="usa-list usa-list--unstyled display-inline-flex flex-justify width-full flex-align-center">
      <li>
        <button
          class="usa-button usa-button--unstyled text-no-underline display-flex flex-align-center copy-button dialog-focus"
          data-ga-category="save_share"
          data-ga-action="cite"
          data-ga-label="copy"
          tabindex="2">
            <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img">
                <use xlink:href="/static/img/sprite.svg#content_copy"></use>
            </svg>
            <span>Copy</span>
        </button>
      </li>
      <li>
          <a
              href="#"
              role="button"
              class="usa-button usa-button--unstyled text-no-underline display-flex flex-align-center export-button"
              data-ga-category="save_share"
              data-ga-action="cite"
              data-ga-label="download"
              title="Download a file for external citation management software"
              tabindex="3">
                <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#file_download"></use>
                </svg>
                <span class="display-none mobile-lg:display-inline">Download .nbib</span>
                <span class="display-inline mobile-lg:display-none">.nbib</span>
            </a>
      </li>
      <li>
          

<div class="display-inline-flex flex-align-center">
  <label class="usa-label margin-top-0">Format:</label>
  <select aria-label="Format" class="usa-select citation-style-selector padding-1 margin-top-0 border-0 padding-right-4" tabindex="4" >
    
      <option data-style-url-name="ama"
              value="AMA"
              >
        AMA
      </option>
    
      <option data-style-url-name="apa"
              value="APA"
              >
        APA
      </option>
    
      <option data-style-url-name="mla"
              value="MLA"
              >
        MLA
      </option>
    
      <option data-style-url-name="nlm"
              value="NLM"
              selected="selected">
        NLM
      </option>
    
  </select>
</div>
      </li>
  </ul>
</div>
    </div>
</div>

        <div class="overlay" role="dialog" hidden>
  <div id="collections-action-dialog" class="dialog collections-dialog" aria-hidden="true">
   <div class="display-inline-flex flex-align-center flex-justify width-full margin-bottom-2">
        <h2 class="usa-modal__heading margin-0">Add to Collections</h2>
    </div>
    <div class="collections-action-panel action-panel">
      


<form id="collections-action-dialog-form"
      class="usa-form maxw-full collections-action-panel-form action-panel-content action-form action-panel-smaller-selectors"
      data-existing-collections-url="/list-existing-collections/"
      data-add-to-existing-collection-url="/add-to-existing-collection/"
      data-create-and-add-to-new-collection-url="/create-and-add-to-new-collection/"
      data-myncbi-max-collection-name-length="100"
      data-collections-root-url="https://www.ncbi.nlm.nih.gov/myncbi/collections/">

    <input type="hidden" name="csrfmiddlewaretoken" value="DowsxxVv3BRo0QQK3n4Rh4XpcMGOtIBGJXEPE0P2Hia7Ds8lRMKYBwLcymDPUo9f">

    <fieldset class="usa-fieldset margin-bottom-2">
        <div class="usa-radio">
            <input type="radio"
            id="collections-action-dialog-new"
            class="usa-radio__input usa-radio__input--tile collections-new  margin-top-0"
            name="collections"
            value="new"
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="collections_radio_new" />
            <label class="usa-radio__label" for="collections-action-dialog-new">Create a new collection</label>
        </div>
        <div class="usa-radio">
            <input type="radio"
            id="collections-action-dialog-existing"
            class="usa-radio__input usa-radio__input--tile collections-existing"
            name="collections"
            value="existing"
            checked="true"
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="collections_radio_existing" />
            <label class="usa-radio__label" for="collections-action-dialog-existing">Add to an existing collection</label>
        </div>
    </fieldset>

    <fieldset class="usa-fieldset margin-bottom-2">
        <div class="action-panel-control-wrap new-collections-controls">
           <label for="collections-action-dialog-add-to-new" class="usa-label margin-top-0">
                Name your collection
               <abbr title="required" class="usa-hint usa-hint--required text-no-underline">*</abbr>
          </label>
          <input
            type="text"
            name="add-to-new-collection"
            id="collections-action-dialog-add-to-new"
            class="usa-input collections-action-add-to-new"
            pattern="[^&quot;&amp;=&lt;&gt;/]*" title="The following characters are not allowed in the Name field: &quot;&amp;=&lt;&gt;/"
            maxlength=""
            data-ga-category="collections_button"
            data-ga-action="create_collection"
            data-ga-label="non_favorties_collection"
            required
          />
        </div>
        <div class="action-panel-control-wrap existing-collections-controls">
             <label for="collections-action-dialog-add-to-existing" class="usa-label margin-top-0">
                Choose a collection
              </label>
              <select id="collections-action-dialog-add-to-existing"
                      class="usa-select collections-action-add-to-existing"
                      data-ga-category="collections_button"
                      data-ga-action="select_collection"
                      data-ga-label="($('.collections-action-add-to-existing').val() === 'Favorites') ? 'Favorites' : 'non_favorites_collection'">
              </select>
              <div class="collections-retry-load-on-error usa-input-error-message selection-validation-message">
                Unable to load your collection due to an error<br>
                <a href="#">Please try again</a>
              </div>
        </div>
    </fieldset>

    <div class="display-inline-flex">
        <button class="usa-button margin-top-0 action-panel-submit"
            type="submit"
            data-loading-label="Adding..."
            data-pinger-ignore
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="add">
          Add
        </button>
        <button class="usa-button usa-button--outline margin-top-0 action-panel-cancel"
                aria-label="Close 'Add to Collections' panel"
                ref="linksrc=close_collections_panel"
                data-ga-category="collections_button"
                data-ga-action="click"
                data-ga-label="cancel">
          Cancel
        </button>
    </div>
</form>
    </div>
  </div>
</div>

        

      </div>
    </div>
  </div>



        
    
    

<footer class="ncbi-footer ncbi-dark-background " >
    
        <div class="ncbi-footer__icon-section">
            <div class="ncbi-footer__social-header">
                Follow NCBI
            </div>

            <div class="grid-container ncbi-footer__ncbi-social-icons-container">
                
                    <a href="https://twitter.com/ncbi"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="40"
                             height="40"
                             viewBox="0 0 40 40"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="m6.067 8 10.81 13.9L6 33.2h4.2l8.4-9.1 7.068 9.1H34L22.8 18.5 31.9 8h-3.5l-7.7 8.4L14.401 8H6.067Zm3.6 1.734h3.266l16.8 21.732H26.57L9.668 9.734Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on X (formerly known as Twitter)</span>
                    </a>
                

                
                    <a href="https://www.facebook.com/ncbi.nlm"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="16"
                             height="29"
                             focusable="false"
                             aria-hidden="true"
                             viewBox="0 0 16 29"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg">
                            <path d="M3.8809 21.4002C3.8809 19.0932 3.8809 16.7876 3.8809 14.478C3.8809 14.2117 3.80103 14.1452 3.54278 14.1492C2.53372 14.1638 1.52334 14.1492 0.514288 14.1598C0.302626 14.1598 0.248047 14.0972 0.248047 13.8936C0.256034 12.4585 0.256034 11.0239 0.248047 9.58978C0.248047 9.37013 0.302626 9.30224 0.528931 9.3049C1.53798 9.31688 2.54837 9.3049 3.55742 9.31555C3.80103 9.31555 3.8809 9.26097 3.87957 9.00272C3.87158 8.00565 3.85428 7.00592 3.90753 6.00884C3.97142 4.83339 4.31487 3.73115 5.04437 2.78467C5.93095 1.63318 7.15699 1.09005 8.56141 0.967577C10.5582 0.79319 12.555 0.982221 14.5518 0.927641C14.7102 0.927641 14.7462 0.99287 14.7449 1.13664C14.7449 2.581 14.7449 4.02668 14.7449 5.47104C14.7449 5.67604 14.6517 5.68669 14.4946 5.68669C13.4523 5.68669 12.4113 5.68669 11.3703 5.68669C10.3506 5.68669 9.92057 6.10868 9.90593 7.13904C9.89661 7.7647 9.91525 8.39303 9.89794 9.01869C9.88995 9.26364 9.96583 9.31822 10.2015 9.31688C11.7204 9.30623 13.2393 9.31688 14.7595 9.3049C15.0257 9.3049 15.0723 9.3728 15.0444 9.62439C14.89 10.9849 14.7515 12.3467 14.6144 13.7085C14.5691 14.1571 14.5785 14.1585 14.1458 14.1585C12.8386 14.1585 11.5313 14.1665 10.2254 14.1518C9.95119 14.1518 9.89794 14.2317 9.89794 14.4899C9.90593 19.0799 9.89794 23.6752 9.91125 28.2612C9.91125 28.5674 9.8407 28.646 9.53186 28.6433C7.77866 28.6273 6.02414 28.6366 4.27094 28.634C3.82499 28.634 3.87158 28.6992 3.87158 28.22C3.87602 25.9472 3.87913 23.6739 3.8809 21.4002Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on Facebook</span>
                    </a>
                

                
                    <a href="https://www.linkedin.com/company/ncbinlm"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="25"
                             height="23"
                             viewBox="0 0 26 24"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="M14.6983 9.98423C15.6302 9.24808 16.5926 8.74754 17.6762 8.51991C19.673 8.09126 21.554 8.30824 23.1262 9.7526C24.2351 10.7723 24.7529 12.1115 25.0165 13.5612C25.1486 14.3363 25.2105 15.1218 25.2015 15.9081C25.2015 18.3043 25.2015 20.6898 25.2082 23.0806C25.2082 23.3468 25.1549 23.444 24.8621 23.4414C23.1297 23.4272 21.3992 23.4272 19.6704 23.4414C19.4041 23.4414 19.3429 23.3588 19.3442 23.1019C19.3535 20.5194 19.3442 17.9368 19.3442 15.3543C19.3442 14.0005 18.3258 12.9448 17.0266 12.9488C15.7273 12.9528 14.6983 14.0071 14.6983 15.361C14.6983 17.9328 14.6917 20.5047 14.6983 23.0753C14.6983 23.3708 14.6198 23.444 14.3296 23.4427C12.6185 23.4294 10.9079 23.4294 9.19779 23.4427C8.93155 23.4427 8.86099 23.3735 8.86232 23.1086C8.8783 19.7619 8.88628 16.4144 8.88628 13.066C8.88628 11.5688 8.87874 10.0708 8.86365 8.57182C8.86365 8.3575 8.90758 8.27896 9.14054 8.28029C10.9048 8.29094 12.6687 8.29094 14.4321 8.28029C14.6464 8.28029 14.6983 8.34818 14.6983 8.54653C14.6903 9.00047 14.6983 9.45441 14.6983 9.98423Z">
                            </path>
                            <path d="M6.55316 15.8443C6.55316 18.2564 6.55316 20.6699 6.55316 23.082C6.55316 23.3629 6.48127 23.4388 6.19906 23.4374C4.47737 23.4241 2.75568 23.4241 1.03399 23.4374C0.767751 23.4374 0.69986 23.3629 0.701191 23.1006C0.709178 18.2648 0.709178 13.4281 0.701191 8.59053C0.701191 8.34026 0.765089 8.27237 1.01669 8.2737C2.74991 8.28435 4.48048 8.28435 6.20838 8.2737C6.47462 8.2737 6.5465 8.33627 6.54517 8.6065C6.54783 11.0186 6.55316 13.4308 6.55316 15.8443Z">
                            </path>
                            <path d="M3.65878 0.243898C5.36804 0.243898 6.58743 1.45529 6.58743 3.1406C6.58743 4.75801 5.32145 5.95742 3.60819 5.96807C3.22177 5.97614 2.83768 5.90639 2.47877 5.76299C2.11985 5.61959 1.79344 5.40546 1.51897 5.13334C1.24449 4.86123 1.02755 4.53668 0.881058 4.17902C0.734563 3.82136 0.661505 3.43788 0.666231 3.05141C0.67555 1.42601 1.9362 0.242566 3.65878 0.243898Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on LinkedIn</span>
                    </a>
                

                
                    <a href="https://github.com/ncbi"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="28"
                             height="27"
                             viewBox="0 0 28 28"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="M16.7228 20.6334C17.5057 20.5527 18.2786 20.3944 19.0301 20.1608C21.3108 19.4193 22.5822 17.8259 22.963 15.4909C23.1228 14.5112 23.1814 13.5287 22.9883 12.5437C22.8106 11.6423 22.4013 10.8028 21.8007 10.1076C21.7526 10.0605 21.7197 10 21.7064 9.934C21.6931 9.86799 21.7 9.79952 21.7262 9.73748C22.0856 8.6206 21.9711 7.51969 21.601 6.42677C21.582 6.3497 21.5345 6.2827 21.468 6.23923C21.4016 6.19577 21.3211 6.17906 21.2429 6.19248C20.7329 6.21649 20.2313 6.33051 19.7611 6.52928C19.1103 6.7908 18.4899 7.12198 17.9104 7.51703C17.84 7.56996 17.7581 7.60551 17.6713 7.62078C17.5846 7.63605 17.4954 7.6306 17.4112 7.60489C15.2596 7.05882 13.0054 7.06203 10.8554 7.61421C10.7806 7.63586 10.7018 7.63967 10.6253 7.62534C10.5487 7.611 10.4766 7.57892 10.4148 7.53167C9.64788 7.03247 8.85171 6.58918 7.96368 6.33359C7.65781 6.24338 7.34123 6.19458 7.02239 6.18849C6.94879 6.17986 6.87462 6.19893 6.81432 6.242C6.75402 6.28507 6.71191 6.34904 6.69621 6.42145C6.32342 7.51437 6.2209 8.61527 6.56307 9.73348C6.59635 9.84264 6.64694 9.93316 6.54177 10.0516C5.47666 11.2604 5.09988 12.6834 5.19574 14.2676C5.2663 15.4244 5.46201 16.5466 6.01454 17.5769C6.84399 19.1171 8.21664 19.9119 9.85158 20.3352C10.3938 20.4706 10.9444 20.5698 11.4998 20.632C11.5384 20.7492 11.4506 20.7798 11.408 20.8291C11.1734 21.1179 10.9894 21.4441 10.8634 21.7942C10.7622 22.0458 10.8315 22.4039 10.6065 22.5516C10.263 22.7766 9.83827 22.8485 9.42421 22.8871C8.17936 23.0056 7.26471 22.4877 6.6283 21.4348C6.25552 20.8184 5.76956 20.3325 5.08523 20.0663C4.76981 19.9325 4.42139 19.8967 4.08537 19.9638C3.7898 20.029 3.73788 20.1901 3.93891 20.4111C4.03639 20.5234 4.14989 20.6207 4.27575 20.6999C4.9796 21.1318 5.51717 21.7884 5.80152 22.5636C6.37002 23.9973 7.48039 24.5697 8.93825 24.6323C9.43741 24.6575 9.93768 24.615 10.4254 24.5058C10.5892 24.4672 10.6531 24.4872 10.6517 24.6762C10.6451 25.4936 10.6637 26.3123 10.6517 27.131C10.6517 27.6635 10.1684 27.9297 9.58663 27.7393C8.17396 27.2671 6.84977 26.5631 5.66838 25.656C2.59555 23.2891 0.720966 20.1861 0.217704 16.3376C-0.357453 11.9127 0.911353 8.00824 3.98551 4.73881C6.11909 2.42656 8.99932 0.939975 12.1203 0.540191C16.5351 -0.0601815 20.4347 1.14323 23.7232 4.16373C26.2449 6.47869 27.724 9.37672 28.1048 12.7726C28.5828 17.0325 27.3686 20.7945 24.4768 23.9827C22.9762 25.6323 21.0956 26.8908 18.9982 27.6488C18.8783 27.6927 18.7585 27.738 18.636 27.7726C18.0356 27.9404 17.6189 27.6395 17.6189 27.0098C17.6189 25.7452 17.6308 24.4806 17.6295 23.2159C17.6329 22.9506 17.6128 22.6856 17.5696 22.4238C17.4325 21.6664 17.3419 21.484 16.7228 20.6334Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on GitHub</span>
                    </a>
                

                
                    <a href="https://ncbiinsights.ncbi.nlm.nih.gov/"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="26"
                             height="26"
                             viewBox="0 0 27 27"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="M23.7778 26.4574C23.1354 26.3913 22.0856 26.8024 21.636 26.3087C21.212 25.8444 21.4359 24.8111 21.324 24.0347C19.9933 14.8323 14.8727 8.80132 6.09057 5.85008C4.37689 5.28406 2.58381 4.99533 0.779072 4.99481C0.202773 4.99481 -0.0229751 4.83146 0.00455514 4.21479C0.0660406 3.08627 0.0660406 1.95525 0.00455514 0.826734C-0.0413285 0.0815827 0.259669 -0.0193618 0.896534 0.00266238C6.96236 0.222904 12.3693 2.24179 16.9889 6.16209C22.9794 11.2478 26.1271 17.7688 26.4372 25.648C26.4629 26.294 26.3179 26.5271 25.6609 26.4684C25.0827 26.417 24.4991 26.4574 23.7778 26.4574Z">
                            </path>
                            <path d="M14.8265 26.441C14.0924 26.441 13.2371 26.6795 12.6626 26.3786C12.0092 26.0372 12.3781 25.0644 12.246 24.378C11.1154 18.5324 6.6849 14.5497 0.74755 14.1001C0.217135 14.0615 -0.0104482 13.9422 0.0134113 13.3659C0.0519536 12.1454 0.0482829 10.9213 0.0134113 9.69524C-0.00127145 9.14464 0.196946 9.03268 0.703502 9.04736C9.21217 9.27128 16.5994 16.2511 17.2804 24.7231C17.418 26.4446 17.418 26.4446 15.6579 26.4446H14.832L14.8265 26.441Z">
                            </path>
                            <path d="M3.58928 26.4555C2.64447 26.4618 1.73584 26.0925 1.06329 25.4289C0.39073 24.7653 0.00933763 23.8617 0.0030097 22.9169C-0.00331824 21.9721 0.365937 21.0635 1.02954 20.3909C1.69315 19.7184 2.59675 19.337 3.54156 19.3306C4.48637 19.3243 5.39499 19.6936 6.06755 20.3572C6.7401 21.0208 7.1215 21.9244 7.12782 22.8692C7.13415 23.814 6.7649 24.7226 6.10129 25.3952C5.43768 26.0677 4.53409 26.4491 3.58928 26.4555Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI RSS feed</span>
                    </a>
                
            </div>
        </div>
    

    <div data-testid="gridContainer"
         class="grid-container ncbi-footer__container">
        <div class="grid-row ncbi-footer__main-content-container"
             data-testid="grid">
            
                <div class="ncbi-footer__column">
                    
                        <p class="ncbi-footer__circled-icons-heading">
                            Connect with NLM
                        </p>
                    

                    <div class="ncbi-footer__circled-icons-list">
                        
                            <a href=https://twitter.com/nlm_nih class="ncbi-footer__social-icon ncbi-footer__social-icon--circled" target="_blank" rel="noreferrer noopener">
                                <svg width="32"
                                     height="32"
                                     viewBox="0 0 40 40"
                                     fill="none"
                                     xmlns="http://www.w3.org/2000/svg"
                                     focusable="false"
                                     aria-hidden="true">
                                    <path d="m6.067 8 10.81 13.9L6 33.2h4.2l8.4-9.1 7.068 9.1H34L22.8 18.5 31.9 8h-3.5l-7.7 8.4L14.401 8H6.067Zm3.6 1.734h3.266l16.8 21.732H26.57L9.668 9.734Z">
                                    </path>
                                </svg>
                                <span class="usa-sr-only">NLM on X (formerly known as Twitter)</span>
                            </a>
                        

                        
                            <a href=https://www.facebook.com/nationallibraryofmedicine class="ncbi-footer__social-icon ncbi-footer__social-icon--circled" target="_blank" rel="noreferrer noopener">
                                <svg width="13"
                                     height="24"
                                     viewBox="0 0 13 24"
                                     fill="none"
                                     xmlns="http://www.w3.org/2000/svg"
                                     focusable="false"
                                     aria-hidden="true">
                                    <path d="M4.11371 23.1369C4.11371 23.082 4.11371 23.0294 4.11371 22.9745V12.9411H0.817305C0.6709 12.9411 0.670898 12.9411 0.670898 12.8016C0.670898 11.564 0.670898 10.3287 0.670898 9.09341C0.670898 8.97903 0.705213 8.95158 0.815017 8.95158C1.8673 8.95158 2.91959 8.95158 3.97417 8.95158H4.12057V8.83263C4.12057 7.8055 4.12057 6.7738 4.12057 5.74897C4.1264 4.92595 4.31387 4.11437 4.66959 3.37217C5.12916 2.38246 5.94651 1.60353 6.95717 1.1921C7.64827 0.905008 8.3913 0.764035 9.13953 0.778051C10.0019 0.791777 10.8644 0.830666 11.7268 0.860404C11.8869 0.860404 12.047 0.894717 12.2072 0.90158C12.2964 0.90158 12.3261 0.940469 12.3261 1.02968C12.3261 1.5421 12.3261 2.05452 12.3261 2.56465C12.3261 3.16857 12.3261 3.7725 12.3261 4.37642C12.3261 4.48165 12.2964 4.51367 12.1912 4.51138C11.5369 4.51138 10.8804 4.51138 10.2261 4.51138C9.92772 4.51814 9.63058 4.5526 9.33855 4.61433C9.08125 4.6617 8.84537 4.78881 8.66431 4.97766C8.48326 5.16652 8.3662 5.40755 8.32972 5.66661C8.28476 5.89271 8.26027 6.1224 8.25652 6.35289C8.25652 7.19014 8.25652 8.02969 8.25652 8.86923C8.25652 8.89439 8.25652 8.91955 8.25652 8.95615H12.0219C12.1797 8.95615 12.182 8.95616 12.1614 9.10714C12.0768 9.76596 11.9876 10.4248 11.9029 11.0813C11.8312 11.6319 11.7626 12.1824 11.697 12.733C11.6719 12.9434 11.6787 12.9434 11.4683 12.9434H8.26338V22.899C8.26338 22.979 8.26338 23.0591 8.26338 23.1392L4.11371 23.1369Z">
                                    </path>
                                </svg>
                                <span class="usa-sr-only">NLM on Facebook</span>
                            </a>
                        

                        
                            <a href=https://www.youtube.com/user/NLMNIH class="ncbi-footer__social-icon ncbi-footer__social-icon--circled" target="_blank" rel="noreferrer noopener">
                                <svg width="21"
                                     height="15"
                                     viewBox="0 0 21 15"
                                     fill="none"
                                     xmlns="http://www.w3.org/2000/svg"
                                     focusable="false"
                                     aria-hidden="true">
                                    <path d="M19.2561 1.47914C18.9016 1.15888 18.5699 0.957569 17.2271 0.834039C15.5503 0.678484 13.2787 0.655608 11.563 0.65332H9.43556C7.71987 0.65332 5.4483 0.678484 3.77151 0.834039C2.43098 0.957569 2.097 1.15888 1.74242 1.47914C0.813665 2.32097 0.619221 4.62685 0.598633 6.89384C0.598633 7.31781 0.598633 7.74101 0.598633 8.16345C0.626084 10.4121 0.827391 12.686 1.74242 13.521C2.097 13.8412 2.4287 14.0425 3.77151 14.1661C5.4483 14.3216 7.71987 14.3445 9.43556 14.3468H11.563C13.2787 14.3468 15.5503 14.3216 17.2271 14.1661C18.5676 14.0425 18.9016 13.8412 19.2561 13.521C20.1712 12.6929 20.3725 10.451 20.3999 8.22064C20.3999 7.74025 20.3999 7.25986 20.3999 6.77946C20.3725 4.54907 20.1689 2.30724 19.2561 1.47914ZM8.55942 10.5311V4.65201L13.5601 7.50005L8.55942 10.5311Z"
                                          fill="white" />
                                </svg>
                                <span class="usa-sr-only">NLM on YouTube</span>
                            </a>
                        
                    </div>
                </div>
            

            
                <address class="ncbi-footer__address ncbi-footer__column">
                    
        <p>
            <a class="usa-link usa-link--external"
            href="https://www.google.com/maps/place/8600+Rockville+Pike,+Bethesda,+MD+20894/%4038.9959508,
            -77.101021,17z/data%3D!3m1!4b1!4m5!3m4!1s0x89b7c95e25765ddb%3A0x19156f88b27635b8!8m2!3d38.9959508!
            4d-77.0988323"
            rel="noopener noreferrer" target="_blank">National Library of Medicine
            <br/> 8600 Rockville Pike<br/> Bethesda, MD 20894</a>
        </p>
    
                </address>
            

            
                <ul class="usa-list usa-list--unstyled ncbi-footer__vertical-list ncbi-footer__column">
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.nlm.nih.gov/web_policies.html" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            Web Policies
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.nih.gov/institutes-nih/nih-office-director/office-communications-public-liaison/freedom-information-act-office" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            FOIA
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.hhs.gov/vulnerability-disclosure-policy/index.html" class="usa-link usa-link--external usa-link--alt ncbi-footer__link" rel="noreferrer noopener" target='_blank' >
        

        
            HHS Vulnerability Disclosure
        

        
    </a>


                        </li>
                    
                </ul>
            

            
                <ul class="usa-list usa-list--unstyled ncbi-footer__vertical-list ncbi-footer__column">
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://support.nlm.nih.gov/" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            Help
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.nlm.nih.gov/accessibility.html" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            Accessibility
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.nlm.nih.gov/careers/careers.html" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            Careers
        

        
    </a>


                        </li>
                    
                </ul>
            
        </div>

        
            <div class="grid-row grid-col-12" data-testid="grid">
                <ul class="ncbi-footer__bottom-links-list">
                    
                        <li class="ncbi-footer__bottom-list-item">
                            









    <a href="https://www.nlm.nih.gov/" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            NLM
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__bottom-list-item">
                            









    <a href="https://www.nih.gov/" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            NIH
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__bottom-list-item">
                            









    <a href="https://www.hhs.gov/" class="usa-link usa-link--external usa-link--alt ncbi-footer__link" rel="noreferrer noopener" target='_blank' >
        

        
            HHS
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__bottom-list-item">
                            









    <a href="https://www.usa.gov/" class="usa-link usa-link--external usa-link--alt ncbi-footer__link" rel="noreferrer noopener" target='_blank' >
        

        
            USA.gov
        

        
    </a>


                        </li>
                    
                </ul>
            </div>
        
    </div>
</footer>

    


        
        
    
  <script  type="text/javascript" src="https://cdn.ncbi.nlm.nih.gov/core/pinger/pinger.js"> </script>


    
        

<button class="back-to-top" data-ga-category="pagination" data-ga-action="back_to_top">
    <label>Back to Top</label>
    <svg class="usa-icon order-0" aria-hidden="true" focusable="false" role="img">
        <use xlink:href="/static/img/sprite.svg#arrow_upward"></use>
    </svg>
</button>
    


        
    
    
    
        
    <script type="application/javascript">
    window.ncbi = window.ncbi || {};
    window.ncbi.pmc = window.ncbi.pmc || {};
    window.ncbi.pmc.options = {
        logLevel: 'INFO',
        
        staticEndpoint: '/static/',
        
        citeCookieName: 'pmc-cf',
    };
</script>
    <script type="module" crossorigin="" src="/static/assets/base-133c6271.js"></script>
    
    <script type="text/javascript" src="https://cdn.ncbi.nlm.nih.gov/core/jquery/jquery-3.6.0.min.js">&#xA0;</script>
    <script type="text/javascript">
        jQuery.getScript("https://cdn.ncbi.nlm.nih.gov/core/alerts/alerts.js", function () {
            galert(['div.nav_and_browser', 'div.header', '#universal_header', '.usa-banner', 'body > *:nth-child(1)'])
        });
    </script>


    <script type="text/javascript">var exports = {};</script>
     <script src="/static/CACHE/js/output.13b077bc3ffd.js"></script>

    <script type="module" crossorigin="" src="/static/assets/article-44d04358.js"></script>
    
    

    </body>
</html>
